SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2002
Commission file number 1-11037

Praxair, Inc. 2003
Form 10-K

Praxair, Inc. Tel. (203) 837-2000
39 Old Ridgebury Road State of incorporation: Delaware
Danbury, Connecticut 06810-5113 IRS identification number: 06-124 9050

Securities registered pursuant to Section 12(b) of the Act:


Title of each class: Registered on :

Common Stock ($0.01 par value) New York Stock Exchange
Common Stock Purchase Rights New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Security Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes [X] No [ ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K [X]

Indicate by checkmark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). [X]

The aggregate market value of the voting and non-voting common stock held by non-affiliates, computed by reference to the price at which the stock was last sold on June 30, 2003, was approximately $9.8 billion.

At January 30, 2004, 325,288,575 shares of common stock of Praxair, Inc. were outstanding.

Documents incorporated by reference:

Portions of the 2003 Annual Report to Shareholders of the Registrant are incorporated in Parts I, II and IV of this report. Also, portions of the Proxy Statement of Praxair, Inc., dated March 2, 2004, are incorporated in Part III of this report.

The Index to Exhibits is located on page 14 of this report.


Forward-looking statements

The forward-looking statements contained in this document concerning demand for products and services, the expected macroeconomic environment, sales and earnings growth, projected capital and acquisition spending, the impact of required changes in accounting, the impact of accounting and other estimates, and other financial goals involve risks and uncertainties, and are subject to change based on various factors. These risk factors include the impact of changes in worldwide and national economies, the performance of stock markets, the cost and availability of electric power, natural gas and other materials, and the ability to achieve price increases to offset such cost increases, inflation in wages and other compensation, development of operational efficiencies, changes in foreign currencies, changes in interest rates, the continued timely development and acceptance of new products and services, the impact of competitive products and pricing, and the impact of tax and other legislation and regulation in the jurisdictions in which the company operates as well as new accounting rules and practices.



INDEX
Part I PAGE
Item 1: Business
Item 2: Properties
Item 3: Legal Proceedings
Item 4: Submission of Matters to a Vote of Security Holders
 
Part II
Item 5: Market for Registrant's Common Equity and Related Stockholder Matters
and Issuer Purchases of Equity Securities
Item 6: Selected Financial Data
Item 7: Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 7a: Quantitative and Qualitative Disclosures About Market Risk
Item 8: Financial Statements and Supplementary Data
Item 9: Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Item 9a: Controls and Procedures
 
Part III
Item 10: Directors and Executive Officers of the Registrant 10
Item 11: Executive Compensation 10
Item 12: Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder Matters
10
Item 13: Certain Relationships and Related Transactions 11
Item 14: Principal Accountant Fees and Services 11
 
Part IV
Item 15: Exhibits, Financial Statement Schedules, and Reports on Form 8-K 12
 
Signatures 13
Index to Exhibits 14

PART I

Praxair, Inc. and Subsidiaries


Item 1. Business

General
Praxair, Inc. (Praxair or company) was founded in 1907 and became an independent publicly traded company in 1992. Praxair was the first company in the United States to produce oxygen from air using a cryogenic process and continues to be a major technological innovator in the industrial gases industry.

Praxair is the largest industrial gases company in North and South America and is rapidly growing in Asia, and has a well-established business in southern Europe. Praxair’s primary products for its industrial gases business are atmospheric gases (oxygen, nitrogen, argon, rare gases), process gases (carbon dioxide, helium, hydrogen, electronic gases, specialty gases, acetylene). The company also designs, engineers, and builds equipment that produces industrial gases for internal use and external sale. The company’s surface technology segment, operated through Praxair Surface Technologies, Inc., supplies wear-resistant and high-temperature corrosion-resistant metallic and ceramic coatings and powders. Sales for Praxair were $5,613 million, $5,128 million, and $5,158 million for 2003, 2002 and 2001, respectively. Refer to Note 4 of the section captioned “Notes to Consolidated Financial Statements” in Praxair’s 2003 annual report to shareholders for information related to Praxair’s segment information.

Praxair serves approximately 25 industries as diverse as healthcare and petroleum refining; computer-chip manufacture and beverage carbonation; fiber-optics and steel making; and aerospace, chemicals and water treatment. In 2003, 93% sales were generated from industrial gases in four regional segments (North America, Europe, South America, and Asia), with the balance generated from the Surface Technologies segment. Praxair provides a competitive advantage to its customer base by continuously developing new products and applications which allow them to improve their productivity, energy efficiency and environmental performance.

Industrial Gases Products and Manufacturing Processes
Atmospheric gases are the highest volume products produced by Praxair. Using air as its raw material, Praxair produces oxygen, nitrogen and argon through several air separation processes, of which, cryogenic air separation, is the most prevalent process. As a pioneer in the industrial gases industry, Praxair is a leader in developing a wide range of proprietary and patented applications and supply systems technology, including small cryogenic nitrogen plants. Praxair also led the development and commercialization of non-cryogenic air separation technologies for the production of industrial gases. These technologies open important new markets and optimize production capacity for the company by lowering the cost of supply of industrial gases. These technologies include proprietary vacuum pressure swing adsorption (“VPSA”) and membrane separation to produce gaseous oxygen and nitrogen, respectively. Praxair also manufactures precious metal and ceramic sputtering targets used primarily in the production of semiconductors.

2


PART I (Continued)

Praxair, Inc. and Subsidiaries


Process gases, including carbon dioxide, hydrogen, carbon monoxide, helium and acetylene, are produced by different methods than air separation technologies. Most carbon dioxide is purchased from by-product sources, including chemical plants, refineries, industrial processes, and is recovered from carbon dioxide wells, and is processed in Praxair’s plants to produce commercial carbon dioxide. Hydrogen and carbon monoxide are produced by either steam methane reforming of natural gas or by purifying by-product sources obtained from the chemical and petrochemical industries. Most of the helium sold by Praxair is sourced from certain helium-rich natural gas streams in the United States, with additional supplies being acquired from outside the United States. Acetylene is typically produced from calcium carbide and water or purchased as a chemical by-product.

Industrial Gases Distribution
There are three basic distribution methods for industrial gases: (i) on-site or tonnage; (ii) merchant liquid; and (iii) packaged or cylinder gases. These distribution methods are often integrated, with products from all three supply modes coming from the same plant. The method of supply is generally determined by the lowest cost means of meeting the customer’s needs, depending upon factors such as volume requirements, purity, pattern of usage, and the form in which the product is used (as a gas or as a cryogenic liquid).

On-site. Customers that require the largest volumes of product (typically oxygen, nitrogen and hydrogen) and that have a relatively constant demand pattern are supplied by cryogenic and process gas on-site plants. Praxair constructs plants on or adjacent to these customers’ sites and supplies the product directly to customers. Because these are usually dedicated plants, the product supply contracts generally are total requirement contracts, typically having 10-20 year terms and containing minimum purchase requirements and price escalation provisions. Many of the cryogenic on-site plants also produce liquid products for the merchant market. New advanced air separation processes allow on-site delivery to customers with smaller volume requirements. Customers using these systems usually enter into requirement contracts with terms typically ranging from 5-15 years.

Merchant. The merchant business is generally associated with distributable liquid oxygen, nitrogen, argon, carbon dioxide, hydrogen and helium. The deliveries generally are made from Praxair’s plants by tanker trucks to storage containers owned or leased and maintained by Praxair or the customer at the customer’s site. Due to distribution cost, merchant oxygen and nitrogen generally have a relatively small distribution radius from the plants at which they are produced. Merchant argon, hydrogen and helium can be shipped much longer distances. The agreements used in the merchant business are usually three to five year requirement contracts, except for carbon dioxide, which typically has one-year requirement contracts in the United States.

Packaged Gases. Customers requiring small volumes are supplied products in metal containers called cylinders, under medium to high pressure. Packaged gases include atmospheric gases, carbon dioxide, hydrogen, helium and acetylene. Praxair also produces and distributes in cylinders a wide range of specialty gases and mixtures. Cylinders may be delivered to the customer’s site or picked up by the customer at a packaging facility or retail store. Packaged gases are generally sold by purchase orders.

A substantial amount of the cylinder gases sold in the United States is distributed by independent distributors that buy merchant gases in liquid form and repackage the products in their facilities. These businesses also distribute welding equipment purchased from manufacturers of such products. Over time, Praxair has acquired several independent industrial gases and welding products distributors at various locations in the United States and continues to sell merchant gases to other independent distributors. Between its own distribution business, joint ventures and sales to independent distributors, Praxair is represented in 42 states, the District of Columbia and Puerto Rico.

3


PART I (Continued)

Praxair, Inc. and Subsidiaries


Surface Technologies
Praxair’s surface technologies segment supplies wear-resistant and high-temperature corrosion-resistant metallic and ceramic coatings and powders to the aircraft, printing, textile, plastics, primary metals, petrochemical, and other industries. It also provides aircraft engine and airframe component overhaul services, and manufactures a complete line of electric arc, plasma, and high velocity oxygen fuel spray equipment as well as arc and flame wire equipment used for the application of wear resistant coatings. The coatings extend wear life and are applied at Praxair’s facilities using a variety of thermal spray coatings processes. The coated parts are finished to the customer’s precise specifications before shipment.

Inventories — Praxair carries inventories of merchant and cylinder gases, hardgoods and coatings materials to supply products to its customers on a reasonable delivery schedule. On-site plants and pipeline complexes have limited inventory. Inventories, inventory obsolescence and backlogs are not material to Praxair’s business.

Customers — Praxair is not dependent upon a single customer or a few customers.

International — Praxair is a global enterprise with 50% of its 2003 sales outside of the United States. It conducts industrial gases business through subsidiary and affiliated companies in Argentina, Belgium, Bolivia, Brazil, Canada, Chile, Colombia, Costa Rica, France, Germany, India, Israel, Italy, Japan, South Korea, Malayasia, Mexico, the Netherlands, the People’s Republic of China, Paraguay, Peru, Portugal, Spain, Taiwan, Thailand, Turkey, Uruguay and Venezuela. S.I.A.D. (Societa Italiana Acetilene & Derivati S.p.A.), an Italian company carried at equity, also has established positions in Austria, Bulgaria, Croatia, the Czech Republic, Hungary, Romania and Slovenia. Praxair’s surface technologies business has operations in Brazil, France, Germany, Italy, Japan, Singapore, South Korea, Taiwan, Spain, Switzerland and the United Kingdom.

Praxair’s international business is subject to risks customarily encountered in foreign operations, including fluctuations in foreign currency exchange rates and controls, import and export controls, and other economic, political and regulatory policies of local governments. Also, see Note 1 of the section captioned “Notes to Consolidated Financial Statements”, and the section captioned “Management’s Discussion and Analysis — Market Risk and Sensitivity Analysis” in Praxair’s 2003 Annual Report to Shareholders.

Seasonality — Praxair’s business is generally not subject to seasonal fluctuations to any significant extent.

Research and Development — Praxair’s research and development is directed toward developing new and improved methods for the production and distribution of industrial gases and the development of new markets and applications for these gases. This results in the frequent introduction of new industrial gas applications, and the development of new advanced air separation process technologies. Research and development for industrial gases is principally conducted at Tonawanda, New York; Burr Ridge, Illinois; Rio de Janeiro, Brazil; and Norwood, Massachusetts.

Praxair conducts research and development for its surface technologies to improve the quality and durability of coatings and the use of specialty powders for new applications and industries. Surface technologies research is conducted at Indianapolis, Indiana.

Patents and Trademarks — Praxair owns or licenses a large number of United States and foreign patents that relate to a wide variety of products and processes. Praxair’s patents expire at various times over the next 20 years. While these patents and licenses are considered important, Praxair does not consider its business as a whole to be materially dependent upon any one particular patent or patent license. Praxair also owns a large number of trademarks.

4


PART I (Continued)

Praxair, Inc. and Subsidiaries


RAW MATERIALS AND ENERGY COSTS
Energy is the single largest cost item in the production and distribution of industrial gases. Most of Praxair’s energy requirements are in the form of electricity, natural gas and diesel fuel for distribution. Praxair minimizes the financial impact of variability in these costs through the management of customer contracts which typically have escalation and pass-through clauses.

The supply of energy has not been a significant issue during the past two years in the geographic areas where we conduct business. However, the outcome of regional energy situations or new energy situations is unpredictable and may pose unforeseen future risks.

For carbon dioxide, carbon monoxide, helium, hydrogen, specialty gases and surface technologies, raw materials are largely purchased from outside sources. Praxair has contracts or commitments for, or readily available sources of, most of these raw materials; however, their long-term availability and prices are subject to market conditions.

Competition — Praxair operates within a highly competitive environment. Some of its competitors are larger in size and capital base than Praxair. Competition is based on price, product quality, delivery, reliability, technology and service to customers.

Major competitors in the industrial gases industry both in the United States and worldwide include Air Products and Chemicals, Inc., Airgas Inc., The BOC Group p.l.c., L’Air Liquide S.A., The Messer Group and Linde AG. At a worldwide level, there are no congruent competitors for the surface technologies business. However, principal domestic competitors are Sermatech International, Inc., a subsidiary of Teleflex, Inc., Chemtronics, Inc., a subsidiary of GKN p.l.c. and Johnson Matthey Electronics, a subsidiary of Honeywell. International competitors in surface technologies vary from country to country.

Employees and Labor Relations — As of December 31, 2003, Praxair had 25,438 employees worldwide. Of this number, 9,826 are employed in the United States. Praxair has collective bargaining agreements with unions at numerous locations throughout the world which expire at various dates. Praxair considers relations with its employees to be good.

Environment — Information required by this item is incorporated herein by reference to the section captioned “Management’s Discussion and Analysis — Costs Relating to the Protection of the Environment” in Praxair’s 2003 Annual Report to Shareholders.

Website Access to Reports — Praxair’s company website is http://www.praxair.com. The company makes its periodic and current reports available, free of charge, on its website as soon as practicable after such material is electronically filed with, or furnished to, the Securities and Exchange Commission (SEC). The SEC is located at 450 Fifth Street NW, Washington, D.C. 20549 and its website address is http://www.sec.gov. In addition, investors may also access from this site other investor information such as press releases, business trends, presentations, etc.

5


PART I (Continued)

Praxair, Inc. and Subsidiaries


Item 2. Properties

Praxair’s worldwide headquarters is located in leased office space in Danbury, Connecticut, and Praxair’s European headquarters is in leased space in Madrid, Spain. Other principal administrative offices are owned in Tonawanda, New York, Rio de Janeiro, Brazil and leased in Shanghai, China.

Praxair designs, engineers, manufactures and operates facilities that produce and distribute industrial gases. These industrial gas production facilities and certain components are designed and/or manufactured at its facilities in Tonawanda, New York; Norwood, Massachusetts; Burr Ridge, Illinois and Rio de Janeiro, Brazil. Praxair’s Italian equity affiliate, Societa Italiana Acetilene & Derivati S.p.A. (S.I.A.D.) also has such capacity.

The following table summarizes production locations for Praxair by segment. No significant portion of these assets was leased at December 31, 2003. Generally, these facilities are fully utilized and are sufficient to meet our manufacturing needs. The majority of the Surface Technologies locations are in the United States.

Number of Locations at December 31, 2003

ASU (a) Hydrogen CO2 (b) Other (c)




North America       170     24     51     354  
Europe       39     3     3     54  
South America       36     1     19     100  
Asia       17     2     12     44  
Surface Technologies       --     --     --     49  




    Total       262     30     85     601  





(a) Cryogenic air separation plants.
(b) Carbon dioxide plants.
(c) Other includes non-cryogenic plants, packaged gas plants, helium plants, specialty gas plants, and Surface Technologies plants.

No single production location is material except for the following pipeline complexes:

Supply System Number of
Production Locations
Number of
Connected Plants (a)
Plant Type
Northern Indiana   5   14   ASU/Hydrogen/CO2  
Houston   3   8   ASU  
Gulf Coast   4   12   Hydrogen/Carbon Monoxide  
Detroit   1   7   ASU/Hydrogen  
Louisiana   3   4   Hydrogen/Carbon Monoxide  
Southern Brazil (b)   9   9   ASU  
Northern Spain   5   6   ASU/Hydrogen/CO2  

(a) A production location contains one or more independently productive plants.
(b) Locations are partially owned and partially leased.

6


Item 3. Legal Proceedings

Information required by this item is incorporated herein by reference to the section captioned “Notes to Consolidated Financial Statements — Note 20 Commitments and Contingencies” in Praxair’s 2003 Annual Report to Shareholders.

Item 4. Submission of Matters to a Vote of Security Holders

Praxair did not submit any matters to a shareholder vote during the fourth quarter of 2003.

7


PART II

Praxair, Inc. and Subsidiaries


Item 5. Market for Registrant’s Common Equity and Related Shareholder Matters

Market, trading, shareholder and dividend information for Praxair’s common stock is incorporated herein by reference to the section captioned “Information for Investors” in Praxair’s 2003 Annual Report to Shareholders.

On October 28, 2003, Praxair’s Board of Directors declared a two-for-one split of the company’s common stock. The stock split was effected in the form of a stock dividend of one additional share for each share owned by stockholders of record on December 5, 2003, and each share held in treasury as of the record date. The additional shares were distributed to such holders on December 15, 2003.

Praxair’s annual dividend on its common stock for 2003 was $0.46 per share. On January 26, 2004, Praxair’s Board of Directors declared a dividend of $0.15 per share for the first quarter of 2004, or $0.60 per share annualized, which may be changed as Praxair’s earnings and business prospects warrant. The declaration of dividends is a business decision made by the Board of Directors based on Praxair’s earnings and financial condition and other factors the Board of Directors considers relevant.

Item 6. Selected Financial Data

Selected financial data for the five years ended December 31, 2003 is incorporated herein by reference to the section captioned “Five-Year Financial Summary” in Praxair’s 2003 Annual Report to Shareholders. This summary should be read in conjunction with the Consolidated Financial Statements and related Notes to Consolidated Financial Statements.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Information required by this item is incorporated herein by reference to the section captioned “Management’s Discussion and Analysis” in Praxair’s 2003 Annual Report to Shareholders.

Item 7a. Quantitative and Qualitative Disclosures About Market Risk

Information required by this item is incorporated herein by reference to the section captioned “Management’s Discussion and Analysis” in Praxair’s 2003 Annual Report to Shareholders.

Item 8. Financial Statements and Supplementary Data

Information required by this item is incorporated herein by reference to the sections captioned “Consolidated Statement of Income,” “Consolidated Balance Sheet,” “Consolidated Statement of Cash Flows,” “Consolidated Statement of Shareholders’ Equity” and “Notes to Consolidated Financial Statements” in Praxair’s 2003 Annual Report to Shareholders.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

8


Item 9a. Controls and Procedures

(a) Based on an evaluation of the effectiveness of Praxair’s disclosure controls and procedures, which was made under the supervision and with the participation of management, including Praxair’s principal executive officer and principal financial officer, the principal executive officer and principal financial officer have each concluded that, as of the end of the annual period covered by this report, such disclosure controls and procedures are effective in ensuring that information required to be disclosed by Praxair in reports that it files under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission’s rules and forms.

(b) During the annual period covered by this report, no significant change was made to Praxair’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, Praxair’s internal control over financial reporting.

9


PART III

Praxair, Inc. and Subsidiaries


Item 10. Directors and Executive Officers of the Registrant

Certain information required by this item is incorporated herein by reference to the sections captioned “The Board of Directors”, and “Executive Officers” in Praxair’s Proxy Statement for the Annual Meeting of Shareholders to be held on April 27, 2004.

Identification of the Audit Committee:
Praxair has a separately-designated Audit Committee established in accordance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). The members of that Audit Committee are H. Mitchell Watson, Jr., Chairman, Alejandro Achaval, Raymond W. LeBoeuf, Benjamin F. Payton, and Wayne T. Smith.

Audit Committee Financial Expert:
The Praxair Board of Directors has determined that each of H. Mitchell Watson, Jr., Raymond W. LeBoeuf, and Wayne T. Smith is an “audit committee financial expert” as defined by Item 401(h) of Regulation S-K of the Exchange Act and is independent within the meaning of Item 7(d)(3)(iv) of Schedule 14A of the Exchange Act.

Section 16(a) Beneficial Ownership Reporting Compliance:
Based solely upon a review of SEC Forms 3, 4 and 5 furnished to Praxair and written representations to the effect that no Form 5 is required, Praxair believes that during the period January 1, 2003 to December 31, 2003, all reports required by Section 16(a) of the Securities and Exchange Act of 1934 have been filed by its officers and directors.

Code of Ethics:
Praxair has adopted a “code of ethics” that applies to the Company’s directors and all employees, including its Chief Executive Officer, Chief Financial Officer, and Controller. This code of ethics, comprising Praxair’s “Business Integrity and Ethics Policy” and its “Standards of Business Integrity”, is posted on the Company’s public website, praxair.com.

Item 11. Executive Compensation

Information required by this item is incorporated herein by reference to the sections captioned “Shareholder Return” and “Executive Compensation” in Praxair’s Proxy Statement for the Annual Meeting of Shareholders to be held on April 27, 2004.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Information required by this item is either incorporated by reference to the section captioned “Share Ownership” in Praxair’s Proxy Statement for the Annual Meeting of Shareholders to be held April 27, 2004, or is furnished below.

The following table provides information as of December 31, 2003, about company stock that may be issued upon the exercise of options, warrants, and rights granted to employees or members of Praxair’s board of directors under existing equity compensation plans, including plans approved by shareholders and a plan which has not been approved by shareholders in accordance with applicable New York Stock Exchange rules. The equity compensation plan not approved by shareholders was terminated in March 2001 and directors and officers of the company were not eligible to participate in that plan. The material features of this plan, referred to as the “1996 Plan”, are disclosed in Note 18 to the consolidated financial statements.

10




  (a) (b) (c)
Plan Category Number of securities to be issued upon exercise of outstanding options, warrants and rights Weighted-average exercise price of outstanding options, warrants and rights Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
Equity compensation plans approved by security holders 14,044,594 $24.41 9,535,170*
Equity compensation plans not approved by security holders 8,408,897 $22.04 0
Total
  
22,453,491 $23.52 9,535,170

* Includes 100,000 shares available under the shareholder-approved stock option plan for non-employee directors. This plan provides for a fixed annual grant (on April 1st) of options to purchase 5,000 shares to each non-employee director of Praxair, Inc. then active. Under the terms of the plan, no grants may be made after December 31, 2005. The shares reported in this column for that plan are calculated assuming 10 eligible grantees on each of the two remaining grant dates: April 1, 2004 and April 1, 2005.

Item 13. Certain Relationships and Related Transactions

There have been no transactions or relationships since the beginning of 2003, which are reportable under this item.

Item 14. Principal Accountant Fees and Services

Information required by this item is incorporated herein by reference to the section captioned “The Independent Auditors” in Praxair’s Proxy Statement for the Annual Meeting of Shareholders to be held on April 27, 2004.

11


PART IV

Praxair, Inc. and Subsidiaries


Item 15. Exhibits, Financial Statement Schedules, and Reports on Form 8-K

(a) Financial Statements and Schedules

Financial Statements Page No. in Praxair's 2003
Annual Report (AR)*
Consolidated Statements of Income for the Years Ended December 31, 2003, 2002 and 2001               AR-23
Consolidated Balance Sheets at December 31, 2003 and 2002               AR-24
Consolidated Statements of Cash Flows for the Years Ended December 31, 2003, 2002 and 2001               AR-25
Consolidated Statement of Shareholders' Equity for the Years Ended December 31, 2003, 2002 and 2001               AR-26
Notes to Consolidated Financial Statements               AR-41 to AR-61
Report of Independent Auditors               AR-63

  *   Incorporated by reference to the indicated pages of the 2003 Annual Report to Shareholders. With the exception of this information and the information incorporated in Items 3, 5, 6, 7, 7A, and 8, the 2003 Annual Report to Shareholders is not to be deemed filed as part of this Annual Report on Form 10-K.

Financial Statement Schedules

All financial statement schedules have been omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.

(b) Reports on Form 8-K

Dated December 9, 2003. Item 5 — Other Events. Praxair, Inc. announced that its Board of Directors has adopted a policy statement on stockholder’s rights plans and advanced by eight years the expiration of Praxair’s existing rights plan.

Dated January 6, 2004. Item 5 — Other Events. On December 31, 2003, Mr. Dale F. Frey retired from Praxair’s Board of Directors.

Dated January 28, 2004. Item 9 — Regulation FD Disclosure. On January 27, 2004, Praxair, Inc. issued a press release setting forth Praxair, Inc.‘s fourth quarter 2004 earnings.

(c) Exhibits

Exhibits filed as a part of this annual report on Form 10-K are listed in the Index to Exhibits located on page 14 of this Report.

12


SIGNATURES

Praxair, Inc. and Subsidiaries


Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PRAXAIR, INC.
(Registrant)
 
 
Date: March 8, 2004
By: /s/ Patrick M. Clark
Patrick M. Clark
Vice President and Controller
(On behalf of the Registrant and as Chief Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on February 24, 2004.

/s/ James S. Sawyer
James S. Sawyer
Senior Vice President and
Chief Financial Officer
/s/ Dennis H. Reilley
Dennis H. Reilley
Chairman, President and Chief
Executive Officer and Director
/s/ Alejandro Achaval
Alejandro Achaval
Director
     
     
/s/ Claire W. Gargalli
Claire W. Gargalli
Director
/s/ Ronald L. Kuehn, Jr.
Ronald L. Kuehn, Jr.
Director
/s/ Raymond W. LeBoeuf
Raymond W. LeBoeuf
Director
     
     
/s/ Benjamin F. Payton
Benjamin F. Payton
Director
/s/ G. Jackson Ratcliffe, Jr.
G. Jackson Ratcliffe, Jr.
Director
/s/ Wayne T. Smith
Wayne T. Smith
Director
     
     
/s/ H. Mitchell Watson, Jr
H. Mitchell Watson, Jr.
Director

13


INDEX TO EXHIBITS

Praxair, Inc. and Subsidiaries


    Exhibit No.           Description

2.01 Agreement and Plan of Merger dated as of December 22, 1995 among Praxair, Inc., PX Acquisition Corp. and CBI Industries, Inc. (Filed as Exhibit 2 to the Company's Current Report on Form 8-K dated December 22, 1995, Filing No. 1-11037, and incorporated herein by reference).
3.01 Restated Certificate of Incorporation (Filed as Exhibit 3.01 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
3.02 Amended By Laws of Praxair, Inc. (Filed as Exhibit 3.02 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
3.03 Certificate of Designations for the 7.48% Cumulative Preferred Stock, Series A. (Filed on February 7, 1997 as Exhibit 3.3 to Amendment #1 to the Company's Registration Statement on Form S-3, Registration No. 333-18141).
3.04 Certificate of Designations for the 6.75% Cumulative Preferred Stock, Series B. (Filed on February 7, 1997 as Exhibit 3.4 to Amendment #1 to the Company's Registration Statement on Form S-3, Registration No. 333-18141).
4.01 Common Stock Certificate (Filed as Exhibit 4.01 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
4.02 Stockholder Protection Rights Agreement, dated as of June 30, 2002, between the registrant and Registrar and Transfer Company as Rights Agent. (Filed on June 27, 2002 as Exhibit 99.1 to the Company's Registration Statement on Form 8-A, Filing No. 1-11037, and incorporated herein by reference).
4.02a Amendment #1, dated as of December 9, 2003, to the Stockholder Protection Rights Agreement between the registrant and Registrar and Transfer Company as Rights Agent (Filed as Exhibit 4 to the Company’s Current Report on Form 8-K dated December 9, 2003, Filing No. 1-11037, and incorporated herein by reference.)
4.03 Indenture, dated as of July 15, 1992, between Praxair, Inc. and State Street Bank and Trust Company, successor trustee to Fleet Bank of Connecticut and the ultimate successor trustee to Bank of America Illinois (formerly Continental Bank, National Association) (Filed as Exhibit 4 to the Company's Form 10-Q for the quarter ended June 30, 1992, Filing No. 1-11307, and incorporated herein by reference).
4.04 Copies of the agreements relating to long-term debt which are not required to be filed as exhibits to this Annual Report on Form 10-K will be furnished to the Securities and Exchange Commission upon request.
4.05 Series A Preferred Stock Certificate. (Filed on February 7, 1997 as Exhibit 4.3 to Amendment #1 to the Company's Registration Statement on Form S-3, Registration No. 333-18141).
4.06 Series B Preferred Stock Certificate. (Filed on February 7, 1997 as Exhibit 4.4 to Amendment #1 to the Company's Registration Statement on Form S-3, Registration No. 333-18141).
*10.01 Amended and Restated 2002 Praxair, Inc. Long Term Incentive Plan.

14


INDEX TO EXHIBITS (Continued)

Praxair, Inc. and Subsidiaries


    Exhibit No.           Description

*10.02 Form of Executive Severance Compensation Agreement.
*10.03 2002 Praxair, Inc. Variable Compensation Plan (Filed as Exhibit 10.03 to the Company's 2001 Annual Report on Firm 10-K, Filing No. 1-11037, and incorporated herein by reference).
*10.04 Amended and Restated 1995 Stock Option Plan for Non-Employee Directors.
*10.05 Special Severance Protection Program (Filed as Exhibit 10.05 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
*10.06 Amended and Restated Praxair, Inc. Director’s Fees Deferral Plan.
*10.07 Amended and Restated 1993 Praxair Compensation Deferral Program (Filed as Exhibit 10.07 to the Company's 1996 Annual Report on Form 10-K, Filing No. 1-11037, and incorporated herein by reference).
*10.07a First Amendment, dated as of April 1, 2001, to the Amended and Restated 1993 Praxair Compensation Deferral Program (Filed as Exhibit 10.07a to the Company's 2001 Annual Report on Firm 10-K, Filing No. 1-11037, and incorporated herein by reference).
*10.07b Second Amendment, dated as of October 28, 2003, to the Amended and Restated 1993 Praxair Compensation Deferral Program.
10.08 Transfer Agreement dated January 1, 1989, between Union Carbide Corporation and the registrant  (Filed as Exhibit 10.06 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
10.08a Amendment No. 1 dated as of December 31, 1989, to the Transfer Agreement (Filed as Exhibit 10.07 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
10.08b Amendment No. 2 dated as of July 2, 1990, to the Transfer Agreement (Filed as Exhibit 10.08 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
10.08c Amendment No. 3 dated as of January 2, 1991, to the Transfer Agreement (Filed as Exhibit 10.09 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).

15


INDEX TO EXHIBITS (Continued)

Praxair, Inc. and Subsidiaries


    Exhibit No.           Description

10.09 Transfer Agreement dated January 1, 1989, between Union Carbide Corporation and Union Carbide Coatings Service Corporation (Filed as Exhibit 10.14 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
10.09a Amendment No. 1 dated as of December 31, 1989, to the Transfer Agreement (Filed as Exhibit 10.15 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
10.09b Amendment No. 2 dated as of July 2, 1990, to the Transfer Agreement (Filed as Exhibit 10.16 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
10.10 Additional Provisions Agreement dated as of June 4, 1992 (Filed as Exhibit 10.21 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
10.11 Amended and Restated Realignment Indemnification Agreement dated as of June 4, 1992 (Filed as Exhibit 10.23 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
10.12 Environmental Management, Services and Liabilities Allocation Agreement dated as of January 1, 1990 (Filed as Exhibit 10.13 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
10.12a Amendment No. 1 to the Environmental Management, Services and Liabilities Allocation Agreement dated as of June 4, 1992 (Filed as Exhibit 10.22 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
10.13 Danbury Lease-Related Services Agreement dated as of June 4, 1992 (Filed as Exhibit 10.24 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
10.13a First Amendment to Danbury Lease-Related Services Agreement (Filed as Exhibit 10.13a to the Company's 1994 Annual Report on Form 10-K, Filing No. 1-11037, and incorporated herein by reference).
10.14 Danbury Lease Agreements, as amended (Filed as Exhibit 10.26 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
10.14a Second Amendment to Linde Data Center Lease (Danbury) (Filed as Exhibit 10.14a to the Company's 1993 Annual Report on Form 10-K, Filing No. 1-11037, and incorporated herein by reference).
10.14b Fourth Amendment to Carbide Center Lease (Filed as Exhibit 10.14b to the Company's 1993 Annual Report on Form 10-K, Filing No. 1-11037, and incorporated herein by reference).
10.14c Third Amendment to Linde Data Center Lease (Filed as Exhibit 10.14c to the Company's 1994 Annual Report on Form 10-K, Filing No. 1-11037, and incorporated herein by reference).

16


INDEX TO EXHIBITS (Continued)

Praxair, Inc. and Subsidiaries


    Exhibit No.           Description

10.14d Fifth Amendment to Carbide Center Lease (Filed as Exhibit 10.14d to the Company's 1994 Annual Report on Form 10-K, Filing No. 1-11037, and incorporated herein by reference).
10.15 Employee Benefits Agreement dated as of June 4, 1992 (Filed as Exhibit 10.25 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
10.15a First Amendatory Agreement to the Employee Benefits Agreement (Filed as Exhibit 10.15a to the Company's 1994 Annual Report on Form 10-K, Filing No. 1-11037, and incorporated herein by reference).
10.16 Tax Disaffiliation Agreement dated as of June 4, 1992 (Filed as Exhibit 10.20 to the Company's Registration Statement on Form 10, Filing No. 1-11037, and incorporated herein by reference).
10.17 Credit Agreement dated as of July 12, 2000 among Praxair, Inc,, The Banks Party Thereto, Morgan Guaranty Trust Company of New York, Bank of America, N. A. and Credit Suisse First Boston as Co-Syndication Agents and The Chase Manhattan Bank as Administrative Agent (Filed as Exhibit 10.17b to the Company's 2000 Annual Report on Form 10-K, Filing No. 1-11037, and incorporated herein by reference).
*10.19 Praxair, Inc. Plan for Determining Performance-Based Awards Under Section 162(m)  (Filed as Exhibit 10.19 to the Company's 2001 Annual Report on Form 10-K, Filing No. 1-11037, and incorporated herein by reference).
12.01 Computation of Ratio of Earnings to Fixed Charges.
13.01 Praxair's 2003 Annual Report to Shareholders (such report, except for those portions which are expressly referred to in this Form 10-K, is furnished for the information of the Commission and is not deemed "filed" as part of this Form 10-K).
21.01 Subsidiaries of Praxair, Inc.
23.01 Consent of Independent Accountants.
32.01 Rule 13a-14(a) Certification.
32.02 Rule 13a-14(a) Certification.

Copies of exhibits incorporated by reference can be obtained from the SEC and are located in SEC File No. 1-11037.

* Indicates a management contract or compensatory plan or arrangement.

17


2002 PRAXAIR, INC. LONG TERM INCENTIVE PLAN

Praxair, Inc. and Subsidiaries


Exhibit 10.01

Amended and Restated
As of February 24, 2004

Section 1. Purpose. The purpose of the 2002 Praxair, Inc. Long Term Incentive Plan (hereinafter referred to as the “Plan”) is to (a) advance the interests of Praxair, Inc. (the “Company”) and its stockholders by providing incentives and rewards to those employees who are in a position to contribute to the long term growth and profitability of the Company; (b) assist the Company and its subsidiaries and affiliates in attracting, retaining, and developing highly qualified employees for the successful conduct of their business; and (c) make the Company’s compensation program competitive with those of other major employers.

Section 2. Definitions.

               2.1 A “Change in Control of the Company” shall be deemed to occur if any of the following circumstances shall occur:

(i)  

individuals who, on January 1, 2003, constitute the Board (the “Incumbent Directors”) cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director subsequent to January 1, 2003, whose election or nomination for election was approved by a vote of at least two-thirds of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without objection to such nomination) shall be an Incumbent Director; provided, however, that no individual elected or nominated as a director of the Company initially as a result of an actual or threatened election contest with respect to directors or any other actual or threatened solicitation of proxies or consents by or on behalf of any person other than the Board shall be deemed an Incumbent Director;


(ii)  

any “person” (as such term is defined in Section 3(a)(9) of the Securities Exchange Act of 1934 (the “Exchange Act”) and as used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act) is or becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 20% or more of the combined voting power of the Company’s then outstanding securities eligible to vote for the election of the Board (the “Company Voting Securities”); provided, however, that the event described in this paragraph (ii) shall not be deemed to be a Change in Control by virtue of any of the following acquisitions, (A) by the Company or any Subsidiary; (B) by any employee benefit plan sponsored or maintained by the Company or Subsidiary; (C) by any underwriter temporarily holding securities pursuant to an offering of such securities; (D) pursuant to a Non-Qualifying Transaction (as defined in paragraph (iii)); or (E) pursuant to any acquisition by a Participant (as defined in Section 2.11) or any group of persons including a Participant (or any entity controlled by a Participant or any group of persons including a Participant);


(iii)  

the consummation of a merger, consolidation, share exchange or similar form of corporate transaction involving the Company or any of its Subsidiaries that requires the approval of the Company’s stockholders, whether for such transaction or the issuance of securities in the transaction (a “Business Combination”), unless immediately following such Business Combination (A) more than 50% of the total voting power of (x) the corporation resulting from such Business Combination (the “Surviving Corporation”); or (y) if applicable, the ultimate parent corporation that directly or indirectly has beneficial ownership of 100% of the voting securities eligible to elect directors of the Surviving Corporation (the “Parent Corporation”), is represented by Company Voting Securities that were outstanding immediately prior to such Business Combination (or, if applicable, shares into which such Company Voting Securities were converted pursuant to such Business Combination), and such voting power among the holders thereof is in substantially the


1




same proportion as the voting power of such Company Voting Securities among the holders thereof immediately prior to the Business Combination; (B) no person (other than any employee benefit plan sponsored or maintained by the Surviving Corporation or the Parent Corporation), is or becomes the beneficial owner, directly or indirectly, of 20% or more of the total voting power of the outstanding voting securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation); and (C) at least a majority of the members of the board of directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation) were Incumbent Directors at the time of the Board’s approval of the execution of the initial agreement providing for such Business Combination (any Business Combination which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a “Non-Qualifying Transaction”); or

(iv)  

The stockholders of the Company approve a plan of complete liquidation or dissolution of the Company or a sale or disposition of all or substantially all of the Company’s assets.


               Notwithstanding the foregoing, a Change in Control of the Company shall not be deemed to occur solely because any person acquires beneficial ownership of more than 20% of the Company Voting Securities as a result of the acquisition of Company Voting Securities by the Company which reduces the number of Company Voting Securities outstanding; provided, that if after such acquisition by the Company such person becomes the beneficial owner of additional Company Voting Securities that increases the percentage of outstanding Company Voting Securities beneficially owned by such person, a Change in Control of the Company shall then occur.

               2.2 “Code” means the Internal Revenue Code of 1986, as now or hereafter amended.

               2.3 “Committee” shall mean the Compensation and Management Development Committee of the Board of Directors of the Company or such other Committee appointed by the Board for the purpose of administering this Plan comprising two or more members of the Board who are “non-employee” directors within the meaning of Rule 16b-3 under the Exchange Act.

               2.4 “Disability” means a Participant’s inability to engage in any substantial gainful activity because of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted, or can be expected to last, for a continuous period of six months or longer.

               2.5 “Eligible Employee” means any employee of the Company or of a participating Subsidiary or Affiliate of the Company except those union-represented employees where no agreement has been reached with their collective bargaining representative for their participation in this Plan. No “Eligible Employee” shall be a member of the Committee.

               2.6 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

               2.7 “Executive Officer” shall mean an Executive Officer of the Company, as such term is defined within the meaning of the Exchange Act or for purposes of Section 16 of the Exchange Act.

               2.8 “Incentive Stock Option” means any stock option granted pursuant to this Plan which is designated as such by the Committee and which complies with Section 422 of the Code.

               2.9 “Market Price” is the mean of the high and low prices of the Common Stock of the Company as reported in the New York Stock Exchange-Composite Transactions on the date for which a Market Price is to be determined under this Plan (or on the next preceding day such Stock was traded on a stock exchange included in the New York Stock Exchange-Composite Transactions if it was not traded on any such exchange on such date).

               2.10 “Non-Qualified Stock Option” means any stock option granted pursuant to this Plan which is not an Incentive Stock Option.

               2.11 “Participant” shall mean an individual selected to participate in the Plan pursuant to Section 3.

2



               2.12 “Performance Award” shall mean a payment pursuant to Section 8 herein.

               2.13 “Restricted Stock” means Stock of the Company subject to restrictions on the transfer of such Stock, conditions for forfeiture of such Stock, or any other limitations or restrictions as determined by the Committee.

               2.14 “Retirement” shall mean termination of employment with the Company or a Subsidiary or Affiliate, other than for cause, with the right to receive immediately a non- actuarially reduced pension under the Company’s Retirement Program; provided, however, that if the Participant is employed by a foreign affiliate of the Company and/or is not eligible to participate in the Company’s Retirement Program, “Retirement” shall mean termination of employment with the Company or a Subsidiary or Affiliate, other than for cause, after the Participant has (i) attained age 65; (ii) attained age 62 and completed at least 10 years of employment with the Company; or (iii) accumulated 85 points, where each year of the Participant’s age and each year of employment with the Company count for one point.

               2.15 “Stock” shall mean the Common Stock, $0.01 par value, of the Company.

               2.16 “Subsidiary” and “Affiliate” of the Company each shall mean any entity in which the Company has a 50% or greater ownership interest, directly or indirectly.

Section 3. Participation. The Participants in the Plan (“Participants”) shall be those Eligible Employees who are selected to participate in the Plan by the Committee. Any Eligible Employee, or each member of any group of Eligible Employees, to whom the Committee by resolution has granted an award (or as to whom the Committee has delegated to the Chief Executive Officer the right to allocate awards pursuant to Section 4) shall be deemed a Participant with respect to such award.

Section 4. Administration. The Plan shall be administered and interpreted by the Committee, which shall have sole authority to make rules and regulations for the administration of the Plan. The interpretations and decisions of the Committee with regard to the Plan shall be final and conclusive and binding upon all Participants. The Committee may request advice or assistance or employ such persons (including without limitation, legal counsel and accountants) as it deems necessary for the proper administration of the Plan. The Committee shall (i) determine the number and types of awards to be made under the Plan; (ii) select the awards to be made to Participants; (iii) set the exercise price, the number of options to be awarded, and the number of shares to be awarded out of the total number of shares available for award; (iv) delegate to the Chief Executive Officer of the Company the right to allocate awards among Eligible Employees who are not Executive Officers of the Company, such delegation to be subject to such terms and conditions as the Committee in its discretion shall determine; (v) establish administrative regulations to further the purpose of the Plan; and (vi) take any other action desirable or necessary to interpret, construe or implement properly the provisions of the Plan.

Section 5. Awards.

               5.1   Types of Awards . Awards under this Plan may be in any of the following forms (or a combination thereof) (i) stock option awards; (ii) grants of Stock or Restricted Stock; or (iii) Performance Awards. All awards shall be made pursuant to award agreements between the Participant and the Company. The agreements shall be in such form as the Committee approves from time to time.

               5.2   Maximum Amount Available. The total number of shares of Stock (including Restricted Stock, if any) optioned or granted under this Plan during the term of the Plan shall not exceed 15,800,000 shares. Solely for the purpose of computing the total number of shares of stock optioned or granted under this Plan, there shall not be counted (i) any shares which have been forfeited; (ii) any shares covered by an option which, prior to such computation, has terminated in accordance with its terms or has been cancelled by the Participant or the Company; and (iii) any shares otherwise deliverable

3


to a Participant or his/her transferee upon exercise of an option, or upon the grant or vesting of a Stock Award (as defined in Section 7.1), which are withheld by the Company in order to satisfy tax withholding or exercise price obligations. In addition, there shall be credited to the number of authorized shares remaining for grant or option under this Plan, any share which is delivered to the Company by a Participant or his/her transferee in satisfaction of tax withholding or exercise payment obligations.

               5.3   Adjustment in the Event of Recapitalization, etc. In the event of any change in the outstanding shares of the Company by reason of any stock split, stock dividend, recapitalization, merger, consolidation, combination or exchange of shares or other similar corporate change or in the event of any special distribution to the stockholders, the Committee shall make such equitable adjustments in the number of shares and prices per share applicable to options then outstanding and in the number of shares which are available thereafter for Stock Option Awards (as defined in Section 6.1) or other awards, both under the Plan as a whole and with respect to individuals and award type, as the Committee determines are necessary and appropriate. Any such adjustment shall be conclusive and binding for all purposes of the Plan.

Section 6. Stock Options.

               6.1   Award Types. The Company may award options to purchase the Common Stock of the Company (hereinafter referred to as “Stock Option Awards”) to such Participants as the Committee (or the Chief Executive Officer of the Company, if the Committee in its discretion delegates the right to allocate awards pursuant to Section 4) authorizes and under such terms as the Committee establishes. The Committee shall determine with respect to each Stock Option Award, and designate in the grant, whether a Participant is to receive an Incentive Stock Option or a Non-Qualified Stock Option.

               6.2   Per-Participant Limits. The maximum number of shares of Stock with respect to which Stock Option Awards may be granted under this Plan during any calendar year to any Participant is 1,000,000 except in the case of a multi-year grant, in which case the maximum number of shares for the Participant shall be 1,000,000 times the number of years during which the Participant is not to receive any additional grants of Stock Option Awards.

               6.3    Exercise Price. The exercise price of each share of Stock subject to a Stock Option Award shall be specified in the grant, but in no event shall the exercise price be less than the closing price of the Common Stock of the Company on the date the award is granted as reported in the New York Stock Exchange-Composite Transactions. If the Participant to whom an Incentive Stock Option is granted owns, at the time of the grant, more than ten percent (10%) of the combined voting power of the Participant’s employer or a parent or subsidiary of the employer, the exercise price of each share of Stock subject to such grant shall be not less than one hundred ten percent (110%) of the closing price described in the preceding sentence.

               6.4   Repricing. Without the prior approval of the Company’s shareholders, (a) the exercise price of any Stock Option Award granted pursuant to this Plan shall not be changed following the date of its grant, other than such equitable changes as may arise in connection with the adjustments permitted under Section 5.3 and no Stock Option Award may be cancelled and replaced with a new Stock Option Award with a lower exercise price where the economic effect would be the same as reducing the exercise price of the cancelled option.

         6.5  Transferability .

        (a) Stock Option Awards shall not be transferable by the Participant other than:

(i)  

In the case of the Participant’s death, pursuant to the beneficiary designation then on file with the Company, or, in the absence of such a beneficiary designation (or if the


4


designated beneficiary has pre-deceased the Participant), by will or the laws of descent and distribution (in which case the Company without liability to any other person, may rely on the directions of the executor or administrator of the Participant’s estate with respect to the disposition or exercise of such options);

(ii)  

In the Committee’s discretion, the terms of a Non-Qualified Stock Option may permit the Participant to transfer the Stock Option Award to (w) his or her spouse, children (including by adoption), stepchildren or grandchildren (referred to herein as the Participant’s “Family Members”), (x) a trust or trusts for the exclusive benefit of such Family Members, (y) a partnership in which such Family Members are the only partners, or (z) such other persons or entities as the Committee may approve on a case-by-case basis; or


(iii)  

In the case of a transferee’s death, to his/her estate without rights to further distribution.


        (b) Any transfer pursuant to this Section 6.5 shall be subject to the following:

(i)  

there may be no consideration for any such transfer;


(ii)  

the stock option agreement pursuant to which such Stock Option Award is granted must be approved by the Committee, and must expressly provide for transferability in a manner consistent with this Section 6.5; and


(iii)  

subsequent transfers of transferred Stock Option Awards shall be prohibited except those in accordance with this Section 6.5.


        (c) Following transfer, any transferred Stock Option Award shall continue to be subject to the same terms and conditions as were applicable immediately prior to transfer. The events of death, Disability, Retirement and termination of employment with respect to an outstanding Stock Option Award shall be in relation to the original grantee Participant notwithstanding an earlier transfer of the Stock Option Award. Following such events, the Stock Option Award shall be exercisable by the transferee only to the extent and for the periods specified in Sections 6.7 and 6.8 hereof.

        6.6 Duration of Stock Option Awards. A Stock Option Award by its terms shall be of no more than ten (10) years’ duration, except that an Incentive Stock Option granted to a Participant who, at the time of the grant, owns Stock representing more than ten percent (10%) of the combined voting power of the Participant’s employer or a parent or subsidiary of the employer shall by its terms be of no more than five (5) years’ duration.

        6.7 Initial Vesting. A Stock Option Award by its terms shall be exercisable only after the earliest of:

 

     (i) such period of time as the Committee shall determine and specify in the grant, but in no event less than three years following the date of grant of such award provided that options granted may partially vest after no less than one year so long as the entire grant does not vest fully until at least three years have elapsed from the date of grant;


 

     (ii) the Participant’s death; or


 

     (iii) a Change in Control of the Company.


In the event of the Participant’s Disability or Retirement or the termination by the Company of the Participant’s employment other than for cause, a Stock Option Award shall not be exercisable at the time of such event but shall become exercisable at the time specified in clauses (i), (ii) and (iii) above. Notwithstanding the foregoing, in the event of a Participant’s Retirement prior to the first anniversary

5


date after the date of a Stock Option Award, such Stock Option Award shall not vest but shall be immediately forfeited.








6




               6.8   Exercise Period. A Stock Option Award is only exercisable by a Participant (or, if the Stock Option Award has been duly transferred pursuant to Section 6.5, the transferee) while the Participant is in active employment with the Company, or its Subsidiary or Affiliate, except:

(i)  

in the case of a Participant’s death, the Stock Option Award shall remain exercisable by the transferee of the award during a three (3) year period following the date of death;


(ii)  

in the case of a Participant’s Retirement or Disability, the Stock Option Award, to the extent not forfeited in accordance with Section 6.7 above, shall remain exercisable during the original grant duration as specified in the grant agreement;


(iii)  

in the case of termination by the Company of the Participant’s employment other than for cause, the Stock Option Award shall remain exercisable during a three (3) year period commencing on the effective date of such termination;


(iv)  

in the case of termination by the Participant or the Company, of the Participant’s employment within two (2) years after a Change in Control of the Company, unless such termination of employment is for cause, the Stock Option Award shall remain exercisable during a three-year period commencing on the effective date of termination; or


(v)  

if the Committee decides that it is in the best interest of the Company to permit individual exceptions.


               In no event may a Stock Option Award be exercised after its expiration date.

               For purposes of this Plan, the employment of individuals employed by a Subsidiary or Affiliate of the Company shall be deemed to have been terminated by the Company at such time as the Company ceases to hold, either directly or indirectly, at least 50% of the total ownership interests of the entity.

               6.9    Manner of Exercise. A Stock Option Award may be exercised by the Participant (or, if the Stock Option Award has been duly transferred pursuant to Section 6.5, the transferee) with respect to part or all of the shares subject to the option by giving written notice to the Company or its designee of the exercise of the option according to such procedures as the Vice President, Human Resources may establish.

               6.10   Payment of Exercise Price. The exercise price for the shares for which an option is exercised shall be paid by the exerciser within ten (10) business days after the date of exercise and the terms of the Stock Option Award may provide that the exercise price may be paid:

(a)  

in cash;


(b)  

in whole shares of Common Stock of the Company owned by the exerciser prior to exercising the option;


(c)  

by having the Company withhold shares that otherwise would be delivered to the exerciser pursuant to the exercise of the option in an amount equaling in value the exercise price;


(d)  

in a combination of either cash and delivery of shares, or cash and withholding of shares; or


(e)  

by whatever other means the Committee may deem appropriate, other than by a loan by the Company to the exerciser.


               The Company shall establish procedures in connection with payments pursuant to (b), (c), (d), and (e) above, to ensure that the Plan does not become subject to variable accounting by virtue of such payment methods. The value of any share of Common Stock delivered or withheld in payment of the exercise price shall be its Market Price on the date the option is exercised.

7


        6.11   Limits on Incentive Stock Options. The aggregate fair market value of all shares of Stock with respect to which Incentive Stock Options are exercisable for the first time by a Participant in any one calendar year, under this Plan or any other stock option plan maintained by the Company (or by any subsidiary or parent of the Company), shall not exceed $100,000. The fair market value of such shares of Stock shall be the mean of the high and low prices of the common Stock of the Company as reported in the New York Stock Exchange- Composite Transactions on the date the related Stock Option Award is granted (or on the next preceding day such Stock was traded on a stock exchange included in the New York Stock Exchange-Composite Transactions if it was not traded on any such exchange on the date the related stock option is granted).

        6.12    Payment of Taxes. To enable the Company to meet any applicable federal, state or local withholding tax requirements arising as a result of the exercise of a Stock Option Award, whether exercised by the Participant or his/her transferee, a Participant or the Participant’s estate shall pay to the Company the amount of tax to be withheld, or may elect to satisfy such obligation:

        (a) by delivering to the Company other shares of Common Stock of the Company owned by the Participant prior to exercising the option;

        (b) by making a payment to the Company consisting of a combination of cash and such shares of Common Stock; or

        (c) if the exerciser is the grantee Participant, by having the Company withhold shares that otherwise would be delivered to the Participant pursuant to the exercise of the option for which the tax is being withheld, provided that withholding by such method shall be limited to the minimum required applicable tax withholding.

        Such an election shall be made in such manner as may be prescribed by the Committee and the Committee shall have the right, in its discretion, to disapprove such election. Any such election must be made prior to the date to be used to determine the tax to be withheld and shall be irrevocable. The value of any share of Common Stock to be withheld by the Company or delivered to the Company pursuant to this Section 6.12 shall be the Market Price on the date used to determine the amount of tax to be withheld.

Section 7. Grants of Stock.

               7.1    Award Types. The Committee may grant, either alone or in addition to other awards granted under the Plan, shares of Stock or Restricted Stock (hereinafter referred to as a “Stock Award”) to such Participants as the Committee (or the Chief Executive Officer of the Company, if the Committee in its discretion delegates the right to allocate awards pursuant to Section 4) authorizes and under such terms as the Committee establishes. The Committee, in its discretion, may also make a cash payment to a Participant granted shares of Stock or Restricted Stock under the Plan to allow such Participant to satisfy tax obligations arising out of receipt of the Stock or Restricted Stock. Alternatively, the terms of the Stock or Restricted Stock grant may allow for the Participant to satisfy tax withholding obligations by the means set forth in Section 7.7.

               7.2   Aggregate and Individual Limits. Notwithstanding any provision in this Plan to the contrary, the combined number of shares granted under the Plan pursuant to Stock Awards or Performance Awards shall not exceed 20% of the maximum number of shares of Stock available for award under this Plan as provided in Sections 5.2 and 5.3. In addition, no more than 300,000 shares as a Stock Award shall be granted to one individual in a calendar year unless pursuant to a multi-year award. Grants of Stock other than Restricted Stock shall only be made in lieu of salary or cash bonus.

               7.3    Vesting Periods. A grant of Restricted Stock pursuant to this Section 7 shall be subject to a minimum vesting period of at least three (3) years, or such longer period as the Committee, in its sole

8


discretion, may determine. Notwithstanding the foregoing, the Committee may grant shares of Restricted Stock with a vesting period of at least two (2) years, or such longer period as the Committee, in its sole discretion, may determine, so long as vesting is based on performance criteria.

               7.4   Rights as a Stockholder. The Participant shall have, with respect to Restricted Stock, all of the rights of a stockholder of the Company, including the right to vote the shares and the right to receive any dividends, unless the Committee shall otherwise determine.

               7.5   Transferability. Restricted Stock may not be sold or transferred by the Participant until any restrictions that have been established by the Committee have lapsed.

               7.6    Forfeiture. Upon a termination by the Participant or the Company, of the Participant’s employment for any reason during the period any restrictions are in effect, all Restricted Stock held by the Participant shall be forfeited without compensation to the Participant unless the Committee decides that it is in the best interest of the Company to permit individual exceptions.

               7.7   Payment of Taxes. To enable the Company to meet any applicable federal, state or local withholding tax requirements arising as a result of the grant or vesting of a Stock Award, the Participant shall pay the Company the amount of tax to be withheld or may elect to satisfy such obligation:

(a)  

by having the Company withhold shares that otherwise would be delivered to the Participant pursuant to the granting or vesting of a Stock Award for which the tax is being withheld;


(b)  

by delivering to the Company other shares of Common Stock of the Company owned by the Participant prior to the grant or vesting of a Stock Award; or


(c)  

by making a payment to the Company consisting of a combination of cash and such shares of Common Stock. Such an election shall be made prior to the date to be used to determine the tax to be withheld. The value of any share of Common Stock to be withheld by the Company or delivered to the Company pursuant to this Section 7 shall be the Market Price on the date used to determine the amount of tax to be withheld. Section 8. Performance Awards.


               8.1    Award Types. The Committee may grant, either alone or in addition to other awards granted under the Plan, awards of Stock and other awards that are valued in whole or in part by reference to, or are otherwise based on, the market value of the Common Stock, or other securities of the Company (“Performance Awards”) to such Participants as the Committee (or the Chief Executive Officer of the Company, if the Committee in its discretion delegates the right to allocate awards pursuant to Section 4) authorizes and under such terms as the Committee establishes. Performance Awards may be paid in Common Stock, Restricted Stock or other securities of the Company, cash or any other form of property as the Committee shall determine.

               8.2    Terms and Conditions of Awards. Performance Awards shall entitle the Participant to receive an award if the measures of performance established by the Committee are met. The measures of performance shall be established by the Committee in its absolute discretion except that the performance measurement period shall be a period of at least twelve (12) months. The Committee shall determine the times at which Performance Awards are to be made and all conditions of such awards.

               8.3    Aggregate and Individual Limits. Notwithstanding any provision in this Plan to the contrary, the combined number of shares granted under this Plan pursuant to Performance Awards or Stock Awards shall not exceed 20% of the maximum number of shares of Stock available for award under this Plan as provided in Sections 5.2 and 5.3. In addition, no more than 300,000 shares pursuant to any

9


Performance Awards shall be granted to one individual in a calendar year unless pursuant to a multi-year award.

               8.4   Transferability. The Participant shall not be permitted to sell, assign, tra nsfer, pledge or otherwise encumber shares received pursuant to this Section 8 prior to the date on which any applicable restriction or performance period established by the Committee lapses.

               8.5   Payment of Taxes. To enable the Company to meet any applicable federal, state or local withholding tax requirements arising as a result of the vesting or payment of Performance Awards, a Participant shall pay the Company the amount of tax to be withheld or may elect to satisfy such obligation:

(a)  

by having the Company withhold shares that otherwise would be delivered to the Participant pursuant to the vesting or payment of Performance Awards for which the tax is being withheld;


(b)  

by delivering to the Company other shares of Common Stock of the Company owned by the Participant prior to the vesting or payment of Performance Awards; or


(c)  

by making a payment to the Company consisting of a combination of cash and such shares of Common Stock.


        Such an election shall be made prior to the date used to determine the tax to be withheld. The value of any share of Common Stock to be withheld by the Company or delivered to the Company pursuant to this Section 8.5 shall be the Market Price on the date used to determine the amount of tax to be withheld.

Section 9. General Provisions.

               9.1   Assignment. Subject to the provisions of Section 6.5, if applicable, any assignment or transfer of any awards without the written consent of the Company shall be null and void.

               9.2   No Trust. Nothing contained herein shall require the Company to segregate any monies from its general funds, or to create any trusts, or to make any special deposits for any immediate or deferred amounts payable to any Participant for any year.

               9.3   No Right to Employment. Participation in this Plan shall not affect the Company’s right to discharge a Participant.

               9.4   Cancellation and Rescission of Awards.

(a)  

The Committee shall have the discretion with respect to any award granted under this Plan to establish upon its grant conditions under which (i) the award may be later forfeited, cancelled, rescinded, suspended, withheld or otherwise limited or restricted; or (ii) gains realized by the grantee in connection with an award or an award’s exercise may be recovered; provided that such conditions and their consequences are (A) clearly set forth in the grant agreement or other grant document; and (B) fully comply with applicable laws. These conditions may include, without limitation, actions by the Participant which constitute a conflict of interest with the Company, are prejudicial to the Company’s interests, or are in violation of any non-compete agreement or obligation, any confidentiality agreement or obligation, the Company’s applicable policies or the Participant’s terms and conditions of employment.


(b)  

The Committee may require, upon exercise, payment or delivery pursuant to an award, that the Participant certify in a manner acceptable to the Company that he or she is in compliance with the terms and conditions of the award grant.


Section 10. Amendment, Suspension, or Termination.

10


               10.1   The Board of Directors may suspend, terminate, or amend the Plan, including, but not limited to, such amendments as may be necessary or desirable resulting from changes in the federal income tax laws and other applicable laws, but may not, without the affirmative vote of a majority of all votes duly cast on the matter at a meeting of the stockholders of the Company (provided that the total votes cast on the matter represent over 50% of the shares entitled to vote on the matter): (a) increase the total number of shares of Stock that may be optioned or granted under this Plan; (b) amend Section 6.4 with respect to re-pricing of Stock Option Awards; (c) change the eligibility requirements for participation in the Plan; or (d) adopt any other material revision to this Plan that would require the approval of the stockholders under the rules promulgated by the New York Stock Exchange.

               10.2   It is the Company’s intent that the Plan comply in all respects with Rule 16b-3 under the Exchange Act and any related regulations. If any provision of this Plan is later found not to be in compliance with such Rule and regulations, the provisions shall be deemed null and void. All grants to, and exercises of options by Executive Officers under this Plan shall be executed in accordance with the requirements of Section 16 of the Exchange Act and regulations promulgated thereunder.

Section 11. Governing Law.

        The validity, construction and effect of the Plan and any rules and regulations relating to the Plan shall be determined in accordance with the laws of the State of Connecticut and applicable federal law.

Section 12. Effective Date and Duration of the Plan.

        This Plan shall be effective as of January 1, 2002. No award shall be granted under this Plan on or after January 1, 2012.

11

EXECUTIVE SEVERANCE COMPENSATION AGREEMENT

Praxair, Inc. and Subsidiaries


Exhibit 10.02

December 5, 2003

NAME
ADDRESS

Dear Mr.    :

        The Board of Directors (the “Board”) of Praxair, Inc. (“Praxair”) recognizes that the possibility of a Change in Control of Praxair exists, and the uncertainty and questions which it may raise among management may result in the departure or distraction of management personnel to the detriment of Praxair or its majority-owned subsidiaries incorporated in the United States (hereinafter to be referred to collectively as the “Company”).

        The Board of Praxair has determined that appropriate steps should be taken to reinforce and encourage the continued attention and dedication of members of the Company’s management, including yourself, to their assigned duties without distraction in the face of potentially disturbing circumstances arising from a possible Change in Control of Praxair.

        In order to induce you to remain in the employ of the Company and in consideration of your continued service to the Company, Praxair agrees that you shall receive the severance benefits set forth in this Severance Compensation Agreement (“Agreement”) in the event your employment with the Company is terminated subsequent to a Change in Control under the circumstances described below.

        1. Definitions .

                     a." Change in Control " means the occurrence of any one of the following events with respect to Praxair:

(i)

individuals who, on January 1, 2003, constitute the Board (the “Incumbent Directors”) cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director subsequent to January 1, 2003, whose election or nomination for election was approved by a vote of at least two-thirds of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without objection to such nomination) shall be an Incumbent Director; provided , however , that no individual elected or nominated as a director of the Company initially as a result of an actual or threatened election contest with respect to directors or any other actual or threatened solicitation of proxies [or consents] by or on behalf of any person other than the Board shall be deemed an Incumbent Director;


(ii)

any “person” (as such term is defined in Section 3(a)(9) of the Securities Exchange Act of 1934 (the “Exchange Act”) and as used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act) is or becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 20% or more of the combined voting power of the Company’s then outstanding securities eligible to vote for the election of the Board (the “Company Voting Securities”); provided , however , that the event described in this paragraph (ii) shall not be deemed to be a Change in Control by virtue of any of the following acquisitions: (A) by the Company or any Subsidiary, (B) by any employee benefit plan sponsored or maintained by the



 

Company or Subsidiary, (C) by any underwriter temporarily holding securities pursuant to an offering of such securities, or (D) pursuant to a Non-Qualifying Transaction (as defined in paragraph (iii));


(iii)

the consummation of a merger, consolidation, statutory share exchange or similar form of corporate transaction involving the Company or any of its Subsidiaries that requires the approval of the Company’s stockholders, whether for such transaction or the issuance of securities in the transaction (a “Business Combination”), unless immediately following such Business Combination: (A) more than 50% of the total voting power of (x) the corporation resulting from such Business Combination (the “Surviving Corporation”), or (y) if applicable, the ultimate parent corporation that directly or indirectly has beneficial ownership of 100% of the voting securities eligible to elect directors of the Surviving Corporation (the “Parent Corporation”), is represented by Company Voting Securities that were outstanding immediately prior to such Business Combination (or, if applicable, shares into which such Company Voting Securities were converted pursuant to such Business Combination), and such voting power among the holders thereof is in substantially the same proportion as the voting power of such Company Voting Securities among the holders thereof immediately prior to the Business Combination, (B) no person (other than any employee benefit plan sponsored or maintained by the Surviving Corporation or the Parent Corporation), is or becomes the beneficial owner, directly or indirectly, of 20% or more of the total voting power of the outstanding voting securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation) and (C) at least a majority of the members of the board of directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation) were Incumbent Directors at the time of the Board’s approval of the execution of the initial agreement providing for such Business Combination (any Business Combination which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a “Non-Qualifying Transaction”); or


(iv)

The stockholders of the Company approve a plan of complete liquidation or dissolution of the Company or a sale or disposition of all or substantially all of the Company’s assets.


Notwithstanding the foregoing, a Change in Control of the Company shall not be deemed to occur solely because any person acquires beneficial ownership of more than 20% of the Company Voting Securities as a result of the acquisition of Company Voting Securities by the Company which reduces the number of Company Voting Securities outstanding; provided, that if after such acquisition by the Company such person becomes the beneficial owner of additional Company Voting Securities that increases the percentage of outstanding Company Voting Securities beneficially owned by such person, a Change in Control of the Company shall then occur.


                     b. " Code " shall mean the Internal Revenue Code of 1986, as amended.

                     c. " Date of Termination " shall mean

(i)

in case employment is terminated for Total Disability, thirty (30) days after Notice of Termination is given (provided that you shall not have returned to the full-time performance of your duties during such thirty (30) day period), and


(ii)

in all other cases, the date specified in the Notice of Termination (which shall not be less than thirty (30) nor more than sixty (60) days, respectively, from the date such Notice of Termination is given).


               d. " Good Reason for Resignation " shall mean, without your express written consent, any of the following:

2


(i)

a change in your status or position with the Company which in your reasonable judgment does not represent a promotion from your status or position immediately prior to the Change in Control, or the assignment to you of any duties or responsibilities or diminution of duties or responsibilities which in your reasonable judgment are inconsistent with your status or position with the Company in effect immediately prior to the Change in Control, it being understood that any of the foregoing in connection with termination of your employment for Cause, Retirement, or Total Disability shall not constitute Good Reason for Resignation;


(ii)

a reduction by the Company in the annual rate of your base salary as in effect immediately prior to the date of a Change in Control or as the same may be increased from time to time thereafter, or the Company's failure to increase the annual rate of your base salary for a calendar year in an amount at least equal to the percentage increase in base salary for all domestic employees of the Company with Severance Compensation Agreements in the preceding calendar year. Within three (3) days after your request, the Company shall notify you of the average percentage increase in base salary for all such employees of the Company in the calendar year preceding your request;


(iii)

the Company's requiring your office to be located at a different place than where your office is located immediately prior to a Change in Control where the relocation would meet the Code's standards for the exclusion of reimbursed moving expenses from taxable income, except for required travel on the Company's business to an extent substantially consistent with your business travel obligations immediately prior to a Change in Control;


(iv)

the failure by the Company to continue in effect compensation or benefit plans in which you participate, which in the aggregate provide you compensation and benefits substantially equivalent to those prior to a Change in Control;


(v)

the failure of the Company to obtain a satisfactory agreement from any Successor (as defined in Paragraph 4a hereof) to assume and agree to perform this Agreement, as contemplated in Paragraph 4a hereof;


(vi)

any purported termination of your employment which is not effected pursuant to a Notice of Termination satisfying the requirements hereof; for purposes of this Agreement, no such purported termination shall be effective for any purpose except to constitute a Good Reason for Resignation.


               e. "Incentive Compensation Award" shall mean payment or payments under Incentive Compensation Plans.

               f. “ Incentive Compensation Plans ” shall mean any annual variable compensation or incentive compensation plans maintained by the Company, in which awards are paid in cash including, but not limited to the 2002 Praxair, Inc. Variable Compensation Plan, or any successor plan thereto.

               g. " Notice of Termination " shall mean a written notice as provided in Paragraph 10 hereof.

               h. " Pension Plan " shall mean the Praxair Pension Plan, as it may be amended prior to a Change in Control.

               i. " Pension Program " shall mean the Pension Plan plus any excess or supplemental pension plans maintained by the Company.

               j. " Account-Based Participant " shall mean a participant in the Pension Plan accruing an Account-Based benefit under the Pension Plan.

3


               k. " Traditional-Design Participant " shall mean a participant in the Pension Plan accruing a benefit under the Pension Plan other than an Account-Based benefit.

               l. “ Retirement ” shall mean (1) voluntary retirement before your mandatory retirement age, if any, (termination of your employment by you before your mandatory retirement age, if any, with Good Reason for Resignation shall not be deemed a Retirement for purposes of this Agreement) or (2) termination in accordance with any retirement arrangement other than under the Pension Program, which is established with your consent with respect to you or (3) mandatory retirement as set forth under the policy of the Company as it existed prior to the Change in Control or as agreed to by you following a Change in Control.

               m. “ Termination for Cause ” shall mean termination of your employment upon your willfully engaging in conduct demonstrably and materially injurious to the Company, monetarily or otherwise, provided that there shall have been delivered to you a copy of a resolution duly adopted by the unanimous affirmative vote of the entire membership of the Board of the Company at a meeting of the Board of the Company called and held for such purpose (after reasonable notice to you and an opportunity for you, together with your counsel, to be heard before the Board of the Company), finding that in the good faith opinion of the Board of the Company you were guilty of the conduct set forth and specifying the particulars thereof in detail.

        For purposes of this Paragraph 1m, no act, or failure to act, on your part shall be deemed “willful” unless done, or omitted to be done, by you not in good faith and without reasonable belief that your action or omission was in the best interest of the Company. Any act or failure to act based upon authority given pursuant to a resolution duly adopted by the Board of the Company or based upon the advice of counsel for the Company shall be conclusively presumed to be done or omitted to be done by you in good faith and in the best interests of the Company.

               n. “ Total Disability ” shall mean that based on objective medical evidence, as the result of an illness or injury you cannot perform the essential functions of your regular job for a period of six months or more, with or without an accommodation; and you are under the “regular and appropriate care” of a physician. “Regular and Appropriate Care” means that you are being treated by a physician as often as is medically required, and are receiving care that conforms to generally accepted medical standards for treating the sickness or injury; is consistent with the stated severity of the medical condition to effectively treat this illness or injury; and , is provided by a physician whose specialty or experience is the most appropriate for the disability according to generally accepted medical practics.

        2. Compensation Upon Termination . Following a Change in Control, you shall be entitled to the following benefits:

               a. Termination Benefits . If your employment by the Company shall be terminated subsequent to the Change in Control and during the term of this Agreement (a) by reason of your death after you have received a Notice of Termination, (b) by the Company other than for Cause, or (c) by you for Good Reason for Resignation, then you shall be entitled to the benefits provided below, without regard to any contrary provision of any plan:

(i)

Accrued Salary . The Company shall pay you, not later than the fifth (5th) day following the Date of Termination, your full base salary and vacation pay accrued through the Date of Termination at the rate in effect at the time the Notice of Termination is given (or at the rate in effect immediately prior to a Change in Control, if such amounts were higher).


(ii)

Accrued Incentive Compensation . The Company shall pay you, not later than thirty (30) days following your Date of Termination, the amount of your Accrued Incentive Compensation. If the Date of Termination is after the end of a Variable Compensation Year, but before Incentive Compensation for said Variable Compensation Year has been paid, the Company shall pay you as Incentive Compensation for that Variable Compensation Year the greatest of: (a) an amount that bears the same ratio to your total base salary in said Variable Compensation Year as the Incentive Compensation paid to you during the immediately prior Variable Compensation Year bears to your base salary for said prior Variable Compensation Year, (b) an amount that bears the same ratio to your base salary for such Variable Compensation Year as the Incentive Compensation paid to you during the three (3) immediately prior Variable Compensation Years bears to your base salary for said three (3) prior years, (c) the average of the Incentive Compensation paid to you during the three (3) years immediately prior to said Variable Compensation Year, or (d) the amount of your target variable compensation payment for such Variable Compensation Year.


In addition, if the Date of Termination is other than the first day of a Variable Compensation Year, the Company shall pay you, as Incentive Compensation for the Variable Compensation Year in which the Date of Termination occurs, the greatest of: (a) an amount that bears the same ratio to your total base salary earned (up to the Date of Termination) in said Variable Compensation Year as the Incentive Compensation paid to you during the immediately prior Variable Compensation Year bears to your base salary for said prior Variable Compensation Year, (b) an amount that bears the same ratio to your total base salary earned (up to the Date of Termination) for such Variable Compensation Year as the Incentive Compensation paid to you during the three (3) Variable Compensation Years immediately prior to such Variable Compensation Year bears to your base salary for said three (3) prior years, (c) the average of the Incentive Compensation paid to you during the three (3) years immediately prior to said Variable Compensation Year multiplied by a fraction, the numerator of which is the total number of days which have elapsed in the current Variable Compensation Year to the Date of Termination, and the denominator of which is three hundred sixty-five (365), or (d) the amount of your target variable compensation payment for such Variable Compensation Year multiplied by a fraction, the numerator of which is the total number of days which have elapsed in the current Variable Compensation Year to the Date of Termination, and the denominator of which is three hundred sixty-five (365). Such payment shall be made to you not later than thirty (30) days after the Date of Termination.


If there is more than one Incentive Compensation Program, your accrued Incentive Compensation under each Program shall be determined individually for that Program.


For the purpose of determining the amount of your Accrued Incentive Compensation under this Paragraph 2a(ii), you will be deemed to have been paid the full amount of all prior variable and incentive compensation, whether or not such award was includible in your gross income for Federal Income tax purposes.


For the purpose of this Paragraph 2a(ii), "Incentive Compensation Program" means any of the Incentive Compensation Plans defined in Paragraph 1f and any other plan or program for the payment of incentive compensation, variable compensation, bonus, benefits or awards for which you were, or your position was, eligible to participate; "Incentive Compensation" means any compensation, variable compensation, bonus, benefit or award paid or payable under an Incentive Compensation Program; and "Variable Compensation Year" means a calendar or fiscal plan year of an Incentive Compensation Program.


(iii)

Insurance Coverage . The Company shall arrange to provide you (and your dependents, if applicable) with life, accident and health insurance benefits substantially equivalent to those which you are receiving or entitled to receive immediately prior to the Change in Control. Such insurance benefits shall be provided to you for the longer of (x) thirty six (36) months after such Date of Termination or (y) the period during which such insurance benefits would have been provided to you, as a terminated employee, under the applicable life insurance, medical, health and accident plans of the Company in effect immediately prior to the Change in Control of the Company (except that after a period of thirty six (36) months, such insurance benefits shall be provided to you on the same financial terms and conditions as provided for under the respective plans).


5


Should it be determined that any of the medical benefits to be provided to you under this subsection (iii) could be included in your gross income for federal, state or local tax purposes, then the following shall apply:


(a) If you are at least age 47 with at least seven (7) years of service with the Company on your Date of Termination, then you shall participate in the Company's retiree medical benefit plans as if you retired from the Company on your Date of Termination with eligibility for such plans, except that the Company shall provide such medical coverage at no cost to you for three (3) years following your Date of Termination and thereafter, you shall participate therein on the same terms as other retired employees;


(b) If you are not at least age 47 or do not have at least seven (7) years of service upon your Date of Termination, you will no longer continue to participate in the Company's medical benefit plans, except for COBRA, and (i) the Company shall provide you with a cash payment in an amount equal to the amount required by you to pay for coverage under COBRA for the first eighteen (18) months following your loss of medical coverage, and thereafter, (ii) the Company shall, for the subsequent eighteen (18) months, purchase for you, at its cost, a policy of medical insurance providing benefits substantially similar to the benefits you would have received under the Company's medical benefit plans.


(iv)

Retirement Benefits .


A.

If you are a Traditional-Design Participant, the provisions of this paragraph A shall apply to you.


The Company shall pay you, at the time you are entitled to be paid a retirement pension under the Pension Program, a retirement pension equal to the greater of (x) an amount computed in accordance with the terms of the Pension Program in effect immediately prior to the Change in Control and as if those terms were in effect on the Date of Termination, or (y) an amount computed in accordance with the terms of the Pension Program in effect immediately prior to the Date of Termination, in either case less the amount of retirement pension actually to be paid to you under the Pension Program. In computing the amounts of your retirement pension under clauses (x) and (y) of this Paragraph 2a(iv), three years shall be added to your actual age and to your actual Company Service Credit under the Pension Program so that your retirement pension under clauses (x) and (y) will be the amount it would have been if you had been three years older than you actually were, and had three years more Company Service Credit than you actually had, on the Date of Termination.


If for any reason, the benefits under this subparagraph (iv) cannot be paid under the tax-qualified portion of the Pension Program, the Company shall pay such benefits to you a lump sum not later than thirty (30) days after your Date of Termination, calculated under such one of the following options as would produce the highest lump sum payment: (a) calculated under the same factors (interest rate and mortality) as lump sum payments were made under the Company's Supplemental Retirement Income Plan and Equalization Benefit Plan in effect immediately prior to a Change in Control, (b) calculated under the same factors (interest rate and mortality) as lump sum payments are made under the Company's Supplemental Retirement Income Plan and Equalization Benefit Plan, or other similar plans, as in effect on the Date of Termination, or (c) calculated under the same factors (interest rate and mortality) as lump sum payments would have been calculated under the Company's Supplemental Retirement Income Plan and Equalization Benefit Plan on the Date of Termination, if such factors were determined using the same methodology as such plans used prior to the Change in Control.


6


B.

If you are an Account-Based Participant the provisions of this paragraph B shall apply to you.


To provide benefits to you which are equivalent to the benefits you would have received under the Pension Plan for the three (3) years following your Date of Termination, the Company shall pay you an amount equal to four percent (4%) of Compensation (as defined in the Pension Plan but without regard to the limitations of Code Section401(a)(17) and including amounts deferred by you under any Praxair compensation deferral program) in effect for the year prior to the Change in Control or the year prior to your Date of Termination, whichever is greater, multiplied by three (3). Such amount shall be paid to you not later than the fifth (5th) day following the Date of Termination.


(v)

S avings Plan . To provide benefits to you which are equivalent to the benefits you would have received under the Savings Program for the three years following your Date of Termination, the Company shall pay you an amount equal to five percent (5%) of Compensation (as defined in the Savings Plan but without regard to the limitations of Code Section 401(a)(17) and including amounts deferred by you under any Praxair compensation deferral program) in effect for the year prior to the Change in Control, or the year prior to your Date of Termination, whichever is greater, multiplied by three (3). Such amount shall be paid to you not later than the fifth (5th) day following the Date of Termination.


(vi)

Outplacement Counseling . The Company shall make available to you, at the Company's expense, outplacement counseling. You may select the organization that will provide the outplacement counseling, however, the Company's obligation to provide you benefits under this subsection (vi) shall be limited to $35,000.


(vii)

Financial Counseling . The Company shall, within 30 days of the Date of Termination, make available to you three individual financial counseling sessions, of at least two hours each and at times and locations that are convenient to you, with a nationally recognized financial counseling firm. The financial counseling firm may also provide you with tax counseling and tax preparation services. You may select the organization that will provide the financial and tax counseling, however, the Company's obligation to provide you benefits under this subsection (vi) shall be limited to $10,000. At the financial counseling sessions, the financial counseling firm shall provide you with detailed financial advice that is tailored to your particular personal and financial situation. The Company shall specify to you the information regarding your personal and financial situation that you must provide to the financial counseling firm in order for the firm to provide the counseling services required by this Section 2(a)(vi). The Company shall take all reasonable and appropriate measures to assure that the financial counseling firm preserves the confidentiality of all information conveyed by you to the counseling firm.


(viii)

Severance Payment . The Company shall pay as severance pay to you, not later than the fifth (5th) day following the Date of Termination, a lump sum severance payment (the "Severance Payment") equal to three (3) times the sum of the following:


(a) the greater of your annual base compensation which was payable to you by the Company immediately prior to the Date of Termination and your annual base compensation which was payable to you by the Company immediately prior to a Change in Control, whether or not such annual base compensation was includible in your gross income for federal income tax purposes; plus


(b) the greater of: (y) the amount of your target variable compensation payment for the year in which the Change in Control occurs, or if higher, in the year in which your Date of Termination occurs, or (z) an amount that bears the same ratio to your annual base salary in effect immediately prior to the Date of Termination, or, if higher, your annual base salary in effect immediately prior to the Change in Control, as the Incentive Compensation awarded to you during the three (3) immediately prior Incentive Compensation Years bears to your base salary for said three (3) prior years (whether or not such award was includible in your gross income for federal income tax purposes); plus


The Severance Payment shall not be reduced to the extent the Company could not properly deduct amounts paid pursuant to Paragraph 2a(i) through 2a(vii) hereof or otherwise pursuant to section 280G of the Code.


(ix)

Payment of Taxes .


(a) For purposes of this subparagraph (viii), the following terms shall have the following meanings:


(I)

Payment shall mean any payment or distribution (or acceleration of benefits) by the Company to or for your benefit (whether paid or payable or distributed or distributable (or accelerated) pursuant to the terms of this Agreement or otherwise, but determined without regard to any additional payments required under this subsection (ix)). In addition, Payment shall mean the amount of income deemed to be received by you as a result of the acceleration of the exercisability of any of your options to purchase stock of the Company or the acceleration of the lapse of any restrictions on performance stock or restricted stock of the Company held by you or the acceleration of any payment from any deferral plan of the Company.


(II)

Excise Tax shall mean the excise tax imposed by Section 4999 of the Code, or any interest or penalties incurred by you with respect to such excise tax.


(III)

Income Tax shall mean all taxes other than the Excise Tax (including any interest or penalties imposed with respect to such taxes) including, without limitation, any income and employment taxes imposed by any federal (including (i) FICA and medicare taxes, and (ii) the tax resulting from the loss of any federal deductions or exemptions which would have been available to you but for receipt of the Payment), state, local, commonwealth or foreign government.


(b) In the event it shall be determined that a Payment would be subject to an Excise Tax, then you shall be entitled to receive an additional payment (a "Gross-Up Payment") in an amount such that after payment by you of Income Tax and Excise Tax imposed upon the Gross-Up Payment, you retain an amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Payment.


(c) All determinations required to be made under this subsection (viii), including whether and when a Gross-Up Payment is required and the amount of such Gross-Up Payment and the assumptions to be utilized in arriving at such determination, shall be made by the public accounting or actuarial consulting firm that is retained by the Company as of the date immediately prior to the Change in Control (the "Firm") which shall provide detailed supporting calculations both to the Company and to you within fifteen (15) business days of the receipt of notice from you that there has been a Payment, or such earlier time as is requested by the Company (collectively, the "Determination"). In the event that the Firm is serving as accountant, auditor or


8


consultant for the individual, entity or group affecting the Change in Control, you may appoint another nationally recognized public Firm to make the determinations required hereunder (which Firm shall then be referred to as the Firm hereunder). All fees and expenses of the Firm shall be borne solely by the Company. Any Gross-Up Payment, as determined pursuant to this subsection (viii), shall be paid by the Company to you within ten (10) days of your receipt of the Determination. If the Firm determines that no Excise Tax is payable by you, you may request the Firm to furnish you with a written opinion that failure to report the Excise Tax on your applicable federal income tax return would not result in the imposition of a negligence or similar penalty. The Determination by the Firm shall be binding upon the Company and you. As a result of the uncertainty in the application of Section 4999 of the Code at the time of the Determination, it is possible that Gross-Up Payments which will not have been made by the Company should have been made ("Underpayment"), consistent with the calculations required to be made hereunder. In the event that the Company exhausts its remedies pursuant to Section (viii)(d) and you thereafter are required to make payment of any Excise Tax or Income Tax, the Firm shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by the Company to or for your benefit.


(d) You shall notify the Company in writing of any claim by the Internal Revenue Service that, if successful, would require the payment by the Company of the Gross-Up Payment or the Underpayment. Such notification shall be given as soon as practicable but no later than ten (10) business days after you are informed in writing of such claim and shall apprise the Company of the nature of such claim and the date on which such claim is requested to be paid. You shall not pay such claim prior to the expiration of the 30-day period following the date on which you give such notice to the Company (or such shorter period ending on the date that any payment of taxes with respect to such claim is due). If the Company notifies you in writing prior to the expiration of such period that it desires to contest such claim, you shall:


(1)

give the Company any information reasonably requested by the Company relating to such claim,


(2)

take such action in connection with contesting such claim as the Company shall reasonably request in writing from time to time, including, without limitation, accepting legal representation with respect to such claim by an attorney reasonably selected by the Company,


(3)

cooperate with the Company in good faith in order effectively to contest such claim, and


(4)

permit the Company to participate in any proceeding relating to such claim; provided, however, that the Company shall bear and pay directly all costs and expenses (including additional interest and penalties) incurred in connection with such contest and shall indemnify and hold you harmless, on an after-tax basis, for any Excise Tax or Income Tax imposed as a result of such representation and payment of costs and expenses. Without limitation on the foregoing provisions of this Section (viii)(d), the Company shall control all proceedings taken in connection with such contest and, at its sole option, may pursue or forego any and all administrative appeals, proceedings, hearings and conferences with the taxing authority in respect of such claim and may, at its sole option, either direct you to pay the tax claimed and sue for a refund or contest the claim in any permissible manner, and you agree to prosecute such contest to a determination before any administrative tribunal, in a court of initial jurisdiction and in one or


9


more appellate courts, as the Company shall determine; provided further, that if the Company directs you to pay such claim and sue for a refund, the Company shall advance the amount of such payment to you on an interest-free basis and shall indemnify and hold you harmless, on an after-tax basis, from any Excise Tax or Income Tax imposed with respect to such advance or with respect to any imputed income with respect to such advance; and provided further, that any extension of the statute of limitations relating to payment of taxes for your taxable year with respect to which such contested amount is claimed to be due is limited solely to such contested amount. Furthermore, the Company's control of the contest shall be limited to issues with respect to which a Gross-Up Payment would be payable hereunder and you shall be entitled to settle or contest, as the case may be, any other issue raised by the Internal Revenue Service or any other taxing authority.


(e) If, after the receipt by you of an amount advanced by the Company pursuant to Section (viii)(d), you become entitled to receive, and receive, any refund with respect to such claim, you shall (subject to the Company's complying with the requirements of Section (viii)(d)) promptly pay to the Company the amount of such refund (together with any interest paid or credited thereon after taxes applicable thereto). If, after the receipt by you of an amount advanced by the Company pursuant to Section (viii)(d), a determination is made that you shall not be entitled to any refund with respect to such claims and the Company does not notify you in writing of its intent to contest such denial of refund prior to the expiration of thirty (30) days after such determination, then such advance shall be forgiven and shall not be required to be repaid and the amount of such advance shall be offset, to the extent thereof, the amount of the Gross-Up Payment required to be paid.


(x)

No Duty to Mitigate . You shall not be required to mitigate the amount of any payment provided for in this Paragraph 2 by seeking other employment or otherwise, nor shall the amount of any payment or benefit hereunder be reduced by any compensation earned by you as the result of employment by another employer or by retirement benefits after the Date of Termination, provided, however, should you become reemployed in a job which (a) offers medical plan benefits which are equal to or greater than the medical plan benefits provided to you under subsection 2(a)(iii), and (b) such medical plan benefits are offered to you at no cost, you shall no longer be eligible to receive medical plan benefits under this Agreement.


               b. Payments While Disabled . During any period prior to the Date of Termination and during the term of this Agreement that you are unable to perform your full-time duties with the Company, whether as a result of your Total Disability or as a result of a physical or mental disability that is not total or is not permanent and therefore is not a Total Disability, you shall continue to receive your base salary at the rate in effect at the commencement of any such period, together with all other compensation and benefits that are payable or provided under the Company’s benefit plans, including its disability plans. After the Date of Termination, your benefits shall be determined in accordance with the Company’s Pension Program, insurance and other applicable programs. The compensation and benefits, other than salary, payable or provided pursuant to this Paragraph 2b shall be the greater of (x) the amounts computed under the Pension Program, disability benefit plans, insurance and other applicable programs in effect immediately prior to a Change in Control and (y) the amounts computed under the Pension Program, disability benefit plans, insurance and other applicable programs in effect at the time the compensation and benefits are paid.

               c. Payments if Terminated for Cause, or by You Except With Good Reason . If your employment shall be terminated by the Company for Cause or by you other than with Good Reason for Resignation, the Company shall pay you your full base salary and accrued vacation pay then in effect through the Date of

10


Termination, at the rate in effect at the time Notice of Termination is given plus any benefits or awards which have been earned or become payable but which have not yet been paid to you. You shall receive any payment due under this subsection c. on your Date of Termination. Thereafter the Company shall have no further obligation to you under this Agreement.

               d. After Retirement or Death . If your employment shall be terminated by your Retirement, or by reason of your death, your benefits shall be determined in accordance with the Company's retirement and insurance programs then in effect.

3.

Term of Agreement . This Agreement shall commence on the date hereof and shall continue in effect through December 31, 2004; provided, however, that commencing on January 1, 2005 and each January 1 thereafter, the term of this Agreement shall automatically be extended for one additional year unless, not later than September 30 of the preceding year, the Company or you shall have given notice that it or you do not wish to extend this Agreement. Notwithstanding any such notice by the Company or you not to extend the Agreement, if a Change in Control shall have occurred:


(a) during the original or extended term of this Agreement or,


(b) after this Agreement has been terminated, but within twelve months after such notice to terminate the Agreement is given by the Company, the attempted termination of the Agreement shall be deemed ineffective and this Agreement shall continue in effect. In any event, the term of this Agreement shall expire on the second (2nd) anniversary of the date of the Change in Control. This Agreement shall terminate if your employment is terminated by you or the Company prior to a Change in Control.


4.

Successors; Binding Agreement .


               a. Successors of the Company . The Company will require any Successor to all or substantially all of the business and/or assets of the Company to expressly assume and agree, by an agreement in form and substance satisfactory to you, to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. Failure of the Company to obtain such assent at least five business days prior to the time a person becomes a Successor (or where the Company does not have at least five business days advance notice that a person may become a Successor, within three business days after having notice that such person may become or has become a Successor) shall constitute Good Reason for Resignation by you and, if a Change in Control has occurred or thereafter occurs, shall entitle you immediately to the benefits provided in Paragraph 2a hereof upon delivery by you of a Notice of Termination which the Company, by executing this Agreement, hereby assents to. For purposes of this Agreement, “Successor” shall mean any person that purchases all or substantially all of the assets of the Company or the Surviving Corporation (and Parent Corporation, if applicable) or obtains or succeeds to, or has the practical ability to control (either immediately or with the passage of time), the Company’s business directly, by merger or consolidation, or indirectly, by purchase of voting securities of the Company or by acquisition of rights to vote voting securities of the Company or otherwise, including but not limited to any person or group that acquires the beneficial ownership or voting rights described in Paragraph 1a(ii).

               b. Your Successor . This Agreement shall inure to the benefit of and be enforceable by your personal or legal representatives, executors, administrators, successors, heirs, distributees, devises and legatees. If you should die following your Date of Termination while any amount would still be payable to you hereunder if you had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to your devisee, legatee or other designee or, if there is no such designee, to your estate.

5.

Relationship to Other Agreements . To the extent that any provision of any other agreement between the Company and you shall limit, qualify or be inconsistent with any provision of this Agreement, then for purposes of this Agreement, while the same shall remain in force, the provision of this Agreement shall control and such provision of such other agreement shall be deemed to have been superseded, and to be of no force or effect, as if such other agreement had been formally amended to the extent necessary to accomplish such purpose.


11


6.

Nature of Payments . All payments to you under this Agreement shall be considered either payments in consideration of your continued service to the Company or severance payments in consideration of your past service to the Company.


7.

Validity . The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.


8.

Counterparts . This Agreement may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.


9.

Notice . Any purported termination of your employment by the Company or by you following a Change in Control shall be communicated to the other party by a Notice of Termination. A Notice of Termination shall indicate the specific termination provision in this Agreement relied upon and shall set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of your employment under the provision so indicated. For the purpose of this Agreement, notices and all other communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered or mailed by United States registered mail, return receipt requested, postage prepaid, addressed to the respective addresses set forth on the first page of this Agreement, provided that all notices to the Company shall be directed to the attention of the Board of Praxair with a copy to the Secretary of Praxair or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon receipt.


10.

Fees and Expenses . Praxair shall pay all legal fees and related expenses incurred by you as a result of your termination following a Change in Control or by you in seeking to obtain or enforce any right or benefit provided by this Agreement (including all fees and expenses, if any, incurred in contesting or disputing any such termination or incurred by you in seeking advice in connection therewith).


11.

Survival . The respective obligations of, and benefits afforded to, the Company and you as provided in Paragraphs 2, 4, 5, 6, 10 and 11 of this Agreement shall survive termination of this Agreement.


12.

Miscellaneous . No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by you and such officer as may be specifically designated by the Board. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement.


13.

Governing Law . The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of Connecticut.


14.

Amendment . No amendment to this Agreement shall be effective unless in writing and signed by both you and the Company.


15.

Place of Execution . This Agreement shall be executed by you at the headquarters of the Company in Danbury, Connecticut, USA.


16.

Duplicate Payments . If the national laws of any country require any payments to you by the Company or any of its subsidiaries or affiliates as a result of your termination due to a Change in Control of the Company, the amount of any such payment shall be deducted from any payment due to you under this Agreement. It is expressly stated as the Company’s intent under this Agreement that the amount you receive from the Company as a result of your termination due to a Change in Control shall be limited to the amount calculated as provided in this Agreement. This paragraph does not limit your ability, without offsetting reductions to the Company’s payment obligation, to receive government payments for which you may be eligible as a result of the termination of your employment.


12


        If this letter sets forth our agreement on the subject matter hereof, kindly sign and return to the Company the enclosed copy of this letter which will then constitute our agreement on this subject.

  Sincerely,
 
  PRAXAIR, INC.
 
 
By:                    
Dennis H. Reilley
Chairman and Chief Executive Officer

13


Agreed to this         day
of          , 2003

-----------------------------------------------------

















14


THE PRAXAIR, INC.
1995 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS

Praxair, Inc. and Subsidiaries


Exhibit 10.04

Amended and Restated
As of December 15, 2003

1.  

Purposes.


        The 1995 Stock Option Plan for Non-Employee Directors (the “Plan”) is established to attract, retain and compensate highly qualified individuals, who are not employees of Praxair, Inc. (the “Company”) or any of its subsidiaries or affiliates for service as members of the Company’s Board of Directors (“Non-Employee Directors”) and to provide them with an ownership interest in the Company’s common stock. The Plan will be beneficial to the Company and its stockholders by allowing these Non-Employee Directors to have a personal financial stake in the Company through an ownership interest in the Company’s common stock, in addition to underscoring their common interest with stockholders in increasing the value of the Company’s stock over the long term.

2.  

Effective Date.


        The Plan shall be effective as of February 21, 1995, subject to the approval of the Plan by the holders of at least a majority of the outstanding shares of Company common stock present, or represented, and entitled to vote at the 1995 Annual Meeting of Stockholders. Grants of options may be made under the Plan on and after its effective date, subject to stockholder approval of the Plan as provided above. In the event such approval is not obtained, any options granted under the Plan shall be null and void.

3.  

Administration of the Plan.


        The Plan shall be administered by the Governance and Nominating Committee of the Company’s Board of Directors (the “Committee”). Subject to the provisions of the Plan, the Committee shall be authorized to interpret the Plan, to establish, amend and rescind any rules and regulations relating to the Plan, and to make, or delegate to the Corporate Secretary or other officer the authority to make, all other determinations necessary or advisable for the administration of the Plan; provided, however, that the Committee shall have no discretion with respect to the eligibility or selection of Non-Employee Directors to receive options under the Plan, the number of shares of stock subject to any such options or the Plan, or the purchase price thereunder; and provided further, that the Committee shall not have the authority to take any action or make any determination that would materially increase the benefits accruing to participants under the Plan. The Committee’s interpretation of the Plan, and all actions taken and determinations made by the Committee pursuant to the powers vested in it hereunder, shall be conclusive and binding upon all parties concerned including the Company, its stockholders and persons or entities to whom options have been granted or transferred under the Plan. The Corporate Secretary of the Company shall be authorized to implement the Plan in accordance with its terms and to take or cause to be taken such actions of a ministerial nature as shall be necessary to effectuate the intent and purposes thereof; including, among other actions, the establishment of administrative procedures and rules for the exercise of options, the payment of option price and tax withholding obligations, the designation of beneficiaries, the transfer of options and the administration of transferred options.

4.  

Participation in the Plan.


        All Non-Employee Directors in service on the grant date (as hereinafter defined) shall be eligible to receive grants hereunder.

        Former Non-Employee Directors who have been granted stock options under this Plan and all Non-Employee Directors so long as they are in such service are hereinafter referred to collectively as “Participants” in the Plan.

1






        A person or entity to whom options granted under this Plan have been assigned or transferred pursuant to Article 10(b) herein is hereinafter referred to as a “Transferee”; such term to include a grantee’s or transferee’s estate and persons or entities holding an option as a beneficiary of a grantee or as a distributee of a grantee’s estate.

5.  

Non-Qualified Stock Options .


        Only non-qualified stock options (“options”) may be granted under this Plan.

6.  

Terms, Conditions and Form of Options.


               (a) Option Grant Dates. Options to purchase 5,000 shares of the Company’s Common Stock (as adjusted pursuant to Section 9) shall be automatically granted on an annual basis to each eligible Non-Employee Director on April 1st (or the first succeeding business day thereafter on which the Company’s common stock is traded on the principal securities exchange on which it is listed) of each year, except for the first year in which case options shall be granted on February 21, 1995.

               (b) Exercise Price. The exercise price per share of stock for which each option is exercisable shall be 100% of the closing price of the Company’s common stock on the date the option is granted, as reported on the New York Stock Exchange — Composite Transactions.

               (c) Exercisability and Term of Options. Each option granted under the Plan shall become exercisable on the second anniversary of its date of grant. Each option granted under the Plan shall expire ten years from the date of grant, and shall be subject to earlier termination as hereinafter provided.

               (d) Termination of Service. In the event of the termination of service on the Board by the grantee of any option by reason of voluntary resignation (other than for disability or mandatory retirement) or failure, as a nominee, to be elected at an Annual Meeting of Shareholders, the then outstanding options held by such grantee and such grantee’s Transferees shall be exercisable on their stated exercisable dates and shall expire three years after such termination, or on their stated expiration dates, whichever occurs first. In the case of removal of a grantee for cause, the then outstanding options held by such grantee and such grantee’s Transferees shall be exercisable only to the extent that they were exercisable on the date of such removal and shall expire six months after such removal or on their stated expiration dates, whichever occurs first. Such options that are not exercisable on the date of such removal shall be forfeited.

               (e) Retirement . In the event of termination of service of a grantee by reason of mandatory retirement pursuant to Board policy, the then outstanding options held by such grantee and such grantee’s Transferees shall be exercisable on their stated exercisable dates and shall expire on their stated expiration dates. In the case of retirement of a grantee prior to the retirement date required by mandatory Board policy, all outstanding options held by such grantee and such grantee’s Transferees on the retirement date shall be exercisable on their stated exercisable dates and shall expire three years after the retirement date, or on their stated expiration dates, whichever occurs first.

               (f) Disability . In the event of termination of service of a grantee by reason of disability (as defined herein), the then outstanding options held by such grantee and such grantee’s Transferees shall be exercisable on their stated exercisable dates and shall expire on their stated expiration dates. “Disability” as used herein shall mean a grantee’s inability to engage in any substantial gainful activity because of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted, or can be expected to last, for a continuous period of six months or longer.

               (g) Death. In the event of a grantee’s death, each of the then outstanding options held by such grantee and such grantee’s Transferees shall become immediately exercisable. Options held by a grantee at the time of his/her death shall be exercisable by the grantee’s designated beneficiary, if any and if alive, by the executor or administrator of the grantee’s estate before distribution to the grantee’s heirs by will or the laws of descent and distribution, or by the distributee(s) of such options by will or the laws of descent and distribution. Any such option shall be so exercisable at any time until the expiration date of the option (as such date may have been adjusted pursuant to Sections 6(d)or 6(e)). A grantee may designate a beneficiary for an option in accordance with procedures established by the Corporate Secretary, however such beneficiary designation shall not be binding on grantee’s


2





        Transferee with respect to any option that has been transferred before the grantee’s death. In the event of the death of a Transferee, any outstanding option then held by the Transferee shall become immediately exercisable, and shall be exercisable only by the executor or administrator of such Transferee’s estate at any time until the expiration date of the option (as such date may have been adjusted pursuant to Sections 6(d) or 6(e)).

               (h) Change in Control . In the event of a Change in Control of the Company (as defined herein), all of the then outstanding options held by a grantee and such grantee’s Transferees shall become immediately exercisable on the date the Change in Control has been deemed to have occurred and shall expire on the earlier of their stated expiration dates or three years after any termination of service of such grantee, other than by reason of mandatory retirement, disability, death or removal for cause (in which cases the expiration provisions of this Plan associated with those events shall apply), which occurs after said Change in Control. “Change in Control” as used herein shall have the meaning set forth in Section 14 herein.

7.  

Exercise and Payment


               (a) Exercise . An option may be exercised by its holder with respect to part or all of the shares subject to the option by giving written notice to the Company of the exercise of the option. The option price for the shares for which an option is exercised shall be paid by the exercisor on or within ten business days after the date of exercise in cash, in whole shares of common stock of the Company owned by the exercisor prior to exercising the option, or in a combination of cash and such shares of common stock. If the exercisor is a Participant, the Participant may elect to satisfy the option price obligation by requesting that the Company withhold a number of shares that would be otherwise issuable pursuant to the exercise having an aggregate value equal to the option price obligation. Such request shall be accompanied by a form approved by the Corporate Secretary and executed by the Participant attesting that the Participant owns, as of the date of exercise, an equal number of shares of the Company’s common stock and has held such number of shares continuously for at least six (6) months prior to the date of exercise. The value of any share of common stock delivered or withheld in payment of the option price shall be the mean of the high and low prices of the stock as reported in the New York Stock Exchange — Composite Transactions on the date the option is exercised.

               (b) Payment of Tax Withholding . To enable the Company to meet any applicable federal, state or local withholding tax requirements arising as a result of the exercise of a stock option, whether by the grantee or by such grantee’s Transferee, the grantee or grantee’s estate shall pay the Company the amount of tax to be withheld, if any, or may elect to satisfy such obligation by delivering to the Company shares of the Company’s common stock owned by the grantee prior to exercising the option, or by making a payment to the Company consisting of a combination of cash and such shares of common stock. If the exercisor is a Participant, the Participant may elect to satisfy the tax obligation by requesting that the Company withhold a number of shares that would be otherwise issuable pursuant to the exercise having an aggregate value equal to the tax obligation. The value of any share of common stock delivered to the Company or withheld in payment of the tax obligation shall be the mean of the high and low prices of the stock as reported in the New York Stock Exchange — Composite Transactions on the date used to determine the amount of tax to be withheld. The Company reserves the right to delay completion of any exercise of an option until the applicable withholding tax has been paid.

8.  

Shares of Stock Subject to the Plan.


               The shares that may be purchased pursuant to options under the Plan shall not exceed an aggregate of 500,000 shares of Company Common Stock (as adjusted pursuant to Section 9). Any shares subject to an option which for any reason expires or is terminated unexercised as to such shares shall again be available for issuance under the Plan.

9.  

Dilution and Other Adjustment.


               In the event of any change in the outstanding shares of Company stock by reason of any stock split, stock dividend, recapitalization, merger, consolidation, combination or exchange of shares or other similar corporate change, such equitable adjustments shall be made in the Plan and the grants thereunder, including the exercise price of

3


outstanding options, as the Committee determines are necessary or appropriate, including, if necessary, any adjustments in the maximum number of shares referred to in Section 8 of the Plan. Such adjustment shall be conclusive and binding for all purposes of the Plan.

10.  

Miscellaneous Provisions.


               (a) Rights as Stockholder. A grantee or Transferee shall have no rights as a holder of Company common stock with respect to options granted hereunder, unless and until certificates for shares of such stock are issued to the grantee or Transferee, or such shares are credited to the grantee’s or Transferee’s Dividend Reinvestment and Stock Purchase Plan Account.

               (b) Assignment or Transfer. No options granted under the Plan or any rights or interests therein shall be assignable or transferable other than:

(1) In the case of the grantee’s death, pursuant to the beneficiary designation then on file with the Company, or, in the absence of such a beneficiary designation(or if the designated beneficiary has predeceased the grantee), by will or the laws of descent or distribution (in which case, the Company, without liability to any other person, may rely on the directions of the executor or administrator of the grantee’s estate with respect to the disposition or exercise of such options); or

(2) For all options granted hereunder on or after October 21, 1997, and, if the Committee approves, for options granted earlier: By the grantee, in whole or parts to

           (i) the grantee's spouse, children(including by adoption), stepchildren or grandchildren ("Immediate Family Members"),  
           (ii) a trust for the exclusive benefit of such Immediate Family Members,
           (iii) a partnership in which such Immediate Family Members are the only partners, or
           (iv) such other persons or entities as the Committee may approve on a case-by-case basis;

so long as such transfer under this Article 10(b)(2) does not cause the total number of shares included in all unexpired, unexercised options held by the grantee’s Transferees to exceed the total number of shares included in all unexpired, unexercised options held by the grantee; or

(3) In the case of a Transferee’s death, to his/her estate without rights to further distribution.

               (c) Transfer of Options . Any transfer of an option pursuant to Article 10(b) herein is subject to acceptance by the Company and shall be effected according to such procedures as the Corporate Secretary may establish.

               (d) Agreements. All options granted under the Plan shall be evidenced by agreements in such form and containing such terms and conditions (not inconsistent with the Plan) as the Corporate Secretary may adopt.

               (e) Compliance with Regulations. During the term of the Plan and the term of any options granted under the Plan, the Company shall at all times reserve and keep available such number of shares as may be issuable under the Plan, and shall seek to obtain from any regulatory body having jurisdiction any requisite authority required in the opinion of counsel for the Company in order to grant or transfer options to purchase shares of Company common stock or to issue such stock pursuant thereto. If, in the opinion of counsel for the Company, the transfer, issue or sale of any options or shares of its stock under the Plan shall not be lawful for any reason, including the inability of the Company to obtain from any regulatory body having jurisdiction authority deemed by such counsel to be necessary to such transfer, issuance or sale, the Company shall not be obligated to transfer, issue or sell any such options or shares. In any event, the Company shall not be obligated to transfer, issue or sell any options or shares to any Participant or Transferee unless a registration statement which complies with the provisions of the Securities Act of 1933, as amended (the “Securities Act”), is in effect at the time with respect to such options or shares or other appropriate action has been taken under and pursuant to the terms and provisions of the Securities Act, or the Company receives evidence satisfactory to the Committee that the transfer, issuance or sale of such options or shares, in the absence of an effective registration statement or other appropriate action, would not constitute a violation of the terms and provisions of the Securities Act.

4





               (f) Costs and Expenses. The costs and expenses of administering the Plan shall be borne by the Company and not charged to any option or to any Participant or Transferee.

11.  

Amendment and Termination of the Plan.


               (a) Amendments. The Board of Directors of Praxair, Inc. may from time to time amend the Plan in whole or in part; provided that no such action shall adversely affect any rights or obligations with respect to any options theretofore granted under the Plan.

               Unless the holders of at least a majority of the outstanding shares of Company common stock present, or represented, and entitled to vote at a meeting of stockholders shall have first approved thereof, no amendment of the Plan shall be effective which would (i) materially increase the maximum number of shares which may be issued under the Plan, or (ii) materially increase the benefits accruing to Participants under the Plan, or (iii) materially modify the requirements as to eligibility for participation in the Plan.

               With the consent of the grantee, the Committee may direct the Corporate Secretary to amend any outstanding agreement evidencing options granted to such grantee under the Plan, whether held by grantee or by his/her Transferee, so long as such amendment is not inconsistent with the terms of the Plan. No such consent shall be required from grantees for amendments pursuant to Article 10(b)(2) herein relating to the transferability of options granted before October 21, 1997. No such consent shall be required from a Transferee with respect to amendments of any kind to options held by such Transferee, so long as grantee has provided such consent.

               (b) Termination. The Committee may terminate the Plan (but not any options theretofore granted under the Plan) at any time. The Plan (but not any options theretofore granted under the Plan) shall in any event terminate on, and no options shall be granted after, December 31, 2005.

12.  

Compliance with SEC Regulations.


        It is the Company’s intent that the Plan comply in all respects with Rule 16b-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any related regulations. If any provision of this Plan is later found not to be in compliance with such Rule and regulations, the provision shall be deemed null and void. All grants, transfers and exercises of options under this Plan shall be executed in accordance with the requirements of Section 16 of the Exchange Act and regulations promulgated thereunder.

13.  

Governing Law.


               The validity and construction of the Plan and any agreements entered into thereunder shall be governed by the laws of the State of Connecticut.

14.  

Change-in-Control


               A “Change in Control” shall be deemed to occur in the event, and on the first date, that any of the following circumstances have occurred (as used herein, “Board” shall refer to the Board of Directors of Praxair, Inc.):

                             (i) individuals who, on October 22, 1996, constitute the Board (the “Incumbent Directors”) cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director subsequent to October 22, 1996, whose election or nomination for election was approved by a vote of at least two-thirds of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without objection to such nomination) shall be an Incumbent Director; provided, however, that no individual elected or nominated as a director of the Company initially as a result of an actual or threatened election contest

5


        with respect to directors or any other actual or threatened solicitation of proxies [or consents] by or on behalf of any person other than the Board shall be deemed an Incumbent Director;

                             (ii) any “person” (as such term is defined in Section 3(a)(9) of the Securities Exchange Act of 1934 (the “Exchange Act”) and as used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act) is or becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 20% or more of the combined voting power of the Company’s then outstanding securities eligible to vote for the election of the Board (the “Company Voting Securities”); provided, however, that the event described in this paragraph (ii) shall not be deemed to be a Change in Control by virtue of any of the following acquisitions: (A) by the Company or any Subsidiary, (B) by any employee benefit plan sponsored or maintained by the Company or Subsidiary, (C) by any underwriter temporarily holding securities pursuant to an offering of such securities, (D) pursuant to a Non-Qualifying Transaction (as defined in paragraph (iii));

                             (iii) the consummation of a merger, consolidation, share exchange or similar form of corporate transaction involving the Company or any of its Subsidiaries that requires the approval of the Company’s stockholders, whether for such transaction or the issuance of securities in the transaction (a “Business Combination”), unless immediately following such Business Combination: (A) more than 50% of the total voting power of (x) the corporation resulting from such Business Combination (the “Surviving Company”), or (y), if applicable, the ultimate parent corporation that directly or indirectly has beneficial ownership of 100% of the voting securities eligible to elect directors of the Surviving Company (the “Parent Company”), is represented by Company Voting Securities that were outstanding immediately prior to such Business Combination (or, if applicable, shares into which such Company Voting Securities were converted pursuant to such Business Combination), and such voting power among the holders thereof is in substantially the same proportion as the voting power of such Company Voting Securities among the holders thereof immediately prior to the Business Combination, (B) no person (other than any employee benefit plan sponsored or maintained by the Surviving Company or the Parent Company), is or becomes the beneficial owner, directly or indirectly, of 20% or more of the total voting power of the outstanding voting securities eligible to elect directors of the Parent Company (or, if there is no Parent Company, the Surviving Company) and (C) at least a majority of the members of the board of directors of the Parent Company (or, if there is no Parent Company, the Surviving Company) were Incumbent Directors at the time of the Board’s approval of the execution of the initial agreement providing for such Business Combination (any Business Combination which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a “Non-Qualifying Transaction”); or

                             (iv) The stockholders of the Company approve a plan of complete liquidation or dissolution of the Company or a sale of all or substantially all of the Company’s assets.

               Notwithstanding the foregoing, a Change in Control of the Company shall not be deemed to occur solely because any person acquires beneficial ownership of more than 20% of the Company Voting Securities as a result of the acquisition of Company Voting Securities by the Company which reduces the number of Company Voting Securities outstanding; provided that, if after such acquisition by the Company, such person becomes the beneficial owner of additional Company Voting Securities that increases the percentage of outstanding Company Voting Securities beneficially owned by such person, a Change in Control of the Company shall then occur.

6




PRAXAIR, INC.
DIRECTOR’S FEES DEFERRAL PLAN

Praxair, Inc. and Subsidiaries


Exhibit 10.06

Amended and Restated
As of January 1, 2004

THIS DOCUMENT CONSTITUTES PART OF A PROSPECTUS COVERING SECURITIES THAT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933.

Section 1. Purpose, Participation

        (a) Purpose: The purpose of this Director’s Fees Deferral Plan (the “Plan”) is to enable Praxair, Inc. (the “Corporation”) to attract and retain Directors of outstanding ability by providing them with a mechanism to defer and accumulate Director’s fees, meaning (1) the retainer, (2) fees for attendance at meetings of the Board of Directors and Board committees of the Corporation, (3) fees for additional or special services as Directors and (4) other compensatory payments made to Directors by the Corporation in connection with their service as Directors.

        (b) Participation: This Plan extends to Directors of the Corporation not employed by the Corporation or any subsidiary.

Section 2. Payment of Deferred Amounts

        (a) Deferral Election : At any time prior to the beginning of a calendar year, a Director may elect that all or any specified portion of the Director’s fees to be earned during such calendar year be credited to a Director’s Cash Account and/or a Director’s Stock Unit Account maintained on such Director’s behalf in lieu of payment (a “Deferral Election”). A Director may also make a Deferral Election during the 30 days following the date on which a Director first becomes eligible to receive Director’s fees, although any Deferral Election made pursuant to this sentence will apply only to all or any specified portion of the Director’s fees earned thereafter. Each Deferral Election must be submitted to the Secretary of the Corporation in writing, and will be deemed to authorize deferral to only a Director’s Cash Account except to the extent deferral to a Director’s Stock Unit Account is expressly specified.

        (b) Effect of Deferral Election : Pursuant to such Deferral Election, the Corporation (i) will not pay the Director’s fees covered thereby and (ii) will make payments in accordance with the Deferral Election and this Section 2.


        (c) Payment Commencement Event . At the time of making the Deferral Election, a Director will designate as a “Payment Commencement Event” either ( 1 ) the termination of the Director’s service as a Director of the Corporation (or any successor) or ( 2 ) the Director’s attainment of an age, not to exceed 75, specified by the Director. A Director may also elect that, notwithstanding any other election made by him pursuant to this Section 2, in the event that the Director terminates service as a Director of the Corporation within one year following a “Change of Control” (as defined in Section 5(h)), the Payment Commencement Event for payments from a deferral account will be the termination of the Director’s service as a Director.

        (d) Payment . Payment of amounts deferred pursuant to the Deferral Election will commence on the last business day of the calendar quarter in which the Payment Commencement Event (either as originally designated or as deferred pursuant to clause ( 1 ) of Section 2(e)) occurs. Payments from a deferral account will be made in a lump sum (in cash or stock as provided in this Plan) unless a timely election of an installment payment schedule pursuant to clause ( 2 ) of Section 2(e) has been made.

        (e) Additional Deferrals . A Director may also (1) elect to defer the Payment Commencement Event to a later date specified by the Director (but not later than attainment of age 75), and/or ( 2 ), for Payment Commencement Events other than a Change of Control, elect that (i) payment from the Director’s Cash Account be made in a number of approximately equal annual cash installments, and/or (ii) payment from the Director’s Stock Unit Account be made in a number of annual installments, each of an approximately equal number of Stock Units. Such installment payments shall be made over a period of time specified by the Director, but not to exceed 15 years. Such elections may be made at any time until 12 months before the Payment Commencement Event designated pursuant to Section 2(c). Each such election must be submitted to the Secretary of the Corporation in writing. A Director may make no more than one election pursuant to clause ( 1 ) in any calendar year. An election of an installment payment schedule pursuant to clause ( 2 ) is irrevocable except as provided in Section 2(g).

        (f) Renewal of Elections . Once a Deferral Election and designation of a Payment Commencement Event has been made, it will be automatically applied to Director’s fees earned in all subsequent calendar years unless the Director changes or revokes either such election or designation. Each such change or revocation must be submitted to the Secretary of the Corporation in writing. However, except as provided in Section 2(e), each Deferral Election and designation of Payment Commencement Event is irrevocable as to Director’s fees earned prior to the calendar year next following any change or revocation.

-2-


        (g) Renewal of Installment Election . An election of an installment payment schedule will automatically apply to amounts credited to a deferral account in each succeeding calendar year unless, prior to the commencement of such calendar year, the Director elects to change or revoke such installment payment schedule election, in which case his/her new election will control only with respect to amounts credited during calendar years following such new election.

        (h) Disability . In the event a Director becomes disabled, the payment commencement date and/or payment schedule with respect to a balance in a deferral account may be accelerated by the Plan Committee, in its sole discretion. ‘Disabled’ means unable to engage in any substantial gainful activity because of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted, or can be expected to last, for a continuous period of six (6) months or longer.

        (i) Death . A Director may designate a beneficiary (and change such beneficiary, from time to time) for payment of any balance of the deferral account at the Director’s death. Upon a Director’s death, any balance in the deferral account (including amounts credited to such account as specified in Section 3(b) and Section 4(b)) will be paid to the deceased Director’s beneficiary at the end of the first calendar quarter which ends at least 30 days after the Director dies. If no beneficiary has been designated, the Director’s estate will be deemed the beneficiary, and any payments pursuant to this Section 2( i ) will be paid, either at the end of the first calendar quarter which ends at least 30 days after appointment of the deceased Director’s legal representative, or such earlier date as may be determined by the Plan Committee, in its sole discretion.

        (j) Mandatory Deferrals . The Board of Directors may, from time to time, determine that certain payments made to Directors shall be mandatorily deferred under this Plan. If, in conjunction with such determination, the Board specifies the deferral account(s) to which such payment shall be credited or the Payment Commencement Event applicable to such deferral, then such specifications shall be applied to the deferral as if the recipient Director had made a timely Deferral Election with respect to such payment under Section 2(a) and had designated a Payment Commencement Event under Section 2(c). With respect to any such mandatory deferral, the Board may also specify restrictions on changes or revocations of Deferral Elections (or deemed Deferral Elections) and Payment Commencement Event designations under Section 2(f), in which event Section 2(f) shall be inoperative as to such mandatory deferral to the extent of the specified restrictions.

-3-


Section 3. Credits and Debits to Director’s Cash Account

        (a) Principal . The Corporation will create and maintain on its books a Director’s Cash Account for each Director who has made a Deferral Election to such an account under Section 2(a). The Corporation will credit to such account the amount of any Director’s fee which would have been paid to the Director but for such Deferral Election, as of the date the fee would have otherwise been payable.

        (b) Interest . At the end of each calendar quarter, regardless of whether any other credits are then made to the Director’s Cash Account or whether the Director is then a Director, the Corporation will also credit to the Director’s Cash Account a sum which is equal to the product of ( i ) the average daily balance in the Director’s Cash Account for the quarter (without regard to any debits made at the end of such quarter), times (ii) one-fourth of the annual Base Rate (prime rate) for corporate borrowers quoted by J. P. Morgan Chase (or any successor thereto) of New York as of the first business day of the quarter.

        (c) Debits . At the end of each calendar quarter, the Corporation will make a payment if required under the payment schedule for such Director’s Cash Account and will debit the Director’s Cash Account for the amount thereof. Payment with respect to a Director’s Cash Account will be in cash only.

        (d) Mid-quarter Payments . If Payment is to be made other than at the end of a calendar quarter in accordance with a determination pursuant to Section 2(h) or to Section 2(i), prior to such payment, the Corporation will credit to the Director’s Cash Account an amount equal to the product of ( i ) the average daily balance In the Director’s Cash Account for the period from the beginning of the calendar quarter to the date of payment (without regard to any debits to be made upon such payment), times ( ii ) a fraction of the annual Base Rate (prime rate) for corporate borrowers quoted by J. P. Morgan Chase (or any successor thereto) as of the first business day of the quarter, the numerator of which is the number of days in the period described in clause ( i ), and the denominator of which is 365.

Section 4. Credits and Debits to Director’s Stock Unit Account

        (a) Stock Units . The Corporation will create and maintain on its books a Director’s Stock Unit Account for each Director who has made a Deferral Election under Section 2(a) and expressly specifies deferral to such an account. The Corporation will credit to such account the number of Stock Units equal to the number of shares of the Corporation’s common stock that could be purchased with the amount of any Director’s fee which would have been paid to the Director but for such Deferral Election, as of the date the fee would have otherwise been

-4-


payable. The number of Stock Units will be calculated to three decimals by dividing the amount of the Director’s fee as to which a Director’s Stock Unit Account Deferral Election was made by the closing price of the Corporation’s common stock as reported on the New York Stock Exchange as of the date the fee would have otherwise been payable.

        (b) Dividends . As of the date any dividend is paid to holders of shares of the Corporation’s common stock, each Director’s Stock Unit Account, regardless of whether the Director is then a Director, will be credited with additional Stock Units equal to the number of shares of the Corporation’s common stock that could have been purchased with the amount which would have been paid as dividends on that number of shares (including fractions of a share to three decimals) of the Corporation’s common stock equal to the number of Stock Units attributed to such Director’s Stock Account as of the record date applicable to such dividend. The number of additional Stock Units to be credited will be calculated to three decimals by dividing the amount which would have been paid as dividends by the closing price of the Corporation’s common stock as reported on the New York Stock Exchange as of the date the dividend would have been paid. In the case of dividends paid in property other than cash, the amount of the dividend shall be deemed to be the fair market value of the property at the time of the payment of the dividend, as determined in good faith by the Plan Committee.

        (c) Debits and Calculation of Payments . The Corporation will debit the Director’s Stock Unit Account for Stock Units as required under the payment schedule for such Director’s Stock Unit Account. Payment with respect to whole Stock Units will be in shares of the Corporation’s common stock only, at the rate of one share of common stock per Stock Unit. Until such time as shares have been listed on The New York Stock Exchange for issuance under this Plan, only Treasury shares shall be used for such payment. With respect to fractional Stock Units, payment will be made in cash only, and calculated by multiplying the fractional number of the Stock Unit to be debited by the closing price of the Corporation’s common stock as reported on the New York Stock Exchange as of the last business day of the week preceding the week of the date the Stock Units are payable. Should payment with respect to Stock Units be made after the record date, but before the payment date applicable to a dividend paid to holders of shares of the Corporation’s common stock, Stock Units credited a Director’s Stock Unit Account in consequence of such dividend payment will be calculated as cash payments and paid within thirty days of such credit.

        (d) Adjustment. If at any time the number of outstanding shares of the Corporation’s common stock is increased as the result of any stock dividend, stock split, subdivision or reclassification of shares, the number of Stock Units with which each Director’s Stock Unit

-5-


Account is credited will be increased in the same proportion as the outstanding number of shares of the Corporation’s common stock is increased. If the number of outstanding shares of common stock is decreased as the result of any combination, reverse stock split or reclassification of shares, the number of Stock Units with which each Director’s Stock Unit Account is credited will be decreased in the same proportion as the outstanding number of shares of the Corporation’s common stock is decreased. In the event the Corporation is consolidated with or merged into any other corporation and holders of shares of the Corporation’s common stock receive shares of the capital stock of the resulting or surviving corporation, there shall be credited to each Director’s Stock Unit Account, in lieu of the extant Stock Units, new Stock Units in an amount equal to the product of the number of shares of capital stock exchanged for one share of the Corporation’s common stock upon such consolidation or merger, and the number of Stock Units with which such account then is credited. If, in such a consolidation or merger, holders of shares of the Corporation’s common stock receive any consideration other than shares of the capital stock of the resulting or surviving corporation or its parent corporation, the Plan Committee will determine any appropriate change in Director’s Stock Unit Accounts.

Section 5. Unfunded Arrangement

        (a) Neither this Plan nor any deferral account will be funded; a deferral account and all entries thereto constitute bookkeeping records only and do not relate to any specific funds or shares of the Corporation. Payments due with respect to balances in a deferral account will be made from the general assets of the Corporation, and the right of any participant to receive future payments under this Plan’s provisions will be an unsecured claim against such assets.

Section 6. Administration

        (a) Plan Committee . The Plan will be administered by a Plan Committee, which will be the Governance and Nominating Committee of the Board of Directors of the Corporation, or such other Committee as may be appointed by the Board of Directors of the Corporation, and may include Directors who have elected to participate in the Plan. No member of the Plan Committee will be liable for any act done or determination made in good faith.

        (b) Committee Determination Final . The construction and interpretation of any provision of the Plan by the Plan Committee, and a determination by the Plan Committee of the amount of any deferral account, will be final and conclusive.

        (c) Amendments . The Corporation, subject to approval of its Board of Directors, reserves the right to terminate, modify or amend this Plan, effective prospectively as of the first day of any calendar quarter; provided, however, that the Plan will not be subject to termination,

-6-


modification or amendment with respect to any balance of a deferral account and rights therein, including the right to future interest pursuant to Section 3(b) and future dividends pursuant to Section 4(b), unless the affected Director consents.

        (d) Non-Alienation . No Director (or estate of a Director) will have power to transfer, assign, anticipate, mortgage or otherwise encumber any rights or any amounts payable hereunder; nor will any such rights or payments be subject to seizure for the payment of any debts, judgments, alimony, or separate maintenance, or be transferable by operation of law in the event of bankruptcy, insolvency, or otherwise.

        (e) Expenses. The expenses of administering the Plan will be borne by the Corporation and not be charged against any deferral account.

        (f) Withholding . The Corporation may deduct from all cash payments any taxes required to be withheld with respect to such payments. In order to enable the Corporation to meet any applicable federal, state or local withholding tax requirements arising as a result of payments made hereunder in the form of stock, a Director shall pay the Corporation the amount of tax to be withheld or may elect to satisfy such obligation by having the Corporation withhold shares that otherwise would be delivered to the Director pursuant to the deferral account payment for which the tax is being withheld, by delivering to the Corporation other shares of common stock of the Corporation owned by the Director prior to the payment date, or by making a payment to the Corporation consisting of a combination of cash and such shares of common stock. Such an election shall be made prior to the date to be used to determine the tax to be withheld. The value of any share of common stock to be withheld by, or delivered to, the Corporation pursuant to this Section 6(f) shall be the closing price of the Corporation’s common stock as reported on the New York Stock Exchange on the date to be used to determine the amount of tax to be withheld.

        (g) Effect of IRS Determination . If any amounts deferred pursuant to the Plan are found in a “determination” (within the meaning of Section 1313(a) of the Internal Revenue Code of 1986, as amended) to have been includible in gross income by a Director prior to payment of such amounts from his/her deferral account, such amounts will be immediately paid to such Director, notwithstanding elections pursuant to Section 2.

        (h) Change of Control . A "Change of Control" means the occurrence of any one of the following events with respect to the Corporation:

-7-


        (i) individuals who, on January 1, 2003, constitute the Board (the”Incumbent Directors “) cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director subsequent to January 1, 2003, whose election or nomination for election was approved by a vote of at least two-thirds of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Corporation in which such person is named as a nominee for director, without objection to such nomination) shall be an Incumbent Director; provided, however, that no individual elected or nominated as a director of the Corporation initially as a result of an actual or threatened election contest with respect to directors or any other actual or threatened solicitation of proxies or consents by or on behalf of any person other than the Board shall be deemed an Incumbent Director;

        (ii) any “person” (as such term is defined in Section 3(a)(9) of the Securities Exchange Act of 1934 (the “Exchange Act”) and as used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act) is or becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Corporation representing 20% or more of the combined voting power of the Corporation’s then outstanding securities eligible to vote for the election of the Board (the “Company Voting Securities”); provided, however, that the event described in this paragraph (ii) shall not be deemed to be a Change in Control by virtue of any of the following acquisitions: (A) by the Corporation or any subsidiary, (B) by any employee benefit plan sponsored or maintained by the Corporation or subsidiary, (C) by any underwriter temporarily holding securities pursuant to an offering of such securities, or (D) pursuant to a Non-Qualifying Transaction (as defined in paragraph (iii);

        (iii) the consummation of a merger, consolidation, statutory share exchange or similar form of corporate transaction involving the Corporation or any of its subsidiaries that requires the approval of the Corporation’s stockholders, whether for such transaction or the issuance of securities in the transaction (a “Business Combination”), unless immediately following such Business Combination: (A) more than 50% of the total voting power of (x) the corporation resulting from such Business Combination (the “Surviving Corporation”), or (y) if applicable, the ultimate parent corporation that directly or indirectly has beneficial ownership of 100% of the voting securities eligible to elect directors of the Surviving Corporation (the “Parent Corporation”), is represented by Company Voting Securities that were outstanding immediately prior to such Business Combination (or, if applicable, shares into which such Company Voting Securities were converted pursuant to such Business Combination), and such voting power among the holders thereof is in substantially the same proportion as the voting power of such Company Voting Securities among the holders thereof immediately prior to the Business Combination, (B) no person (other than any employee benefit plan sponsored or maintained by

-8-


the Surviving Corporation or the Parent Corporation), is or becomes the beneficial owner, directly or indirectly, of 20% or more of the total voting power of the outstanding voting securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation), and (C) at least a majority of the members of the board of directors of the parent Corporation (or, if there is no Parent Corporation, the surviving Corporation) were Incumbent Directors at the time of the Board’s approval of the execution of the initial agreement providing for such Business Combination (any Business Combination which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a “Non-Qualifying Transaction”); or

        (iv) The stockholders of the Corporation approve a plan of complete liquidation or dissolution of the Corporation or a sale or disposition of all or substantially all of the Corporation’s assets.

Notwithstanding the foregoing, a Change in Control of the Corporation shall not be deemed to occur solely because any person acquires beneficial ownership of more than 20% of the Company Voting Securities as a result of the acquisition of Company Voting Securities by the Corporation which reduces the number of Company Voting Securities outstanding; provided, that if after such acquisition by the Corporation such person becomes the beneficial owner of additional Company Voting Securities that increases the percentage of outstanding Company Voting Securities beneficially owned by such person, a Change in Control of the Corporation shall then occur.

        (i) Stock Unit Status . Stock Units are not, and do not constitute, shares of the Corporation’s common stock, and no right as a holder of shares of the Corporation’s common stock devolves upon a Director by reason of participation in this Plan.

        IN WITNESS WHEREOF, Praxair, Inc. has caused this document to be executed as of the 1 st day of January, 2004.

PRAXAIR, INC.
 
 
By:  /s/ David H. Chaifetz
David H. Chaifetz
Vice President, General Counsel and Secretary

-9-

SECOND AMENDMENT
TO THE AMENDED AND RESTATED
1993 PRAXAIR COMPENSATION DEFERRAL PROGRAM

Praxair, Inc. and Subsidiaries


Exhibit 10.07b

As of October 28, 2003

        In accordance with Section 9.8 of the Amended and Restated 1993 Praxair Compensation Deferral Program (the “Program”), the Program is hereby amended as follows:

        1. The references to the “1992 Praxair, Inc. Long Term Incentive Plan” in Section 1 of the Plan are revised to read the “2002 Praxair, Inc. Long Term Incentive Plan”.

        2. The references to "1996 Praxair, Inc. Senior Executive Performance Award Plan" in Sections 1 and 2.21 are revised to read "Praxair, Inc. Plan for Determining Performance-Based Awards Under Section 162(m)".

        3. The reference to "1992 Praxair, Inc. Variable Compensation Plan" in Section 2.20 is revised to read "1992 Praxair, Inc. Variable Compensation Plan".

        4. Section 2.2 of the Plan is amended in its entirety to read as follows:

 

“2.2 ‘Change in Control of the Corporation’ means the occurrence of any one of the following events with respect to the Corporation:


(i)

individuals who, on January 1, 2003, constitute the Board (the “Incumbent Directors”) cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director subsequent to January 1, 2003, whose election or nomination for election was approved by a vote of at least two-thirds of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Corporation in which such person is named as a nominee for director, without objection to such nomination) shall be an Incumbent Director; provided , however , that no individual elected or nominated as a director of the Corporation initially as a result of an actual or threatened election contest with respect to directors or any other actual or threatened solicitation of proxies [or consents] by or on behalf of any person other than the Board shall be deemed an Incumbent Director;


(ii)

any “person” (as such term is defined in Section 3(a)(9) of the Securities Exchange Act of 1934 (the “Exchange Act”) and as used in Sections



1

 

13(d)(3) and 14(d)(2) of the Exchange Act) is or becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Corporation representing 20% or more of the combined voting power of the Corporation’s then outstanding securities eligible to vote for the election of the Board (the “Company Voting Securities”); provided , however, that the event described in this paragraph (ii) shall not be deemed to be a Change in Control by virtue of any of the following acquisitions: (A) by the Corporation or any subsidiary, (B) by any employee benefit plan sponsored or maintained by the Corporation or subsidiary, (C) by any underwriter temporarily holding securities pursuant to an offering of such securities, or (D) pursuant to a Non-Qualifying Transaction (as defined in paragraph (iii));


(iii)  

the consummation of a merger, consolidation, statutory share exchange or similar form of corporate transaction involving the Corporation or any of its subsidiaries that requires the approval of the Corporation’s stockholders, whether for such transaction or the issuance of securities in the transaction (a “Business Combination”), unless immediately following such Business Combination: (A) more than 50% of the total voting power of (x) the corporation resulting from such Business Combination (the “Surviving Corporation”), or (y) if applicable, the ultimate parent corporation that directly or indirectly has beneficial ownership of 100% of the voting securities eligible to elect directors of the Surviving Corporation (the “Parent Corporation”), is represented by Company Voting Securities that were outstanding immediately prior to such Business Combination (or, if applicable, shares into which such Company Voting Securities were converted pursuant to such Business Combination), and such voting power among the holders thereof is in substantially the same proportion as the voting power of such Company Voting Securities among the holders thereof immediately prior to the Business Combination, (B) no person (other than any employee benefit plan sponsored or maintained by the Surviving Corporation or the Parent Corporation), is or becomes the beneficial owner, directly or indirectly, of 20% or more of the total voting power of the outstanding voting securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation) and (C) at least a majority of the members of the board of directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation) were Incumbent Directors at the time of the Board’s approval of the execution of the initial agreement providing for such Business Combination (any Business Combination which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a “Non-Qualifying Transaction”); or


(iv)

The stockholders of the Corporation approve a plan of complete liquidation or dissolution of the Corporation or a sale or disposition of all or substantially all of the Corporation’s assets.


2


 

Notwithstanding   the foregoing, a Change in Control of the Corporation shall not be deemed to occur solely because any person acquires beneficial ownership of more than 20% of the Company Voting Securities as a result of the acquisition of Company Voting Securities by the Corporation which reduces the number of Company Voting Securities outstanding; provided , that if after such acquisition by the Corporation such person becomes the beneficial owner of additional Company Voting Securities that increases the percentage of outstanding Company Voting Securities beneficially owned by such person, a Change in Control of the Corporation shall then occur.”


        5. Section 2.8 of the Plan is deleted in its entirety, and all subsequent paragraphs of Section 2 are renumbered accordingly.

        6. All references to the "Discounted Stock Value Rate" throughout the Plan are hereby deleted from the Plan.

        7. Section 2.15 (formerly Section 2.16) of the Plan is revised to refer to the "Praxair Retirement Savings Plan, as amended from time to time."

        8. Section 2.17 (formerly section 2.18) of the Plan is amended to delete the phrase "less five percent (5%)" therefrom.

        9. Section 8.2(a) of the Plan is amended in its entirety to read as follows:

 

"(a) Accrual Rates. Earnings accruing in accordance with Section 8.1 shall accrue at (i) the Fixed Income Rate, or (ii) the Stock Value Rate, or a combination of the two Rates."


        10. The above amendments are effective as of October 28, 2003.

PRAXAIR, INC.
 
 
By:  /s/ SALLY A. SAVOIA
Sally A. Savoia
Vice President- Human Resources
  Date: October 28, 2003

3

RATIO OF EARNINGS TO FIXED CHARGES

Praxair, Inc. and Subsidiaries


Exhibit 12.01

(Dollar amounts in millions, except ratios) Years Ended December 31,

        2003     2002     2001     2000     1999      





Pre-tax income from continuing operations before    
   adjustment for minority interests in consolidated    
   subsidiaries or income or loss from equity investees     $ 771   $ 717   $ 576   $ 483   $ 627    
       Capitalized interest       (9 )   (9 )   (17 )   (24 )   (30 )  
       Amortization of capitalized interest       12     12     11     10     9      
       Dividends from less than 50%-owned    
         companies carried at equity       19     9     5     3     1      





Adjusted pre-tax income from continuing operations    
    before adjustment for minority interests in    
    consolidated subsidiaries or income or loss    
    from equity investees     $ 793   $ 729   $ 575   $ 472   $ 607    





Fixed charges    
   Interest on long-term and short-term debt     $ 151   $ 206   $ 224   $ 224   $ 204    
   Amortization of capitalized interest       9     9     17     24     30      
   Rental expenses representative    
      of an interest factor       31     32     37     34     32      
   Preferred stock dividend requirements of    
      consolidated subsidiaries       .     1     2     4     8      





Total fixed charges       191     248     280     286     274      
   Less: preferred stock dividend requirements of    
      consolidated subsidiaries       -     (1 )   (2 )   (4 )   (8 )  





Total fixed charges less preferred stock dividends     $ 191   $ 247   $ 278   $ 282   $ 266    





Pre-tax income from continuing operations before    
   adjustment for minority interests in consolidated    
   subsidiaries or income or loss from equity    
   investees plus fixed charges and preferred stock    
   dividend requirements of consolidated subsidiaries     $ 984   $ 977   $ 855   $ 758   $ 881    
Less: preferred stock dividend requirements of    
    consolidated subsidiaries       -     (1 )   (2 )   (4 )   (8 )  





      $ 984   $ 976   $ 853   $ 754 $ 873    





RATIO OF EARNINGS TO FIXED CHARGES    
  AND PREFERRED STOCK DIVIDENDS       5.2     3.9     3.1     2.6     3.2      
 
RATIO OF EARNINGS TO FIXED CHARGES       5.2     3.9     3.1     2.7     3.3      



PRAXAIR, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME

(Dollar amounts in millions, except per share data)

Year Ended December 31,       2003     2002     2001  
 
SALES     $ 5,613   $ 5,128   $ 5,158  
Cost of sales, exclusive of depreciation and amortization       3,328     2,950     3,060  
Selling, general and administrative       766     751     699  
Depreciation and amortization       517     483     499  
Research and development       75     69     66  
Other income (expenses) - net       (5 )   48     (34 )



OPERATING PROFIT       922     923     800  
Interest expense       151     206     224  



INCOME BEFORE TAXES       771     717     576  
Income taxes       174     158     135  



        597     559     441  
Minority interests       (24 )   (20 )   (18 )
Income from equity investments       12     9     9  



INCOME BEFORE CUMULATIVE EFFECT OF ACCOUNTING CHANGES    
        585     548     432  
Cumulative effect of accounting changes       --     (139 )   (2 )



NET INCOME     $ 585   $ 409   $ 430  



PER SHARE DATA (Note 1)    
Basic Earnings per Share    
    Income before cumulative effect of accounting changes     $ 1.79   $ 1.68   $ 1.34  
    Cumulative effect of accounting changes       --     (0.42 )   (0.01 )



    Net income     $ 1.79   $ 1.26   $ 1.33  



Diluted Earnings per Share    
    Income before cumulative effect of accounting changes     $ 1.77   $ 1.66   $ 1.32  
    Cumulative effect of accounting changes       --     (0.42 )   (0.01 )



    Net income     $ 1.77   $ 1.24   $ 1.31  



WEIGHTED AVERAGE SHARES OUTSTANDING (000's) (Note 1)    
    Basic shares outstanding       326,388     325,536     323,020  
    Diluted shares outstanding       330,991     329,489     327,014  

The accompanying Notes on pages 41 to 61 are an integral part of these financial statements.

23


PRAXAIR, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

(Millions of dollars)

December 31,       2003     2002  
     
ASSETS    
Cash and cash equivalents     $ 50   $ 39  
Accounts receivable       962     860  
Inventories       302     277  
Prepaid and other current assets       135     110  


       Total Current Assets       1,449     1,286  
Property, plant and equipment - net       5,252     4,666  
Equity investments       182     184  
Goodwill       1,075     985  
Other intangible assets       56     50  
Other long-term assets       291     230  


       Total Assets     $ 8,305   $ 7,401  


LIABILITIES AND EQUITY    
Accounts payable     $ 413   $ 378  
Short-term debt       133     215  
Current portion of long-term debt       22     23  
Accrued taxes       104     74  
Other current liabilities       445     410  


      Total Current Liabilities       1,117     1,100  
Long-term debt       2,661     2,510  
Other long-term liabilities       916     826  
Deferred credits       328     461  


       Total Liabilities       5,022     4,897  


     
Commitments and contingencies (Note 20)    
     
Minority interests       195     164  
Shareholders' equity    
      Common stock $0.01 par value, authorized 500,000,000 shares,    
        issued 2003-354,951,262 shares and 2002-347,900,750 shares       4     2  
      Additional paid-in capital       2,148     1,965  
      Retained earnings       3,027     2,593  
      Accumulated other comprehensive income (loss)       (1,352 )   (1,673 )
      Less: Treasury stock, at cost (2003-28,865,414 shares and    
        2002-23,364,558 shares)       (739 )   (547 )


       Total Shareholders' Equity       3,088     2,340  


       Total Liabilities and Equity     $ 8,305   $ 7,401  


The accompanying Notes on pages 41 to 61 are an integral part of these financial statements.

24


PRAXAIR, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

(Millions of dollars)

Year Ended December 31,       2003     2002     2001  
     
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS    
     
OPERATIONS    
Net income     $ 585   $ 409   $ 430  
Adjustments to reconcile net income to net cash    
    provided by operating activities    
       Depreciation and amortization       517     483     499  
       Accounting change       --     139     --  
       Special charges       --     --     58  
       Deferred income taxes       33     37     36  
       Non-cash charges (benefits) and other       21     3     (11 )
       Working capital    
          Accounts receivable       (96 )   6     46  
          Inventories       (22 )   4     20  
          Prepaid and other current assets       (19 )   4     11  
          Payables and accruals       78     (41 )   (22 )
       Long-term assets, liabilities and other       40     (43 )   (47 )



     Net cash provided by operating activities       1,137     1,001     1,020  



     
INVESTING    
Capital expenditures (Note 5)       (983 )   (498 )   (595 )
Acquisitions       (73 )   (113 )   (213 )
Divestitures and asset sales       64     24     45  



     Net cash used for investing activities       (992 )   (587 )   (763 )



     
FINANCING    
Short-term debt borrowings (repayments) - net       (94 )   67     21  
Long-term debt borrowings       1,432     1,116     273  
Long-term debt repayments       (1,295 )   (1,428 )   (483 )
Minority interest transactions and other       (5 )   27     (14 )
Issuances of common stock       246     206     142  
Purchases of common stock       (271 )   (276 )   (76 )
Cash dividends       (149 )   (123 )   (110 )



     Net cash used for financing activities       (136 )   (411 )   (247 )



     
Effect of exchange rate changes on cash and cash equivalents       2     (3 )   (2 )



Change in cash and cash equivalents    
        11     --     8  
Cash and cash equivalents, beginning-of-year       39     39     31  



Cash and cash equivalents, end-of-year     $ 50   $ 39   $ 39  



     
SUPPLEMENTAL DATA    
Taxes paid     $ 109   $ 65   $ 57  
Interest paid     $ 168   $ 210   $ 219  
Tax benefits from stock option exercises     $ 24   $ 23   $ 20  
Debt from consolidation of equity companies (Note 14)     $ 9   $ --   $ 65  

The accompanying Notes on pages 41 to 61 are an integral part of these financial statements.

25


PRAXAIR, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(Dollar amounts in millions, except per share data, shares in thousands)

Common Stock Additional
Paid-in
Treasury Stock Retained Accumulated
Other
Comprehensive
Income
         Activity Shares Amounts Capital Shares Amounts Earnings (Loss) Total
 
Balance, December 31, 2000     166,309   $ 2   $ 1,658   6,930   $ (279 ) $ 1,987   $ (1,011 ) $ 2,357  
 
Net income                           430         430  
Translation adjustments                               (270 )   (270 )
Derivative instruments, net of
    $2 million taxes
                              (4 )   (4 )
Minimum pension liability, net of
    $6 million taxes
                              (12 )   (12 )

    Comprehensive income                                   144  
 
Dividends on common stock ($0.34 per share, Note 1)                           (110 )       (110 )
Issuances of common stock    
    For the dividend reinvestment and    
         stock purchase plan       45         1                     1  
    For employee savings and incentive
         plans
      3,787         136     (619 )   25             161  
Purchases of common stock                   1,687     (76 )           (76 )

Balance, December 31, 2001     170,141   $ 2   $ 1,795   7,998   $ (330 ) $ 2,307   $ (1,297 ) $ 2,477  
 
Net income                           409         409  
Translation adjustments                               (284 )   (284 )
Derivative instruments, net of
    $2 million taxes
                              3     3  
Minimum pension liability, net of
    $52 million taxes
                              (95 )   (95 )

    Comprehensive income                                   33  
 
Dividends on common stock ($0.38 per share, Note 1)                           (123 )       (123 )
Issuances of common stock    
    For the dividend reinvestment and    
       stock purchase plan       46                              
    For employee savings and incentive
       plans
      3,763         170     (1,292 )   59             229  
Purchases of common stock                   4,976     (276 )           (276 )

Balance, December 31, 2002     173,950   $ 2   $ 1,965   11,682   $ (547 ) $ 2,593   $ (1,673 ) $ 2,340  
 
Net income                           585         585  
Translation adjustments                               313     313  
Minimum pension liability, net of
    $5 million taxes
                              8     8  

    Comprehensive income                                   906  
 
Dividends on common stock ($0.46 per
    share)
                          (149 )       (149 )
Issuances of common stock    
    For the dividend reinvestment and    
       stock purchase plan       48                             --  
    For employee savings and incentive
       plans
      3,535         183     (1,681 )   79             262  
Purchases of common stock                   4,614     (271 )           (271 )
Two-for-one stock split (Note 1)       177,418     2         14,250         (2 )       --  

Balance, December 31, 2003     354,951   $ 4   $ 2,148   28,865   $ (739 ) $ 3,027   $ (1,352 ) $ 3,088  

The accompanying Notes on pages 41 to 61 are an integral part of these financial statements.

26


MANAGEMENT’S DISCUSSION AND ANALYSIS

OVERVIEW

Praxair is the largest industrial gases supplier in North and South America, is rapidly growing in Asia, and has a strong, well-established businesses in Southern Europe. The company’s primary products are oxygen, nitrogen, argon, carbon dioxide, helium, hydrogen, electronics gases and a wide range of specialty gases. Praxair Surface Technologies supplies high-performance coatings that protect metal parts from wear, corrosion and high heat. All together, Praxair serves approximately 25 industries as diverse as healthcare and petroleum refining; computer-chip manufacture and beverage carbonation; fiber-optics and steel making; and aerospace, chemicals and water treatment. In 2003, 93% sales was generated from industrial gases in four regional segments (North America, Europe, South America, and Asia), with the balance generated from the Surface Technologies segment.

Praxair manufactures and distributes its products through a network of hundreds of production plants, cylinder-filling stations and pipeline complexes in manufacturing enclaves. Major pipeline complexes are located in the United States, Brazil and Spain. This network is a competitive advantage for the company as it provides the foundation of reliability for product supply to our customer base.

Electricity, natural gas and diesel fuel are the largest cost elements in the production and distribution of industrial gases. Praxair minimizes the financial impact of variability in these costs through the management of customer contracts which typically have escalation and pass-through clauses.

Praxair performed well in 2003, despite a relatively weak U.S. economy in the first half. For the full year 2003, the company reported record net income of $585 million, and diluted earnings per share of $1.77, a 7% increase from $548 million and $1.66 per share in 2002, before an accounting change and adjusted for a stock split in December. Full-year sales were $5,613 million, 9% higher than 2002. Sales rose 5% excluding the impact of higher natural gas prices, which are passed through to hydrogen customers, and stronger currencies in Europe and South America. Underlying sales grew from higher volumes in all regions and higher overall pricing. Sales increased strongly to energy, metals, healthcare, and chemicals markets. Manufacturing and electronics sales were also higher versus 2002.

CONSOLIDATED RESULTS

The following table provides summary data for 2003, 2002 and 2001:

(Millions of dollars)         Variance        
Year Ended December 31, 2003 2002 2001(a,b) 2003 vs. 2002 2002 vs. 2001
Sales     $ 5,613   $ 5,128   $ 5,158     +9%     -1%  
Gross margin (c)     $ 2,285   $ 2,178   $ 2,098     +5%     +4%  
  As a percent of sales       40.7%   42.5%   40.7%
Selling, general and administrative     $ 766   $ 751   $ 699     +2%     +7%  
  As a percent of sales       13.6%   14.6%   13.6%
Depreciation and amortization     $ 517   $ 483   $ 499     +7%     -3%  
Other income (expenses) - net     $ (5 ) $ 48   $ (34 )
Operating profit     $ 922   $ 923   $ 800     0%   +15%  
Interest expense     $ 151   $ 206   $ 224     -27%     -8%  
Effective tax rate       22.6%   22.0%   23.4%
Income before cumulative    
   effect of accounting changes     $ 585   $ 548   $ 432     +7%     +27%  
Number of employees       25,438     25,010     24,271     +2%     +3%  

(a) Praxair adopted Statement of Financial Accounting Standards (SFAS) 142, which eliminated the amortization of goodwill beginning in 2002. 2001 reported results included goodwill amortization of $38 million pre-tax and $33 million after-tax.
(b) 2001 reported results include a pre-tax special charge of $70 million ($57 million after-tax) related to restructuring and other actions. The charge was recorded as: $7 million in cost of sales, $5 million in selling, general and administrative, and $58 million in other income (expenses) – net (see Note 3 to the consolidated financial statements).
(c) Gross margin excludes depreciation and amortization expense.

27


2003 Compared With 2002

Sales in 2003 increased $485 million, or 9%, versus 2002. Realized price increases, principally in South America, North America and Europe, increased sales 3%. Overall, currency increased sales by 2%, largely due to the progressive strengthening of the Euro versus the U.S. dollar throughout 2003. Sales increased 1% due to volume as all geographic segments reported year-over-year improvement. Strong volume growth in Asia and South America within the electronics, energy, metals and manufacturing markets offset sluggish but improving conditions in North America markets. Increased natural gas costs, which Praxair is contractually obligated to pass on to on-site hydrogen customers, increased sales by 2%, with no impact on operating profit. Acquisitions in healthcare, packaged gas and on-site markets worldwide increased sales by 1%.

Gross margin in 2003 improved $107 million, or 5%, versus 2002. Gross margin as a percent of sales declined 180 basis points to 40.7%, versus 2002. A 70 basis-point reduction in gross margin percentage was a result of increased natural gas cost pass-throughs, which had no impact on reported gross margin. Energy costs grew faster than our ability to increase prices, primarily in the North American merchant market, further dampening our gross margin as a percent of sales.

Selling, general and administrative expenses in 2003 were $766 million, or 13.6% of sales, versus $751 million or 14.6% of sales for 2002. The dollar increase was principally the result of currency appreciation in Europe and acquisitions. Excluding those factors, underlying operational expenses were essentially flat as a result of continued focus on productivity initiatives.

Depreciation and amortization in 2003 increased $34 million, or 7%, versus 2002. The increase was due to an increase in capital expenditures of $22 million, $9 million in currency appreciation and $3 million in business acquisition activity.

Other income (expenses) – net in 2003 was a loss of $5 million in 2003 versus a $48 million gain in 2002. 2003 included $9 million of losses on net income hedges (primarily in Europe and Brazil). 2002 included $17 million of net income hedge gains (primarily in Brazil) and a $7 million gain from a favorable litigation settlement. Refer to Note 6 to the consolidated financial statements for a summary of the major components of other income (expenses) – net.

Operating profit in 2003 was $922 million, flat compared to 2002. Excluding the impacts of net income hedges in both periods and the litigation settlement in 2002, underlying operating profit improved 4% primarily due to continued progress on productivity initiatives and currency appreciation of the Euro which outpaced inflationary pressures on cost structures.

Interest expense in 2003 declined $55 million, or 27%, versus 2002. The reduction in interest expense is primarily due to the 2002 and 2003 refinancings of debt at lower interest rates.

The effective tax rate for 2003 was 22.6%, versus 22.0% for 2002, due to the lower earnings contribution from Brazil, which has a lower effective tax rate, and lower interest expense in the U.S., which is deductible at a 35% marginal rate. A $10 million tax benefit was recorded in the second quarter of 2003 resulting from the resolution of various tax matters for previous years. For 2004, we expect a full year effective tax rate of approximately 25% as the tax benefit will not recur and effective tax rates in Europe and South America should continue to increase modestly.

At December 31, 2003, minority interests consist of minority shareholders’ investments in Europe (primarily Rivoira S.p.A. in Italy), North America (primarily within Praxair Distribution) and Asia (primarily China and India). The increase in minority interest of $4 million in 2003 was due primarily to the consolidation of joint ventures in Asia and Europe (as a result of increased ownership in these joint ventures).

Our significant equity investments are in Italy, the United States and Spain. Praxair’s share of net income from corporate equity investments increased $3 million in 2003 primarily due to improved profitability of its joint venture in Italy.

Income before accounting changes increased $37 million, or 7%, compared to 2002 primarily due to the reduction of interest expense.

The number of employees at December 31, 2003 was 25,438, reflecting an increase of 428 employees from December 31, 2002. This increase related primarily to new service initiatives in Brazil (+833), partially offset by restructuring actions primarily in Surface Technologies (-144) and the divestiture of Praxair’s operations in Poland (-170).

28


2002 Compared With 2001

Sales in 2002 decreased $30 million, or 1%, versus 2001. Realized price increases in North and South America and acquisitions in our healthcare portfolio each increased sales by 2%, respectively. Sales in 2002 were reduced 3% from currency devaluations, principally in South America. Overall sales volume declined 1% as manufacturing activity in the United States remained sluggish, but was partially offset by volume gains in Europe and Asia, and in the North American healthcare businesses. Reduced natural gas costs, which Praxair is contractually obligated to pass on to on-site hydrogen customers, decreased sales by 1%, with no impact on operating profit.

Gross margin in 2002 improved $80 million, or 4%, versus 2001. Gross margin as a percent of sales improved 180 basis points to 42.5%, versus 2001. This improvement reflected realized pricing initiatives in the North and South American segments; worldwide productivity initiatives related to Six Sigma programs; and the benefits of the restructuring program initiated in the third quarter of 2001. A 60 basis-point improvement in gross margin percentage was a result of natural gas cost pass-throughs, which lowered reported sales, but had no impact on reported gross margins.

Selling, general and administrative expenses for 2002 were $751 million, or 14.6% percent of sales, versus $699 million, or 13.6% of sales for 2001. This increase reflects primarily North American healthcare acquisitions of $17 million. Other factors include service growth initiatives having a higher proportion of selling, general and administrative costs; higher bad-debt expense; and the effects of natural gas pass-through costs on sales.

Other income (expenses) – net in 2002 was a gain of $48 million compared to a loss of $34 million in 2001. 2001 included a $58 million special charge related primarily to severance and asset write-offs. 2002 included $17 million of gains on net income hedges (primarily in Brazil) versus $8 million of such losses in 2001 (primarily in Brazil and Mexico). Refer to Note 6 to the consolidated financial statements for a summary of the major components of other income (expenses) – net. See Note 3 to the consolidated financial statements for more information regarding special charges.

Operating profit in 2002 increased $123 million, or 15%, principally due to the $70 million special charge recorded in the third quarter of 2001 and the elimination of goodwill amortization in 2002 (2001 reported results included goodwill amortization of $38 million). Underlying operating profit increased 2% as a result of productivity improvements and benefits from the 2001 restructuring program which outpaced inflationary pressures.

Interest expense in 2002 declined $18 million, or 8% versus 2001. The decline in interest expense is primarily due to the refinancing of debt at lower interest rates and the reduction of debt versus 2001 levels. 2002 interest expense included $15 million of costs from the early retirement of $300 million of bonds.

The effective tax rate for 2002 was 22.0% versus 23.4% for 2001. The decrease is largely attributable to the effects of foreign tax planning and the discontinuation of goodwill amortization in 2002.

The increase in minority interest of $2 million in 2002 versus 2001 was due to the consolidation of joint ventures in Asia (as a result of our increased ownership in joint venture companies in India and China).

Praxair’s share of net income from corporate equity investments, reflecting activity primarily in Belgium, China and Turkey, was flat for 2002 compared to 2001.

Income before accounting changes increased $116 million, or 27%, reflecting the after-tax benefits of the improvement in operating profit discussed above and lower interest expense due to debt refinancing at lower rates and debt reductions in 2002.

The number of employees at December 31, 2002 was 25,010, which reflected an increase of 739 employees from December 31, 2001. This increase related primarily to acquisitions (approximately 680 employees) and new service initiatives in Brazil, partially offset by restructuring actions.

Accounting Changes

In the second quarter of 2002, Praxair completed the initial goodwill impairment tests required for the adoption of SFAS 142. These tests indicated an impairment of goodwill related to previous acquisitions. As a result, a $139 million non-cash transition charge to earnings was recorded as a cumulative effect of an accounting change, retroactive to January 1, 2002. In the first quarter of 2001, a one-time transition charge of $2 million was recorded for the adoption of SFAS 133, which established new accounting rules for derivatives. For more information, see Note 2 to the consolidated financial statements.

29


Related Party Transactions

The company’s related parties are primarily unconsolidated equity affiliates. The company did not engage in any material transactions involving related parties that included terms or other aspects that differ from those which would be negotiated with independent parties.

Costs Relating to the Protection of the Environment

Praxair’s principal operations relate to the production and distribution of atmospheric and other industrial gases, which historically have not had a significant impact on the environment. However, worldwide costs relating to environmental protection may continue to grow due to increasingly stringent laws and regulations, and Praxair’s ongoing commitment to rigorous internal standards. Environmental protection costs in 2003 included approximately $10 million in capital expenditures and $14 million of expenses, including $3 million for remediation projects. Environmental protection expenditures were approximately $2 million to $3 million higher in 2003 versus 2002 due to the construction of new hydrogen plants. Praxair anticipates that future environmental protection expenditures will be similar to 2003. Based on historical results and current estimates, management does not believe that environmental expenditures will have a material adverse effect on the consolidated financial position or on the consolidated results of operations or cash flows in any given year.

Legal Proceedings

See Note 20 to the consolidated financial statements for information concerning legal proceedings.

SEGMENT DISCUSSION

The following summary of sales and operating profit by segment provides a basis for the discussion that follows:

(Millions of dollars)         Variance        
Year Ended December 31, 2003 2002 2001 2003 vs. 2002 2002 vs. 2001
   
SALES                        
North America     $ 3,627   $ 3,351   $ 3,434     +8%     -2%  
Europe       699     589     537     +19%     +10%  
South America       708     632     674     +12%     -6%  
Asia       389     324     255     +20%     +27%  
Surface Technologies       400     394     410     +2%     -4%  
Eliminations       (210 )   (162 )   (152 )





      $ 5,613   $ 5,128   $ 5,158     +9%     -1%  





OPERATING PROFIT (a,b)    
North America     $ 548   $ 557   $ 545     -2%     +2%  
Europe       170     139     119     +22%     +17%  
South America       114     134     129     -15%     +4%  
Asia       64     51     38     +25%     +34%  
Surface Technologies       26     35     39     -26%     -10%  
All Other       --     7     --  





      $ 922   $ 923   $ 870     0 %   +6%  






(a) Praxair recorded pre-tax charges totaling $70 million in the third quarter of 2001 which are not included in Praxair’s management reporting definition of operating profit (see Note 3 to the consolidated financial statements). Segment operating profit in 2001 excluded $70 million of special charges as follows: North America, $26 million; Europe, $3 million; South America, $30 million; Surface Technologies, $4 million; and All Other $7 million.

(b) Effective in 2002, Praxair adopted SFAS 142, which eliminated the amortization of goodwill prospectively. Goodwill amortization included in the year ended December 31, 2001 was $38 million as follows: North America, $20 million; Europe, $4 million; South America, $9 million; Asia, $3 million; and Surface Technologies, $2 million.

30


North America

The North America operating segment includes Praxair’s industrial and packaged gases operations in the U.S., Canada and Mexico. Praxair’s U.S. and Canadian packaged gases operations within the North American industrial gases business are collectively referred to as Praxair Distribution. North America also includes several product lines servicing the electronics and healthcare industries.

Sales for 2003 increased $276 million, or 8%, versus 2002. The effect of escalating natural gas costs for hydrogen customers increased sales 3% with no impact on operating profit. Overall price increases of 3% were primarily realized in our U.S. and Canadian on-site, merchant and packaged gas business units and in Mexico. Acquisitions by our healthcare and packaged gas business units increased sales by 1%. Sales volumes continued to improve in the chemical, energy, manufacturing and metals end markets as manufacturing activity improved resulting in an increase in sales of 1%.

Operating profit for 2003 decreased $9 million, or 2%, versus 2002. Excluding electricity costs, realized price increases and continued focus on productivity and purchasing initiatives offset underlying inflationary pressures on our cost structures. Electricity costs, on average, increased by 15% in the United States, which marginally outpaced realized price increases primarily in our merchant markets. In addition, tough market conditions prevailed in the first half of 2003 in our electronics markets, marginally decreasing operating profit versus 2002.

Sales for 2002 decreased $83 million, or 2%, versus 2001. The effect of lower natural gas costs reduced sales 2% to hydrogen customers with no impact on operating profit. Overall, realized price increases offset currency devaluations in Mexico and Canada. Acquisitions in North American healthcare and packaged gases increased sales by 2% while lower sales volumes reduced sales by 3% primarily in the packaged gases business as the company focused on tactics to gain share in industrial gases versus lower margin hardgoods. Sales volumes improved in Mexico and healthcare as growth initiatives continued to be implemented. Electronics sales decreased as the slump in worldwide semiconductor markets continued.

Operating profit increased $12 million, or 2%, versus 2001. The elimination of goodwill amortization in 2002 resulted in an improvement of $20 million. Excluding this impact, operating profit decreased 1%. Realized price increases and cost reductions related to productivity initiatives and the restructuring in 2001 offset inflationary pressures on North American cost structures. The impact of lower sales volumes on operating profit was partially mitigated by the effect of North American healthcare organic growth and acquisitions, and good operating-margin enhancement programs in Mexico.

Beginning in 2005, the Medicare Prescription Drug Improvement and Modernization Act of 2003 may reduce sales for certain healthcare products by approximately $5 million to $9 million. Management is currently reviewing the impact of this legislation, but expects to mitigate this exposure with cost reductions in production and distribution.

Europe

Praxair’s European industrial gases business is primarily in Italy and Spain with additional operations in Benelux, Germany, France and Israel. On January 31, 2003, Praxair completed the sale of its Polish business for approximately $50 million. Praxair Polska had $26 million in sales for 2002. On November 26, 2003, Praxair acquired the remaining shares of its Belgium Indugas joint venture and began consolidating its financial results. Indugas had $35 million in sales during 2003.

Sales for 2003 increased $110 million, or 19%, versus 2002. The favorable impact of the stronger Euro currency increased sales by 19%. Sales volumes and realized price increases each favorably impacted sales by 2%, offsetting the net decrease in sales resulting from the Poland divestiture and the Indugas consolidation. Market share penetration in the manufacturing, healthcare and metals markets principally drove the sales volume gains.

31


Operating profit for 2003 increased $31 million, or 22%, versus 2002. The favorable impact of the Euro currency generated 17% of this increase. Underlying operating profit grew 9% as cost reduction programs, the Indugas consolidation, and operating leverage on the sales volume growth significantly outpaced the net impact of pricing and inflation on cost structures. The divestiture of the Poland operations adversely impacted operating profit by 4%.

Sales for 2002 increased $52 million, or 10%, versus 2001. Fueled by infrastructure investments in Spain and market share gains in the food and beverage and welding markets, volumes increased strongly in Europe by 5%. Favorable currency movements impacted sales growth by an additional 4%.

Operating profit for 2002 increased $20 million, or 17%, versus 2001. Currency favorably increased operating profit by 7%. Productivity programs offset inflationary pressures on the underlying cost structure. The favorable sales volume impact resulted in an improvement of 8% on operating profit. The elimination of goodwill amortization in 2002 had a favorable impact of 3%.

South America

Praxair’s South American industrial gases operations are conducted by its subsidiary, White Martins Gases Industriais Ltda. (White Martins), which is the largest industrial gases company in Brazil. White Martins also has operations in Argentina, Bolivia, Chile, Colombia, Paraguay, Peru, Uruguay and Venezuela.

Sales for 2003 increased $76 million, or 12%, versus 2002. The effects of currency adversely impacted reported sales by 7% due principally to devaluation of the Brazilian real which stabilized in the second half of 2003 at approximately 2.9 per U.S. dollar. Strong pricing initiatives resulted in an increase to sales of 9%. Sales volumes were strong, increasing sales by 9% due to strong sales to metal manufacturers supplying export markets, healthcare and chemical customers.

Operating profit for 2003 decreased $20 million, or 15%, versus 2002. 2003 operating profit included $2 million of net income hedge losses and a $5 million expense related to the settlement of legal matters. 2002 operating profit included $20 million of net income hedge gains. Excluding these impacts, underlying operating profit increased 6%. Continued focus on productivity initiatives and pricing actions mostly offset the unfavorable impact of inflation. Severance costs decreased operating profit by 4% as South American management continued to implement productivity improvements. Increased sales volumes improved operating profit by 14% demonstrating favorable operating leverage. In October of 2003, the Brazilian government enacted an increase of 3% to 7.6% to its social security financing tax, which became effective on February 1, 2004. The tax is levied on Brazilian sales and management believes that most, if not all, of the impact can be passed along to customers.

Sales for 2002 decreased $42 million, or 6%, versus 2001. In 2002, the effects of currency devaluations were substantial and adversely impacted reported sales by $149 million, or 22%. Strong pricing initiatives were implemented resulting in a realized price increase of 12%. Sales volumes continued to grow steadily as new, less capital-intensive opportunities were pursued in metal fabrication, pipeline management, site-gas management and recycling market places.

Operating profit for 2002 increased $5 million, or 4%, versus 2001. The elimination of goodwill amortization in 2002 resulted in an improvement of $9 million, or 7%. Excluding this impact, operating profit decreased 3%. 2002 operating profit included a net income hedge gain of $20 million while 2001 included a net income hedge loss of $2 million. The net impact of currency devaluations, inclusive of net income hedges, decreased operating profit by 5%, versus 2001. Partially offsetting this decrease was favorable sales volume growth and cost reduction initiatives which outpaced inflationary impacts on cost structures. The effects of the general strike in Venezuela had a small adverse impact in 2002.

There are significant uncertainties surrounding the economic and political stability in South America which may result in significant currency movements versus the U.S. dollar. During 2003, the fluctuations in the Brazilian real, Venezuelan bolivar and the Argentine peso versus the U.S. dollar resulted in a benefit of approximately $148 million (a charge of $375 million in 2002) to accumulated other comprehensive income in shareholders’ equity. Looking forward, it is not possible to accurately predict how currency fluctuations will impact financial results.

32


Currency movements versus the U.S. dollar have historically impacted reported results, especially in Brazil, Argentina and Venezuela. In 2003, Brazil represented approximately 79% of the company’s South American sales, Venezuela represented approximately 4% and Argentina represented approximately 5%. The functional currency used for translation to the U.S. dollar for Argentina and Brazil are the peso and real, respectively. The company uses the U.S. dollar in Venezuela as its functional currency as it is a highly inflationary economy in accordance with SFAS 52.

To help understand the reported results, the following is a summary of the exchange rates used to translate the financial statements in Brazil, Argentina and Venezuela (rates of exchange expressed in units of local currency per U.S. dollar):

Income Statement Balance Sheet


Average Year-to-Date December 31, December 31,


Currency       2003     2002     2001     2003     2002  





Brazil real       3.06     2.92     2.36     2.89     3.53  
Argentina peso       2.95     3.16     1.00     2.93     3.37  
Venezuela bolivar       1,609     1,162     747     1,600     1,401  

Asia

The Asia segment includes Praxair’s industrial gases operations primarily in China, India, Korea and Thailand, with smaller operations in Japan, Malaysia and Taiwan. Operations in China are also conducted through non-consolidated joint venture companies accounted for as equity investments.

Sales for 2003 increased $65 million, or 20%, versus 2002. Strong volume growth in Chinese metals and electronics markets, Korean electronics markets, Indian metals markets, and Thailand food markets led to volume growth of 14%. Praxair increased its ownership and began consolidating joint venture companies in China, increasing sales by $10 million, or 3%. The effects of favorable currency rates primarily in India, Thailand and Korea, favorably impacted sales by 3%. Management continues to focus investment in China for growth opportunities.

Operating profit for 2003 increased $13 million, or 25%, versus 2002. The consolidation of the joint venture increased operating profit by 6%. Operating profit grew 29% from increased sales volumes as favorable operating leverage was realized on plant infrastructure investments. Cost productivity initiatives partially mitigated the impacts of cost inflation.

Sales for 2002 increased $69 million, or 27%, versus 2001. During the 2001 third quarter, and the first quarter of 2002, Praxair increased its ownership and began consolidating joint venture companies in India and China, respectively, increasing 2002 sales by $51 million or 20%. The remaining sales increase is due to strong volume growth and price increases.

Operating profit for 2002 increased $13 million, or 34%, versus 2001. The consolidation of the India and China joint venture companies increased operating profit by $12 million or 32%. The remaining increase was a result of sales volume growth, productivity initiatives and the elimination of goodwill amortization, partially offset by cost inflation.

Surface Technologies

Praxair’s worldwide Surface Technologies business operates primarily in the U.S. and Europe, with smaller operations in Asia and Brazil.

Sales for 2003 increased $6 million, or 2%, versus 2002 as favorable currency impacts outpaced declining sales volumes. The lower volumes reflect market weakness in the global coatings and aviation services business units.

Operating profit for 2003 decreased $9 million, or 26%, versus 2002 as weakening volumes outpaced cost reduction initiatives. In 2003, $2 million of severance expense was incurred to reduce cost structures in reaction to difficult market conditions in global coatings and aviation services, providing the foundation for favorable operating leverage when market conditions improve.

Sales for 2002 decreased $16 million, or 4%, versus 2001 due primarily to lower sales volumes. The lower volumes reflect weakness in the global coatings and aviation services businesses.

Operating profit decreased $4 million, or 10%, versus 2001. A 5% improvement in operating profit from the discontinuation of goodwill amortization in 2002 was more than offset by volume declines.

All Other

The 2002 operating income of $7 million represents a net gain related to the settlement of litigation with Airgas, Inc.

33


LIQUIDITY, CAPITAL RESOURCES AND FINANCIAL DATA

(Millions of dollars)                
Year Ended December 31,       2003     2002     2001  
NET CASH PROVIDED BY (USED FOR)    
     
OPERATING ACTIVITIES    
Net income plus depreciation and    
     amortization, accounting change and special charges     $ 1,102   $ 1,031   $ 987  
Working capital       (58 )   (27 )   55  
Other - net       93     (3 )   (22 )



Total provided by operating activities     $ 1,137   $ 1,001   $ 1,020  



     
INVESTING ACTIVITIES    
Capital expenditures     $ (983 ) $ (498 ) $ (595 )
Acquisitions       (73 )   (113 )   (213 )
Divestitures and asset sales       64     24     45  



Total used for investing     $ (992 ) $ (587 ) $ (763 )



     
FINANCING ACTIVITIES    
Debt increases (reductions)     $ 43   $ (245 ) $ (189 )
Minority transactions and other       (5 )   27     (14 )
Issuances (purchases) of stock       (25 )   (70 )   66  
Cash dividends       (149 )   (123 )   (110 )



Total used for financing     $ (136 ) $ (411 ) $ (247 )



     
DEBT-TO-CAPITAL RATIO AT DECEMBER 31    
Debt     $ 2,816   $ 2,748   $ 2,989  
Capital(a)     $ 6,099   $ 5,252   $ 5,627  
Debt-to-capital ratio       46.2%   52.3%   53.1%

(a) Includes debt, minority interests, preferred stock and shareholders' equity. See the Five-Year Financial Summary on page 64.

Cash Flow from Operations

Cash flow from operations increased $136 million to $1,137 million in 2003 from $1,001 million in 2002. The improvement is due to increased earnings, an increase in Non-cash (benefits) charges and other and from a reduction in cash payments related to the 2000 and 2001 special charges (see Note 3 to the consolidated financial statements).

Cash flow from operations decreased $19 million to $1,001 million in 2002 from $1,020 million in 2001. This marginal decrease related primarily to working capital, which reflected continued improvement in receivables and inventory management, more than offset by reductions in accounts payable.

Investing

Cash flow used for investing in 2003 totaled $992 million, an increase of $405 million from 2002. The increase is primarily related to the purchase of leased assets for $339 in June 2003 in response to favorable financing conditions (see Note 5 to the Consolidated Financial Statements) and increased capital expenditures for two new steam methane reformers to support North American hydrogen customers. Cash flow used for investing in 2002 totaled $587 million, a decrease of $176 million from 2001. This decrease was due to lower capital expenditures in most business units and decreased healthcare acquisitions versus 2001.The reduction of capital expenditures from 2001 to 2002 was in response to the economic slowdown in several markets, and increased financial rigor in Praxair’s capital appropriation process.

Acquisition expenditures for 2003 totaled $73 million, a decrease of $40 million from 2002. Acquisition expenditures for 2002 totaled $113 million, a decrease of $100 million from 2001. The decrease in both years was due to the smaller number of and amounts paid for acquisitions related to the North American healthcare and electronics businesses.

Divestitures and asset sales in 2003 totaled $64 million, an increase of $40 million from 2002. The increase is due primarily to the sale of Praxair’s Polish business for approximately $50 million. Divestitures and asset sales in 2002 totaled $24 million, a decrease of $21 million from 2001. The decrease is due largely to the absence of $17 million of sale proceeds in 2001 for the sale of an investment in Asia.

34


On a worldwide basis, capital expenditures for the full year 2004 are expected to be in the range of $700 million, anticipating additional investment in hydrogen infrastructure and significant investment in China to supply new contracts awarded in 2003. At December 31, 2003, $222 million of the capital expenditures had been approved and committed. Acquisition expenditures will depend on the availability of opportunities at attractive prices.

Financing

Praxair’s financing strategy is to secure sufficient funds to support its operations in the U.S. and around the world using a combination of local borrowing and intercompany funding to minimize the total cost of funds and to manage and centralize currency exchange exposures. Praxair manages its exposure to interest rate changes through the use of financial derivatives (see Note 15 to the consolidated financial statements and the section entitled “Market Risks and Sensitivity Analyses”).

At December 31, 2003, the company’s total debt outstanding was $2,816 million, an increase of $68 million from 2002. The December 31, 2003 debt balance is comprised of $2,352 million in public notes, $218 million in commercial paper, and the remaining $246 million represents primarily bank borrowings from around the world. As of December 31, 2003, there were no borrowings under Praxair’s $1 billion U.S. bank credit facility. As the result of strong operating cash flow and favorable liquidity, the company canceled its $500 million 364-day revolving credit facility. As a result of the company’s overall improved financial condition, Standard and Poor’s upgraded the company’s long-term debt rating from BBB+ to A- and Moody’s issued a favorable outlook on the company’s A3 rating. Commercial paper was rated P2 by Moody’s and A2 by Standard & Poor’s. At December 31, 2003, Praxair was in compliance with its borrowing covenants.

During 2003, Praxair repaid $300 million of 6.75% notes, $75 million of 6.625% notes, and $250 million of 6.15% notes that were due on March 1, 2003, March 15, 2003, and April 15, 2003, respectively. The repayments were funded through the issuance of commercial paper. During 2002, Praxair redeemed the 8.7% debentures due 2022 resulting in an additional $15 million charge recorded within interest expense for the year ended December 31, 2002.

During 2003, Praxair issued $350 million of 3.95% notes due 2013 and $300 million of 2.75% notes due 2008. The proceeds of these debt issuances were used to refinance commercial paper and purchase $339 million of previously leased assets. During 2002, Praxair issued $500 million of 6.375% notes due 2012 and $250 million of 4.75% notes due 2007. The proceeds were used to repay outstanding commercial paper.

Our debt-to-capital ratio decreased to 46.2% at December 31, 2003 from 52.3% at December 31, 2002. This decrease is due to an increase in the shareholders’ equity component of capital resulting from the impact of 2003 net income and favorable translation adjustments (see the “Five Year Financial Summary” on page 64 for a definition of debt-to-capital).

Off-Balance Sheet Arrangements and Contractual Obligations

The following table sets forth Praxair’s material contractual obligations and other commercial commitments as of December 31, 2003:

(Millions of dollars) Contractual Obligations Other Commercial Commitments


Due or
Expiring by
December 31,
Debt and
Capitalized
Lease
Maturities
Obligations
under
Operating
Leases
Unconditional
Purchase
Obligations
Total Construction
Commitments
Guarantees
And Other
Total
  2004   $ 389   $ 69   $ 108   $ 566   $ 197   $ 121   $ 318  
  2005     172     55     67     294     25     4     29  
  2006     282     42     49     373     --     --     --  
  2007     516     23     41     580     --     --     --  
  2008     556     12     33     601     --     4     4  
  Thereafter     901     17     118     1,036     --     --     --  


      $2,816   $218 $ 416   $ 3,450   $ 222   $ 129   $ 351  



35


Debt and capitalized lease maturities of $2,816 million are more fully described in Note 14 to the consolidated financial statements and are included on the company’s balance sheet as long- and short-term liabilities.

Obligations under operating leases of $218 million represent off-balance sheet, non-cancelable contractual obligations primarily for manufacturing and distribution equipment and office space. See Note 5 to the consolidated financial statements for further details.

Unconditional purchase obligations of $416 million represent contractual commitments under various long- and short-term take-or-pay arrangements with suppliers and are not included on Praxair’s balance sheet. These obligations are primarily minimum purchase commitments for electricity, natural gas and feedstock used to produce atmospheric gases, carbon dioxide and hydrogen. During 2003, payments under these contracts totaled $341 million, including $194 million for electricity and $83 million for natural gas. A significant portion of these risks are passed on to customers through similar take-or-pay contractual arrangements. Purchase obligations which are not passed along to customers do not represent a significant risk to Praxair. In addition, Praxair enters into contracts to purchase products and services that do not have minimum purchase provisions.

Construction commitments of $222 million represent outstanding commitments to customers or suppliers to complete authorized construction projects as of December 31, 2003. A significant portion of Praxair’s capital spending is related to the construction of new production facilities to satisfy customer commitments which may take a year or more to complete.

Guarantees and Other of $129 million include $80 million related to required minimum pension contributions and $49 million related to Praxair’s off-balance sheet contingent obligations under guarantees of certain debt of unconsolidated affiliates. Unconsolidated equity investees had total debt of approximately $145 million at December 31, 2003, which was non-recourse to Praxair with the exception of the guaranteed portions described above. Praxair has no financing arrangements with closely-held related parties.

See Note 20 to the consolidated financial statements for more information concerning commitments and contingencies. In addition, see Note 9 to the consolidated financial statements for a summary of long-term liabilities which consist primarily of pension and other post-retirement benefit costs (OPEB). Also, see the “Pension Benefits” section that follows for a discussion of funding obligations.

Pension Benefits

The company completed its year-end pension plan calculations in early January 2004 based on December 31, 2003 interest rates and asset values. As a result, the non-cash minimum pension liability recorded at December 31, 2003 was reduced by $13 million to $152 million at December 31, 2003 ($99 million after-tax) from $165 million at December 31, 2002 ($107 million after-tax). The adjustment to the pension liability did not affect net income as the offsetting, after-tax charge was made to accumulated other comprehensive income within shareholders’ equity.

Pension contributions were $34 million in 2003 ($7 million in 2002). Estimates of required 2004 contributions are in the range of $80 million assuming that interest rate relief legislation will become law. If interest rate relief is not enacted, then our estimates of the 2004 contributions are in the range of $130 million. In February 2004, contributions of $60 million were paid.

For 2004, Praxair will leave its expected return on plan assets in the U.S. at 8.5%, identical to 2003. In 2004, consolidated pension expense is expected to be approximately $35 million versus $26 million in 2003 and $15 million in 2002.

Insurance

Praxair purchases insurance to limit a variety of risks, including those related to workers compensation, liability (general, products, professional and vehicles) and property. Praxair retains limited potential liability related to deductible amounts. Liabilities related to reported and unreported claims incurred are included in long- and short-term liabilities.

36


CRITICAL ACCOUNTING POLICIES

The policies discussed below are considered by management to be critical to understanding Praxair’s financial statements and accompanying notes prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). Their application places significant importance on management’s judgement as a result of the need to make estimates of matters that are inherently uncertain. Praxair’s financial position, results of operations and cash flows could be materially affected if actual results differ from estimates made. These policies are determined by management and have been reviewed by Praxair’s Audit Committee.

Depreciable Lives of Property, Plant and Equipment

Praxair’s net property, plant and equipment at December 31, 2003 was $5,252 million, representing 63% of the company’s consolidated total assets. Depreciation expense for the year ended December 31, 2003 was $517 million, or 11% of total operating costs. Management judgement is required in the determination of the estimated depreciable lives that are used to calculate the annual depreciation expense and accumulated depreciation.

Property, plant and equipment are recorded at cost and depreciated over the assets’ estimated useful lives on a straight-line basis for financial reporting purposes. The estimated useful life represents the projected period of time that the asset will be productively employed by the company and is determined by management based on many factors, including historical experience with similar assets, technological life cycles, geographic locations and contractual supply relationships with on-site customers. Circumstances and events relating to these assets, such as on-site contract modifications, are monitored to ensure that changes in asset lives or impairments (see “Asset Impairments” below) are identified and prospective depreciation expense or impairment expense is adjusted accordingly. Praxair’s largest asset values relate to cryogenic air separation production plants with average depreciable lives of 15 years.

Based upon the assets as of December 31, 2003, if depreciable lives of machinery and equipment, on average, were increased or decreased by one year, annual depreciation expense would be decreased by approximately $25 million or increased by approximately $30 million, respectively.

Pension Benefits

Pension benefits represent financial obligations that will be ultimately settled in the future with employees who meet eligibility requirements. Because of the uncertainties involved in estimating the timing and amount of future payments, significant estimates are required to calculate pension expense and liabilities related to the company’s plans. The company utilizes the services of several independent actuaries, whose models are used to facilitate these calculations.

Several key assumptions are used in actuarial models to calculate pension expense and liability amounts recorded in the financial statements. Management believes the three most significant variables in the models are the expected long-term rate of return on plan assets, the discount rate, and the expected rate of compensation increase. The actuarial models also use assumptions for various other factors including employee turnover, retirement age, and mortality. Praxair management believes the assumptions used in the actuarial calculations are reasonable and are within accepted practices in each of the respective geographic locations in which we operate.

The weighted average expected long-term rates of return on pension plan assets were 8.5% for U.S. plans and 8.0% for international plans at December 31, 2003. These rates are determined annually by management based on a weighted average of current and historical market trends, historical portfolio performance and the portfolio mix of investments. A 0.50% change in these expected long-term rates of return, with all other variables held constant, would change Praxair’s pension expense by approximately $5 million.

37


The weighted average discount rates for pension plan liabilities were 6.25% for U.S. plans and 6.0% for international plans at December 31, 2003. These rates are used to calculate the present value of plan liabilities and are determined annually by management based on market yields for high-quality fixed income investments on the measurement date. A 0.50% change in these discount rates, with all other variables held constant, would change Praxair’s pension expense by approximately $8 million and would impact the projected benefit obligation (PBO) by approximately $84 million.

The weighted average expected rates of compensation increase for Praxair’s pensions plans were 3.25% for U.S. plans and international plans at December 31, 2003. These estimated annual compensation increases are determined by management every year and are based on historical trends and market indices. A 0.50% change in the expected rate of compensation increase, with all other variables held constant, would change Praxair’s pension expense by approximately $4 million and would impact the projected benefit obligation (PBO) by approximately $23 million. A change in this assumption is usually consistent with a change in the discount rate assumption, and the earnings impacts generally offset one another.

Asset Impairment

At December 31, 2003, the company had goodwill of $1,075 million which represented excess purchase price for acquired businesses over the fair value of the net assets acquired. Management reviews goodwill for impairment annually or when events or circumstances indicate that its value may have declined. In order to evaluate impairment of goodwill, assumptions about the future condition and operations of the business unit to which the goodwill asset relates are made. These assumptions are applied to complex models in which we estimate the fair value of the business unit utilizing projected future cash flows, multiples of earnings and sales and other factors. Using these models, management determines whether an impairment charge is required to reduce goodwill to its estimated fair value.

This evaluation process is complex and involves subjective assumptions about future events and discount factors to be applied to projected cash flows. Estimated values can be affected by many factors beyond the company’s control such as business and economic trends, government regulation, and technological changes. Management believes that the assumptions made to evaluate goodwill impairment are appropriate and reasonable. However, changes in circumstances or conditions affecting these assumptions could result in impairment charges in future periods that may be material. At January 1, 2002, the company adopted SFAS 142 and employing the methodologies noted, determined that goodwill for six reporting units was impaired, which resulted in a pre-tax impairment charge of $146 million. At December 31, 2003, the remaining goodwill has been assigned to eight reporting units in amounts ranging from $7 million to $739 million.

The impairment evaluation process for property, plant and equipment uses projected undiscounted future cash flows. This test is performed when circumstances and events indicate that the carrying amount of an individual asset or grouping of assets may not be recoverable. Should undiscounted cash flows be less than the carrying amount of the assets, an impairment charge reducing the carrying amount to fair value is required. Fair value is determined based on the most appropriate valuation technique, including discounted cash flows.

38


Income Taxes

At December 31, 2003, Praxair had deferred tax assets of $569 million (net of valuation allowances of $99 million), and deferred tax liabilities of $802 million. Income tax expense was $174 million for the year ended December 31, 2003.

In the preparation of consolidated financial statements, Praxair estimates income taxes based on diverse and complex regulations that exist in various jurisdictions where we conduct business. Deferred income tax assets and liabilities represent tax benefits or obligations that arise from temporary differences due to differing treatment of certain items for accounting and income tax purposes. Praxair evaluates deferred tax assets each period to ensure that estimated future taxable income will be sufficient in character (e.g. capital gain versus ordinary income treatment), amount and timing to result in their recovery. We establish a valuation allowance when management determines that it is more likely than not that a deferred tax asset will not be realized to reduce the assets to their realizable value. Considerable judgements are required in establishing deferred tax valuation allowances and in assessing probable exposures related to tax matters. Our tax returns are subject to audit and local taxing authorities could challenge our tax positions. The company’s practice is to review tax-filing positions by jurisdiction and to record provisions for probable tax assessments, including interest and penalties, if applicable. Praxair believes it records and/or discloses such potential tax liabilities as appropriate and has reasonably estimated its income tax liabilities and recoverable tax assets.

NEW ACCOUNTING STANDARDS

See Notes 1 and 2 to the consolidated financial statements for information concerning new accounting standards and for information regarding accounting changes, respectively.

MARKET RISKS AND SENSITIVITY ANALYSES

Praxair is exposed to market risks relating to fluctuations in interest rates and currency exchange rates. The objective of financial risk management at Praxair is to minimize the negative impact of interest rate and foreign exchange rate fluctuations on the company’s earnings, cash flows and equity.

To manage these risks, Praxair uses various derivative financial instruments, including interest rate swaps, currency swaps, forward contracts and commodity contracts. Praxair only uses commonly traded and non-leveraged instruments. These contracts are entered into primarily with major banking institutions thereby minimizing the risk of credit loss. Also, refer to Notes 2 and 15 to the consolidated financial statements for a more complete description of Praxair’s accounting policies and use of such instruments.

The following discussion presents the sensitivity of the market value, earnings and cash flows of Praxair’s financial instruments to hypothetical changes in interest and exchange rates assuming these changes occurred at December 31, 2003. The range of changes chosen for these discussions reflect Praxair’s view of changes which are reasonably possible over a one-year period. Market values are the present values of projected future cash flows based on interest rate and exchange rate assumptions.

39


Interest Rate and Debt Sensitivity Analysis

At December 31, 2003, Praxair had debt totaling $2,816 million ($2,748 million at December 31, 2002). At December 31, 2003, no interest rate swap agreements existed. At December 31, 2002, a $100 million interest rate swap agreement converted outstanding floating rate operating lease payments to fixed rate payments for the period of the swap agreement which matured in 2003. Interest rate swaps are entered into as hedges of underlying financial instruments to effectively change the characteristics of the interest rate without actually changing the underlying financial instrument. For fixed rate instruments, interest rate changes affect the fair market value but do not impact earnings or cash flows. Conversely, for floating rate instruments, interest rate changes generally do not affect the fair market value but impact future earnings and cash flows, assuming other factors are held constant.

At December 31, 2003, Praxair had fixed rate debt of $2,465 million and floating rate debt of $351 million, representing 88% and 12%, respectively, of total debt. At December 31, 2002, Praxair had fixed rate debt of $2,447 million and floating rate debt of $301 million, representing 89% and 11%, respectively, of total debt. Holding other variables constant (such as foreign exchange rates, swaps and debt levels), a one percentage point decrease in interest rates would increase the unrealized fair market value of the fixed rate debt by approximately $119 million ($94 million in 2002). At December 31, 2003 and 2002, the after-tax earnings and cash flows impact for next year resulting from a one percentage point increase in interest rates would be approximately $2 million, holding other variables constant.

Exchange Rate Sensitivity Analysis

Praxair’s exchange rate exposures result primarily from its investments and ongoing operations in South America (primarily Brazil, Argentina and Venezuela), Europe (primarily Spain and Italy), Canada, Mexico, Asia (primarily China, India, Korea and Thailand) and other business transactions such as the procurement of equipment from foreign sources. Among other techniques, Praxair utilizes foreign exchange forward contracts to hedge these exposures. At December 31, 2003, Praxair had $512 million notional amount ($433 million at December 31, 2002) of foreign exchange contracts of which $502 million ($223 million in 2002) are to hedge recorded balance sheet exposures or firm commitments and $10 million ($210 million in 2002) are to hedge anticipated future net income. At December 31, 2003, Praxair’s net income hedges relate to anticipated 2004 net income in Canada.

Holding other variables constant, if there were a 10% adverse change in foreign currency exchange rates for the portfolio, the fair market value of foreign currency contracts outstanding at December 31, 2003 would decrease by approximately $38 million ($28 million at December 31, 2002). Of this decrease, about $1 million ($14 million at December 31, 2002) would impact earnings and the remaining $37 million would be offset by an equal but offsetting gain or loss on the foreign currency fluctuation of the underlying exposure being hedged ($14 million at December 31, 2002).

OUTLOOK

For the full year of 2004, Praxair expects sales growth in the range of 6% to 10%, and operating profit growth of 8% to 14% from 2003. Guidance for diluted earnings per share is $1.90 to $2.05, reflecting growth of 8% to 15%, and assuming a higher effective tax rate of 25%. Full-year capital expenditures are expected to be approximately $700 million, anticipating additional investment in hydrogen infrastructure and investment in China to supply new contracts awarded in 2003.

Praxair provides quarterly updates on operating results, material trends that may affect financial performance, and financial earnings guidance via quarterly earnings releases and investor teleconferences. In addition, Praxair issues press releases whenever significant events occur which may affect financial performance. These materials are available on our website: www.praxair.com.

40


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Operations – Praxair, Inc. (Praxair or company) is one of the largest industrial gases companies worldwide, the largest in North and South America. Praxair produces, sells and distributes atmospheric, process and specialty gases, and high-performance surface coatings to a diverse group of industries including aerospace, chemicals, electronics, energy, food and beverage, healthcare, manufacturing and metals.

Principles of Consolidation – The consolidated financial statements include the accounts of all significant subsidiaries where control exists and, in limited situations, variable interest entities where the company is the primary beneficiary. Equity investments generally consist of 20-50% owned operations where the company exercises significant influence. Operations less than 20% owned, where the company does not exercise significant influence, are generally carried at cost. Pre-tax income from equity investments that are partnerships or limited liability corporations (LLC) is included in Other income (expenses) – net with related taxes included in income taxes and remaining equity earnings are reported as income from equity investments, net of income taxes. Partnership and LLC net assets are reported as equity investments in the balance sheet. Significant intercompany transactions are eliminated and any significant related party transactions have been disclosed.

Use of Estimates – The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and to disclose contingent assets and liabilities at the date of the financial statements during the reporting period. While actual results could differ, management believes such estimates to be reasonable.

Revenue Recognition – Revenue is recognized when: a firm sales agreement exists; product is shipped or services are provided to customers; and collectibility of the fixed or determinable sales price is reasonably assured. A small portion of the company’s revenues relate to long-term construction contracts and are recognized using the percentage-of-completion method. Under this method, revenues from sales of major equipment, such as large air separation facilities, are recognized primarily based on cost incurred to date compared with total estimated cost. Changes to total estimated cost and anticipated losses, if any, are recognized in the period determined. For contracts that contain multiple products and/or services, amounts assigned to each component are based on its objectively determined fair value, such as the sales price for the component when it is sold separately or competitor prices for similar components. Sales returns and allowances are not a normal practice in the industry and are de minimis.

Amounts billed for shipping and handling fees are recorded as sales, generally on FOB destination terms, and costs incurred for shipping and handling are recorded as cost of sales.

Cash Equivalents – Cash equivalents are considered to be highly liquid securities with original maturities of three months or less.

Inventories – Inventories are stated at the lower of cost or market. Cost is determined using the last-in, first-out (LIFO) method for certain U.S. operations and the average cost method for most other operations.

Property, Plant and Equipment – Net – Property, plant and equipment are carried at cost, net of accumulated depreciation. The company capitalizes interest as part of the cost of constructing major facilities (see Note 6). Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets, which range from 3 to 40 years (see Note 10). Praxair uses accelerated depreciation methods for tax purposes where appropriate.

The company performs a test for impairment whenever circumstances and events indicate that the carrying amount of an individual asset or grouping of assets may not be recoverable. Should projected undiscounted cash flows be less than the carrying amount of the asset, an impairment charge reducing the carrying amount to fair value is required. Fair value is determined based on the most appropriate valuation technique, including discounted cash flows.

41


Foreign Currency Translation – For international subsidiaries where the local currency is the functional currency, translation gains and losses are reported as part of the accumulated other comprehensive income (loss) component of shareholders’ equity as a cumulative translation adjustment (see Note 9). For international subsidiaries operating in hyperinflationary economies, the U.S. dollar is the functional currency and translation gains and losses are included in income.

Financial Instruments – Praxair enters into various derivative financial instruments to manage its exposure to fluctuating interest and currency exchange rates and energy costs. Such instruments primarily include interest rate swap agreements; currency swap, forward contracts; and commodity swap agreements. These instruments are not entered into for trading purposes. Praxair only uses commonly traded and non-leveraged instruments.

Effective January 1, 2001, Praxair adopted Statement of Financial Accounting Standards (SFAS) 133, “Accounting for Derivative Instruments and Hedging Activities,” as amended by SFAS 137, 138 and 149. SFAS 133 requires all derivatives to be recorded on the balance sheet at fair value. There are two types of derivatives the company enters into: hedges of fair value exposures and hedges of cash flow exposures. Fair value exposures relate to recognized assets or liabilities, and firm commitments; while cash flow exposures relate to the variability of future cash flows associated with recognized assets or liabilities, or forecasted transactions.

When a derivative is executed and hedge accounting is appropriate, it is designated as either a fair value hedge or a cash flow hedge. Currently, Praxair designates all interest rate and commodity swap agreements as hedges; however, currency contracts are generally not designated as hedges for accounting purposes. All derivatives are linked to an appropriate underlying exposure. On an ongoing basis, the company assesses the hedge effectiveness of all derivatives designated as hedges to determine if they continue to be highly effective in offsetting changes in fair values or cash flows of the underlying hedged items. If it is determined that the hedge is not highly effective, then hedge accounting will be discontinued prospectively.

Changes in the fair value of derivatives designated as fair value hedges are recognized in earnings as an offset to the change in the fair values of the exposures being hedged. The changes in fair value of derivatives that are designated as cash flow hedges are deferred in accumulated other comprehensive income (loss) and are recognized in earnings as the underlying hedged transaction occurs. Any ineffectiveness is recognized in earnings immediately. Derivatives that are entered into for risk management purposes and are not designated as hedges (primarily related to projected net income and currency derivatives other than for firm commitments) are recorded at their fair market values and recognized in current earnings.

Praxair records hedging activity related to debt instruments in interest expense and hedging related to lease obligations and commodity contracts in operating profit. The company recognizes the changes in the fair value associated with currency contracts as follows: hedges of balance sheet exposures, firm commitments and anticipated future net income are recognized in other income (expense) – net and generally offset the underlying hedged items; hedges of net investments in foreign subsidiaries are recognized in the cumulative translation adjustment component of accumulated other comprehensive income (loss) on the consolidated balance sheet to offset translation gains and losses associated with the hedged net investment.

Praxair uses the following methods and assumptions to estimate the fair value of each class of financial instrument. The fair value of interest rate swaps and currency exchange contracts is estimated based on market prices obtained from independent dealer or market quotes. The fair value of long-term debt is estimated based on the quoted market prices for the same or similar issues. Due to their nature, the carrying value of cash, short-term investments and short-term debt, receivables and payables approximates fair value.

42


Goodwill – When a business is acquired, the excess of the purchase price over the fair value of the assets and liabilities acquired is recorded as goodwill (see Note 12). In June 2001, the Financial Accounting Standards Board (FASB) issued SFAS 142, “Goodwill and Other Intangible Assets,” which eliminated the amortization of goodwill effective January 1, 2002. Goodwill is reviewed annually in April and when circumstances or other events indicate that impairment may have occurred. Also, in accordance with SFAS 141, “Business Combinations,” goodwill related to acquisitions after June 30, 2001 has not been amortized.

Prior to SFAS 142, previous accounting standards required goodwill to be amortized over the estimated period of benefit up to 40 years.

Other Intangible Assets – Patents are recorded at historical cost and are amortized over their remaining useful lives. Trademarks and other intangibles are amortized over the estimated period of benefit. Praxair periodically evaluates the recoverability of patents, trademarks and other intangibles by assessing whether the unamortized balance can be recovered over its remaining life through cash flows generated by the related assets. When expected undiscounted cash flows are less than the carrying value of the intangible asset, an impairment loss will be recognized.

Income Taxes – Deferred income taxes are recorded for the temporary differences between the financial statement and tax bases of assets and liabilities using current tax rates. Valuation allowances are established against deferred tax assets whenever circumstances indicate that it is more likely than not that such assets will not be realized in future periods. The provision for income taxes includes probable exposures for tax matters.

Pension and Other Retirement Programs – Most Praxair employees worldwide are covered by various pension plans. The cost of pension benefits under these plans is determined using the “projected unit credit” actuarial cost method. Funding of pension plans varies and is in accordance with local laws and practices.

Praxair accrues the cost of retiree life and health insurance benefits during the employees’ service period when such benefits are earned.

Post-employment Benefits – Praxair recognizes the estimated cost of future benefits provided to former and inactive employees after employment but before retirement on the accrual basis.

Stock Split – On October 28, 2003, Praxair’s board of directors declared a two-for-one split of the company’s common stock. The stock split was effected in the form of a stock dividend of one additional share for each share owned by stockholders of record on December 5, 2003, and each share held in treasury as of the record date. The additional shares were distributed to such holders on December 15, 2003. Information pertaining to shares, earnings per share and dividends per share has been restated in the accompanying financial statements except for the statement of shareholders’ equity and related footnotes to reflect this split.

Stock-based Compensation – Praxair accounts for incentive plans and stock options using the provisions of Accounting Principles Board Opinion 25, “Accounting for Stock Issued to Employees.” Pro forma information required by SFAS 123, “Accounting for Stock-Based Compensation,” as amended by SFAS 148, requires Praxair to disclose pro forma net income and pro forma earnings per share amounts as if compensation expense was recognized based on fair values for options granted after 1994. Pro forma net income and the related basic and diluted earnings per share amounts would be as follows:

(Dollar amounts in millions, except per share data)                
Year Ended December 31,       2003     2002     2001  
     
NET INCOME    
As reported     $ 585   $ 409   $ 430  
Less: total stock-based employee    
     compensation expense determined under fair value    
     based method for all awards, net of related tax    
     effects       (27 )   (25 )   (32 )



Pro forma net income     $ 558   $ 384   $ 398  



     
BASIC EARNINGS PER SHARE    
     As reported     $ 1.79   $ 1.26   $ 1.33  
     Pro forma     $ 1.71   $ 1.18   $ 1.23  
DILUTED EARNINGS PER SHARE    
     As reported     $ 1.77   $ 1.24   $ 1.31  
     Pro forma     $ 1.69   $ 1.17   $ 1.21  

43


The weighted average fair value of options granted during 2003 was $18.47 ($21.37 in 2002 and $16.15 in 2001). These values, which were used as a basis for the pro forma disclosures, were estimated using the Black-Scholes Options-Pricing Model with the following weighted average assumptions used for grants in 2003, 2002, and 2001:

Year Ended December 31,       2003     2002     2001  
     
Dividend yield       1.3%   1.2%   1.2%
Volatility       36.5%   35.8%   35.6%
Risk-free interest rate       2.9%   4.5%   4.7%
Expected term - years       6     6     5  

These pro forma disclosures may not be representative of the effects for future years as options vest over several years and additional awards generally are made each year.

Recently Issued Accounting Standards – In 2003, the FASB added stock-based compensation to its technical agenda and may require all companies to expense the fair value of employee stock options as earned starting in 2005. Until a new statement is issued, the provisions of SFAS 123 (as amended by SFAS 148), which permit the continued use of the intrinsic value method, remain in effect.

In January 2003, the FASB issued FIN 46, “Consolidation of Variable Interest Entities,” and substantially revised the statement throughout 2003 which is effective December 31, 2003 for Praxair. The implementation of this standard and its subsequent revisions did not have a material impact on Praxair’s financial condition or results of operations.

In May 2003, the Emerging Issues Task Force (EITF) of the FASB reached a consensus on Issue 01-8, “Determining Whether an Arrangement Contains a Lease” (EITF 01-8), that outlines specific criteria for determining when a supply arrangement or portion thereof should be accounted for as a lease. EITF 01-8 became effective for Praxair for certain on-site supply arrangements entered into or modified after June 30, 2003 that are dependent upon specific assets used to supply primarily one customer. An arrangement may be considered in part a lease if, among other things, no other asset can be effectively substituted to supply the customer and if there are no other customers using more than a minor amount of the asset in question. Praxair believes that certain of its product supply arrangements may be considered leases under EITF 01-8, however, any resulting prospective change in accounting treatment has not had a material impact on Praxair’s financial condition or results of operations.

In May 2003, the EITF finalized Issue 00-21, “Accounting for Revenue Arrangements with Multiple Deliverables” (EITF 00-21). During December 2003, the Securities and Exchange Commission issued Staff Accounting Bulletin (SAB) 104, “Revenue Recognition,” which incorporated EITF 00-21. The impact of adopting EITF 00-21 and SAB 104 was not material to Praxair’s financial condition or results of operations.

In December 2003, the FASB issued a revision to SFAS No. 132, “Employers’ Disclosures about Pensions and Other Postretirement Benefits” and requires new annual disclosures about the types of plan assets, investment strategy, measurement date, plan obligations, and cash flows as well as the components of the net periodic benefit cost recognized in interim periods. This statement is effective December 31, 2003 for Praxair except for the requirements to disclose future benefit payments and international plan asset information, which will be effective December 31, 2004. Accordingly, Praxair has expanded its pension disclosures (see Note 19).

In January 2004, the FASB issued FASB Staff Position (FSP) 106-1, “Accounting and Disclosure Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act of 2003” which permits a sponsor of a postretirement health care plan that provides a prescription drug benefit to defer accounting for the effects of the Act until the impact can be determined. Accordingly, as of and for the year ended December 31, 2003, the consolidated financial statements and accompanying notes do not reflect the effects of the Act on the Plan. Specific authoritative guidance on the accounting for the federal subsidy is pending and Praxair will implement the appropriate accounting when the standard is finalized.

Reclassifications – Certain prior years’ amounts have been reclassified to conform to the current year’s presentation.

44


NOTE 2. ACCOUNTING CHANGES

2002 Goodwill Impairment – Praxair adopted SFAS 142, “Goodwill and Other Intangible Assets,” effective January 1, 2002. Under the new rule, companies no longer amortize goodwill or indefinite-lived intangible assets (see Note 12). The rule required the company to perform an initial assessment of whether there is an indication that the carrying value of goodwill is impaired. During the second quarter of 2002, Praxair completed the initial impairment test and concluded that certain of its goodwill was impaired, resulting in a non-cash after-tax charge of $139 million or $0.42 per share on a diluted basis. The charge includes the $144 million goodwill write-down, a $2 million charge for goodwill held on an equity investment, which was recorded as a write-down of the investment, and is also net of a $7 million tax benefit. The charge was recorded as a cumulative effect of an accounting change, retroactive to January 1, 2002.

The following is a summary of the impairment charge by business segment, net of a $7 million tax benefit:

(Millions of dollars)
Segment
Reporting Unit Charge
   
South America     Southern Cone, Andean Region     $ 80  
Europe*     Poland, Israel       20  
Asia     India       17  
Surface Technologies     Aviation Services       22  

            $ 139  


* Includes $2 million related to a non-consolidated equity investment.

This assessment must be conducted at least annually at the reporting unit level, and any such impairment must be recorded as a charge to operating earnings. The annual impairment tests for 2002 and 2003 were performed and no additional impairments were indicated.

2001 Derivatives – Effective January 1, 2001, Praxair adopted SFAS 133, “Accounting for Derivative Instruments and Hedging Activities,” as amended by SFAS 137 and 138. SFAS 133 requires all derivatives to be recorded on the balance sheet at fair value. At January 1, 2001, Praxair recorded a one-time after-tax charge as a cumulative effect adjustment for the initial adoption of SFAS 133 totaling $2 million in its consolidated statement of operations, and a deferred loss of $4 million in the accumulated other comprehensive income (loss) component of shareholders’ equity in the condensed consolidated balance sheet (see Notes 1, 14 and15).

NOTE 3. 2001 SPECIAL CHARGES

In the third quarter of 2001, Praxair recorded pre-tax charges totaling $70 million, including $40 million for severance and $30 million for asset write-offs, plant closings and other costs. The special charges were recorded as follows: cost of goods sold, $7 million; selling, general and administrative, $5 million; other income (expenses) – net, $58 million and their income tax benefit was $13 million. The net impact of the charges was $57 million after taxes, or $0.17 per diluted share. The cash requirements of the after-tax charge were originally estimated to be approximately $32 million.

The severance costs, totaling $40 million, were for the elimination of approximately 950 positions in all segments in response to weaker economic conditions and an expected further slowdown in the aviation industry and new business strategies in South America. As of December 31, 2002, all personnel reductions related to these charges had been completed.

Other costs totaling $30 million included asset write-offs and plant closings, partially offset by gains on sales of assets and investments totaling $9 million, and a benefit policy change.

The North America actions related primarily to the elimination of 280 positions in the U.S. industrial and packaged gases business, with smaller reductions in Canada and Mexico. The actions also included certain asset write-offs, partially offset by a benefit policy change.

In South America, the implementation of new business strategies eliminated about 130 positions and certain assets were written down. The company placed greater emphasis on cash flow generation and focused sales growth on less capital-intensive technology and service initiatives.

45


Surface Technologies is a leading supplier of high-performance coatings and repair services for aircraft engines and parts. As a result of certain events during 2001, Surface Technologies anticipated a decline in commercial aircraft engine production and servicing, which expected to be only partially offset by an increase in military orders. As a result, Praxair downsized its aviation business, by reducing its workforce by about 310 positions and consolidated its service locations.

Corporate actions included the elimination of approximately 140 positions in plant engineering and construction, and corporate staff groups, consolidating and focusing its industrial gases research and development programs, including closing a research location, and certain asset write-offs. Asia actions included the elimination of approximately 50 positions. Partially offsetting these costs was a gain on a property sale and a gain on the sale of an equity investment. The charge also included the termination of about 40 positions in Europe.

The table below summarizes the activity in the accrual for special charges for 2001 and earlier years. The remaining accrual at December 31, 2003 contains $1 million related to the 2001 special charges and $15 million related to future lease payments from earlier programs.

(Millions of dollars) Severance Other
Charges
Total
Accrual
   
Balance, December 31, 2000     $ 45   $ 33   $ 78  
Restructuring and other actions       40     30     70  
Adjustments       (4 )   4     --  
2001 activity       (36 )   (41 )   (77 )



Balance, December 31, 2001       45     26     71  
Adjustments       (7 )   (1 )   (8 )
2002 activity       (29 )   (4 )   (33 )



Balance, December 31, 2002       9     21     30  
Adjustments       (2 )   (4 )   (6 )
2003 activity       (6 )   (2 )   (8 )



Balance, December 31, 2003     $ 1   $ 15   $ 16  



NOTE 4. SEGMENT INFORMATION

Praxair operates principally in the industrial gases business through four geographic operating segments: North America, Europe, South America and Asia. In addition, Praxair operates its worldwide Surface Technologies business through its wholly owned subsidiary, Praxair Surface Technologies, Inc. The All Other category is composed of unallocated and/or one-time corporate items.

Praxair evaluates the performance of its operating segments based primarily on operating profit, excluding intercompany royalties and special charges. Sales are determined based on the country in which the legal subsidiary is domiciled. Corporate and globally managed expenses, and research and development costs relating to Praxair’s global industrial gases business, are allocated to operating segments based on sales. Long-lived assets include property, plant and equipment, and patents, trademarks and goodwill.

The table below presents information about reported segments for the years ended December 31, 2003, 2002, and 2001:

(Millions of dollars)       2003     2002     2001  
   
SALES    
North America     $ 3,627   $ 3,351   $ 3,434  
Europe       699     589     537  
South America       708     632     674  
Asia       389     324     255  
Surface Technologies       400     394     410  
Eliminations       (210 )   (162 )   (152 )



      $ 5,613   $ 5,128   $ 5,158  



OPERATING PROFIT (a)    
North America     $ 548   $ 557   $ 545  
Europe       170     139     119  
South America       114     134     129  
Asia       64     51     38  
Surface Technologies       26     35     39  
All Other       --     7     --  



      $ 922   $ 923   $ 870  



TOTAL ASSETS (b)    
North America     $ 4,638   $ 4,366   $ 4,382  
Europe       1,145     852     737  
South America       1,275     1,016     1,464  
Asia       707     653     617  
Surface Technologies       540     514     515  



      $ 8,305   $ 7,401   $ 7,715  



(continued)

46



(Millions of dollars)       2003     2002     2001  
   
DEPRECIATION AND AMORTIZATION (c)    
North America     $ 313   $ 296   $ 306  
Europe       59     49     46  
South America       60     61     79  
Asia       50     43     33  
Surface Technologies       35     34     35  



      $ 517   $ 483   $ 499  



CAPITAL EXPENDITURES AND ACQUISITIONS    
North America (Note 5)     $ 763   $ 359   $ 491  
Europe       115     69     62  
South America       88     98     142  
Asia       56     59     82  
Surface Technologies       34     26     31  



      $ 1,056   $ 611   $ 808  



SALES BY MAJOR COUNTRY    
United States     $ 2,834   $ 2,709   $ 2,848  
Brazil       557     487     484  
All Other-- foreign       2,222     1,932     1,826  



      $ 5,613   $ 5,128   $ 5,158  



LONG-LIVED ASSETS BY MAJOR COUNTRIES    
United States     $ 3,260   $ 3,020   $ 2,924  
Brazil       765     592     855  
All Other-- foreign       2,358     2,089     2,218  



      $ 6,383   $ 5,701   $ 5,997  




(a) Praxair recorded pre-tax charges totaling $70 million in the third quarter of 2001, which is not included in Praxair’s management reporting definition of operating profit (see Note 3). Segment operating profit in 2001 excluded $70 million of special charges as follows: North America, $26 million; Europe, $3 million; South America, $30 million; Surface Technologies, $4 million; and All Other $7 million.

(b) Includes equity investments as of December 31:

              (Millions of dollars)       2003     2002     2001  
   
              North America     $ 53   $ 70   $ 82  
              Europe       110     92     76  
              Surface Technologies       1     (2 )   --  
              Asia       18     24     40  



      $ 182   $ 184   $ 198  




(c) Effective in 2002, Praxair adopted SFAS 142 which eliminated the amortization of goodwill prospectively. Goodwill amortization included in the year ended December 31, 2001 was $38 million as follows: North America, $20 million; Europe, $4 million; South America, $9 million; Asia, $3 million; and Surface Technologies, $2 million.

NOTE 5. LEASES

Operating leases, primarily involving manufacturing and distribution equipment and office space, represent noncancelable commitments extending for more than one year which require future minimum payments totaling $218 million at December 31, 2003 as follows: 2004, $69 million; 2005, $55 million; 2006, $42 million; 2007, $23 million; 2008, $12 million; and $17 million thereafter. The present value of these future lease payments under operating leases is approximately $199 million. Included in these totals are $28 million of lease commitments to Praxair’s former parent company, principally for office space. Total lease and rental expenses under operating leases were $93 million in 2003, $96 million in 2002, and $110 million in 2001.

During June 2003, Praxair terminated leases for U.S. liquid storage equipment and distribution equipment, and for production facilities along the U.S. Gulf Coast and purchased the underlying equipment for a total of $339 million. The equipment leases originated in 1998 and 1999 in sale-leaseback transactions. On June 30, 2003, Praxair purchased the equipment for $230 million and reduced the carrying value of the equipment by deferred gains of $152 million from the original sale-leaseback transactions. The U.S. Gulf Coast leases were initiated by CBI Industries, Inc. (CBI) and were subsequently assumed by Praxair in its acquisition of CBI in 1996. On June 27, 2003, Praxair terminated the leases and purchased the production facility assets for approximately $109 million.

47


NOTE 6. SUPPLEMENTARY INCOME STATEMENT INFORMATION

(Millions of dollars)
Year Ended December 31,
      2003     2002     2001  
   
COST OF SALES EXCLUSIVE OF DEPRECIATION AND    
  AMORTIZATION    
Cost of sales     $ 3,328   $ 2,950   $ 3,053  
Special charges (Note 3)       --     --     7  



      $ 3,328   $ 2,950   $ 3,060  



SELLING, GENERAL AND ADMINISTRATIVE    
Selling     $ 375   $ 356   $ 334  
General and administrative       391     395     360  
Special charges (Note 3)       --     --     5  



      $ 766   $ 751   $ 699  



DEPRECIATION AND AMORTIZATION    
Depreciation and other     $ 510   $ 478   $ 457  
Goodwill amortization       --     --     38  
Amortization of other intangibles       7     5     4  



      $ 517   $ 483   $ 499  



OTHER INCOME (EXPENSES) - NET    
Investment income     $ --   $ 9   $ 10  
Net income hedges (a)       (9 )   17     (8 )
Other currency       (4 )   1     5  
Partnership income       10     9     13  
Special charges (Note 3)       6     8     (58 )
Severance expense       (12 )   (3 )   (2 )
Other       4     7     6  



      $ (5 ) $ 48   $ (34 )



INTEREST EXPENSE    
Interest incurred on debt     $ 165   $ 202   $ 241  
Bond call premium (Note 14)       --     15     --  
Interest capitalized       (9 )   (9 )   (17 )
Amortization of swap termination costs (Note 15)       (5 )   (2 )   --  



      $ 151   $ 206   $ 224  



MINORITY INTERESTS    
Minority interests     $ (24 ) $ (19 ) $ (16 )
Preferred stock dividends       --     (1 )   (2 )



      $ (24 ) $ (20 ) $ (18 )




(a) Represents net losses from hedges in 2003, primarily in Brazil and Europe. Net gains from hedges in 2002 and net losses in 2001 were primarily in Brazil and Mexico.

NOTE 7. PROVISION FOR INCOME TAXES

Pre-tax income applicable to U.S. and foreign operations is as follows

(Millions of dollars)
Year Ended December 31,
      2003     2002     2001  
   
United States     $ 213   $ 233   $ 210  
Foreign    
        558     484     366  



Total income before income taxes     $ 771   $ 717   $ 576  



The following is an analysis of the provision for income taxes:

(Millions of dollars)
Year Ended December 31,
      2003     2002     2001  
   
CURRENT TAX EXPENSE    
U.S. Federal     $ 39   $ 25   $ 38  
State and local       1     5     3  
Foreign       101     91     58  



        141     121     99  



DEFERRED TAX EXPENSE (BENEFIT)    
U.S. Federal       (9 )   50     30  
Foreign       42     (13 )   6  



        33     37     36  



Total income taxes     $ 174   $ 158   $ 135  



48


An analysis of the difference between the provision for income taxes and the amount computed by applying the U.S. statutory income tax rate to pre-tax income follows:

(Dollar amounts in millions)
Year Ended December 31,
2003 2002 2001



   
U.S. statutory income tax rate     $ 270     35.0% $ 251     35.0% $ 202     35.0%
State and local taxes       1     0.1%   3     0.4%   2     0.3%
U.S. tax credits and deductions (a)       (23 )   -3.0%     (4 )   -0.6%     (12 )   -2.1%  
Foreign tax rate differentials (b)       (53 )   -6.8%     (92 )   -12.8%   (47 )   -8.2%  
Tax audit settlement (c)       (10 )   -1.3%     --     --     --     --  
Other-- net       (11 )   -1.4%     --     --     (10 )   -1.6%  



Provision for income taxes     $ 174     22.6% $ 158     22.0% $ 135     23.4%




(a) U.S. tax credits and deductions relate to research and experimentation tax credits, capital loss deductions and donations of certain intellectual property.
(b) Foreign tax rate differentials include various tax incentives in Spain. The company also operates in various jurisdictions in Asia and South America that currently offer tax holidays.
(c) The tax audit settlement represents a non-recurring benefit resulting from the settlement of various tax matters in the United States.

The company recognized $15 million and $23 million during 2002 and 2001, respectively, of tax benefits related to current-year foreign net operating losses.

The company has implemented various tax planning strategies minimizing its state tax liabilities.

During 2003, the taxing authority in Italy decreased its top marginal rate. During 2002, taxing authorities in Belgium, Canada, France and Italy decreased their top marginal tax rates. The effects of these tax rate changes were immaterial.

A provision has not been made for additional federal or foreign taxes at December 31, 2003 on $1,071 million of undistributed earnings of foreign subsidiaries because Praxair has planned to reinvest these funds indefinitely. These earnings could become subject to additional tax if they are remitted as dividends, loaned to Praxair, or upon sale of the subsidiary’s stock. It is not practicable to estimate the amount or timing of the additional tax, if any, that might eventually be paid on the foreign earnings.

NOTE 8. EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income for the period by the weighted average number of Praxair common shares outstanding. Diluted earnings per share is computed by dividing net income for the period by the weighted average number of Praxair common shares outstanding and dilutive common stock equivalents, as follows:

      2003     2002     2001  
   
NUMERATOR (MILLIONS OF DOLLARS)    
Income before cumulative effect    
  of accounting changes     $ 585   $ 548   $ 432  
Cumulative effect of accounting changes    
        --     (139 )   (2 )



Net income     $ 585   $ 409   $ 430  



DENOMINATOR (THOUSANDS OF SHARES)    
Weighted average shares outstanding       325,198     324,311     321,782  
Shares earned and issuable under    
  compensation plans       1,190     1,225     1,238  



Weighted average shares used    
  in basic earnings per share       326,388     325,536     323,020  
Effect of dilutive securities:    
Convertible debt    
        269     55     90  
Employee stock options       4,334     3,898     3,904  



Weighted average shares    
  used in diluted earnings per share       330,991     329,489     327,014  



   
BASIC EARNINGS PER COMMON SHARE    
Income before cumulative effect    
  of accounting changes     $ 1.79   $ 1.68   $ 1.34  
Net income     $ 1.79   $ 1.26   $ 1.33  
   
DILUTED EARNINGS PER COMMON SHARE    
Income before cumulative effect    
  of accounting changes     $ 1.77   $ 1.66   $ 1.32  
Net income     $ 1.77   $ 1.24   $ 1.31  

Stock options for 2,420,200 and 4,907,790 shares were not included in the computation of diluted earnings per share for the years ended December 31, 2002 and 2001, respectively, because the exercise prices were greater than the average market price of the common stock. In 2003, no stock options were excluded from the computation.

49


NOTE 9. SUPPLEMENTARY BALANCE SHEET INFORMATION

(Millions of dollars)            
December 31,       2003     2002  
   
ACCOUNTS RECEIVABLE    
Trade     $ 975   $ 889  
Other       44     29  


        1,019     918  
Less: allowance for doubtful accounts (a)       (57 )   (58 )


      $ 962   $ 860  


INVENTORIES (b)    
Raw materials and supplies     $ 83   $ 78  
Work in process       33     31  
Finished goods       186     168  


      $ 302   $ 277  


PREPAID AND OTHER CURRENT ASSETS    
Deferred income taxes (Note 11)     $ 66   $ 63  
Pension assets (Note 19)       7     4  
Other       62     43  


      $ 135   $ 110  


OTHER LONG-TERM ASSETS    
Deposits     $ 27   $ 21  
Insurance contracts (c)       73     69  
Pension assets (Note 19)       60     --  
Other       131     140  


      $ 291   $ 230  


OTHER CURRENT LIABILITIES    
Accrued expenses     $ 130   $ 128  
Payrolls       76     68  
Pension and postretirement costs (Note 19)       87     37  
Other       152     177  


      $ 445   $ 410  


OTHER LONG-TERM LIABILITIES    
Pension and postretirement costs (Note 19)     $ 491   $ 516  
Other       425     310  


      $ 916   $ 826  


DEFERRED CREDITS    
Deferred income taxes (Note 11)     $ 299   $ 293  
Deferred gain on sale leaseback (Note 5)       --     152  
Other       29     16  


      $ 328   $ 461  



(Millions of dollars)            
December 31,       2003     2002  
   
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)    
Cumulative translation adjustment    
      North America     $ (165 ) $ (190 )
      South America (d)       (1,041 )   (1,189 )
      Europe       7     (106 )
      Asia       (61 )   (69 )
      Surface Technologies       8     (11 )


        (1,252 )   (1,565 )
Derivatives - net of taxes (e)       (1 )   (1 )
Minimum pension liability (net of $53 million and $58    
  million taxes in 2003 and 2002, respectively)       (99 )   (107 )


      $ (1,352 ) $ (1,673 )



(a) Provisions to the allowance for doubtful accounts were $26 million, $40 million and $35 million in 2003, 2002, and 2001, respectively.
(b) Approximately 19% and 26% of total inventories were valued using the LIFO method at December 31, 2003 and 2002, respectively. If inventories had been valued at current costs, they would have been approximately $25 million and $26 million higher than reported at December 31, 2003 and 2002, respectively.
(c) Consists primarily of insurance contracts to be utilized for a non-qualified pension and OPEB obligations (see Note 19).
(d) Consists primarily of currency translation adjustments in Brazil and Argentina.
(e) The derivatives component of accumulated other comprehensive income (loss) relates to the adoption of SFAS 133 (see Notes 2 and 15). The table below summarizes the 2002 and 2003 activity:

              (Millions of dollars)        
   
              Balance, December 31, 2001     $ (4 )
              Change in fair value       (4 )
              Reclassified to earnings - interest expense       5  
              Reclassified to earnings - operating profit       2  

              Balance, December 31, 2002       (1 )
              Change in fair value       --  

              Balance, December 31, 2003     $ (1 )

50


NOTE 10. PROPERTY, PLANT AND EQUIPMENT – NET

Significant classes of property, plant and equipment are as follows:

(Millions of dollars)
December 31,
      2003     2002  
   
Machinery and equipment     $ 9,504   $ 8,273  
Buildings       643     575  
Construction in progress and other       421     338  
Land and land improvements       227     241  


        10,795     9,427  
Less: accumulated depreciation       (5,543 )   (4,761 )


      $ 5,252   $ 4,666  


Machinery and equipment includes production plants, tanks, cylinders, transportation equipment and other assets that have useful lives of 3 to 30 years. Buildings have useful lives of 25 to 40 years and land improvements have useful lives up to 20 years.

NOTE 11. DEFERRED INCOME TAXES

Net deferred tax liabilities are comprised of the following:

(Millions of dollars)
December 31,
      2003     2002  
   
DEFERRED TAX LIABILITIES    
Fixed assets     $ 765   $ 724  
State and local       12     11  
Other       25     18  


Total deferred tax liabilities       802     753  


DEFERRED TAX ASSETS    
Benefit plans and related       157     164  
Inventory       14     13  
Alternative minimum tax and other credits       92     69  
Carryforwards - gross       234     244  
Minimum pension liability       53     58  
Other       118     99  


        668     647  
Less: Valuation allowances       (99 )   (124 )


Total deferred tax assets       569     523  


Net deferred tax liabilities     $ 233   $ 230  


Recorded as:    
Current deferred tax assets (Note 9)     $ 66   $ 63  
Long-term deferred tax liabilities (Note 9)       299     293  


Net deferred tax liabilities     $ 233   $ 230  


The valuation allowances decreased $25 million in 2003 primarily relating to the utilization of capital losses (see Notes 7 and 12) and other tax credit carryforward activity. At December 31, 2003, Praxair has $234 million of deferred tax assets relating to net operating loss and other tax credit carryforwards (primarily foreign). Approximately $78 million expires through 2011. The remaining carryforwards will never expire but are subject to annual usage limitations. A valuation allowance of $99 million has been established related to these carryforwards.

NOTE 12. GOODWILL

As described in Note 2, the company adopted SFAS 142 as of January 1, 2002, which eliminates goodwill amortization expense prospectively. The following table reconciles 2001 reported net income and earnings per share amounts to their respective amounts adjusted to exclude goodwill amortization expense. Results for 2003 and 2002 are presented for comparative purposes.

(Millions of dollars, except per share data)
Year Ended December 31,
      2003     2002     2001  
   
NET INCOME    
Reported net income     $ 585   $ 409   $ 430  
Add back: goodwill amortization, net of tax    
        --     --     33  



Net income excluding goodwill amortization     $ 585   $ 409   $ 463  



PER SHARE DATA    
Basic earnings per share    
Reported net income     $ 1.79 $ 1.26 $ 1.33
Add back: goodwill amortization, net of tax    
        --     --     0.10



Net income excluding goodwill amortization     $ 1.79 $ 1.26 $ 1.43



Diluted earnings per share    
Reported net income     $ 1.77 $ 1.24 $ 1.31
Add back: goodwill amortization, net of tax    
        --     --     0.10



Net income excluding goodwill amortization     $ 1.77 $ 1.24 $ 1.41



51


Changes in the carrying amount of goodwill for the years ended December 31, 2003 and 2002, were as follows:

(Millions of dollars) North
America
South
America
Europe Asia Surface
Technologies
Total
   
Balance, December 31, 2001     $ 712   $ 253   $ 48   $ 35   $ 88   $ 1,136  
Acquisitions       53     2     3     --     --     58  
Cumulative effect of an accounting change (Note 2)       --     (84 )   (18 )   (17 )   (25 )   (144 )
Foreign currency translation       (6 )   (72 )   6     2     5     (65 )






Balance, December 31, 2002       759     99     39     20     68     985  
Acquisitions       26     --     17     5     --     48  
Purchase adjustments*       (13 )   (2 )   --     --     --     (15 )
Foreign currency translation       12     27     10     1     7     57  






Balance, December 31, 2003     $ 784   $ 124   $ 66   $ 26   $ 75   $ 1,075  







* Purchase adjustments in North America pertain to the resolution of tax matters for previous years related to deferred income tax allowances on capital loss carryforwards from the 1996 CBI acquisition. The adjustment to goodwill was offset by a corresponding adjustment to deferred income taxes included in deferred credits.

NOTE 13. OTHER INTANGIBLE ASSETS

(Millions of dollars)
December 31,
      2003     2002  
   
License/use agreements     $ 41   $ 33  
Non-compete agreements       31     29  
Patents and other       17     15  


        89     77  
Less: accumulated amortization       (33 )   (27 )


      $ 56   $ 50  


There are no expected residual values related to these intangible assets. Total estimated annual amortization expense is as follows: 2004, $7 million; 2005, $7 million; 2006, $7 million; 2007, $6 million; 2008, $4 million; and $25 million thereafter.

The weighted average amortization period for intangible assets is approximately 9 years. Additions to other intangible assets for the year ended December 31, 2003 were approximately $8 million, and amortization expense for the years ended December 31, 2003, 2002 and 2001 was $7 million, $5 million and $4 million, respectively.

NOTE 14. DEBT

The following is a summary of Praxair’s outstanding debt at December 31, 2003 and 2002:

(Millions of dollars)       2003     2002  
   
SHORT-TERM    
Canadian borrowings     $ 75   $ 65  
U.S. borrowings       4     7  
South American borrowings       44     64  
Asian borrowings       5     74  
Other international borrowings       5     5  


Total short-term debt       133     215  


LONG-TERM    
U.S.:    
Commercial paper and U.S. borrowings       218     86  
6.625% Notes due 2003       --     75  
6.75% Notes due 2003       --     300  
6.15% Notes due 2003       --     250  
6.85% Notes due 2005       150     150  
6.90% Notes due 2006       250     250  
4.75% Notes due 2007 (a)       249     249  
6.625% Notes due 2007       250     250  
6.50% Notes due 2008       250     250  
2.75% Notes due 2008 (a)       299     --  
6.375% Notes due 2012 (a, b)       539     543  
3.95% Notes due 2013 (a)       349     --  
Other borrowings       42     40  
South American borrowings       33     28  
Asian borrowings       41     52  
Other international borrowings       6     3  
Obligations under capital lease       7     7  


        2,683     2,533  
Less: current portion of long-term debt       (22 )   (23 )


Total long-term debt       2,661     2,510  


Total debt     $ 2,816   $ 2,748  



(a) Amounts are net of unamortized discounts.

(b) December 31, 2003 and 2002 include a $40 million and $45 million fair value increase, respectively, related to SFAS 133 hedge accounting (see Note 15).

52


During 2003, Praxair repaid $300 million of 6.75% notes and $75 million of 6.625% notes that were due on March 1, 2003 and March 15, 2003 respectively. On April 15, 2003, Praxair repaid $250 million of 6.15% notes that were due. The repayments were funded through the issuance of commercial paper. On May 27, 2003 and June 2, 2003, respectively, Praxair issued $350 million of 3.95% due 2013 and $300 million of 2.75% notes due 2008. The proceeds of these debt issuances were used to refinance commercial paper and purchase $339 million of previously leased assets.

On March 19, 2002 and June 19, 2002, respectively, Praxair issued $500 million of 6.375% notes due 2012 and $250 million of 4.75% notes due 2007. The proceeds were used to repay outstanding commercial paper. On July 15, 2002, Praxair redeemed the 8.7% debentures due 2022 resulting in an additional $15 million charge recorded within interest expense for the year ended December 31, 2002.

During 2003, $9 million of long-term debt was assumed through the consolidation of an equity investment in China. During 2001, $65 million of long-term debt was assumed through the consolidation of an equity investment in India.

Praxair maintains a $1 billion credit agreement that expires in 2005. In July 2003, Praxair terminated its $500 million 364-day revolving credit facility. At December 31, 2003, $234 million of commercial paper and notes due in 2004 and ($711 million notes due in 2003 and commercial paper at December 31, 2002) has been classified as long-term because of the company’s intent to refinance this debt on a long-term basis and the availability of such financing under the terms of its credit agreement. No borrowings were outstanding under the credit agreements at December 31, 2003 or 2002 and associated fees were not significant in each of the past three years.

At December 31, 2003 and 2002, the weighted-average interest rate on commercial paper and U.S. bank borrowings was 1.2% and 2.0%, respectively.

Praxair’s major bank credit and long-term debt agreements contain various covenants which may, among other things, restrict the ability of Praxair to merge with another entity, incur or guarantee debt, sell or transfer certain assets, create liens against assets, enter into sale and leaseback agreements, or pay dividends and make other distributions beyond certain limits. These agreements also require Praxair to meet leverage and net worth ratios as defined in the agreements.

Excluding commercial paper and U.S. bank borrowings, scheduled maturities on long-term debt are: 2004, $38 million; 2005, $172 million; 2006, $282 million; 2007, $516 million; 2008, $556 million and $901 million thereafter. At December 31, 2003, $126 million of Praxair’s assets (principally international fixed assets) were pledged as collateral for long-term debt including the current portion of long-term debt.

At December 31, 2003, the estimated fair value of Praxair’s long-term debt portfolio was $2,957 million versus a carrying value of $2,683 million. At December 31, 2002, the estimated fair value of Praxair’s long-term debt portfolio was $2,636 million versus a carrying value of $2,533 million. These differences are attributable to interest rate changes subsequent to when the debt was issued.

NOTE 15. FINANCIAL INSTRUMENTS

The following table is a summary of the notional amount of interest rate and currency derivatives outstanding at December 31, 2003 and 2002 (all maturities within one year):

      2003     2002  
(Millions of dollars)    
   
Interest rate swaps    
   Floating to fixed     $ --   $ 100  


      $ --   $ 100  


Currency contracts    
   Balance sheet items     $ 501   $ 222  
   Firm commitments       1     1  
   Anticipated net income       10     210  


      $ 512   $ 433  


At December 31, 2003 and 2002, the fair value of all derivative contracts has been recorded in the consolidated balance sheet as $4 million in current assets and $2 million in current liabilities.

53


Interest Rate Swaps

During 2003, Praxair’s $100 million notional amount interest rate swap agreement outstanding at December 31, 2002, that converted variable rate lease payments to fixed rate lease payments, matured with an immaterial loss recognized in earnings. Until maturity, this swap agreement was designated as, and was effective as, a cash flow hedge of outstanding lease obligations.

During 2002, Praxair entered into and terminated $500 million notional amount of interest rate swap agreements that effectively converted fixed rate interest to variable rate interest on the $500 million 6.375% notes that mature in April 2012. The termination resulted in a cash gain of $47 million, which Praxair recognized in earnings and was equally offset with a charge to earnings for the changes in fair value of the underlying debt instrument. The fair value increase to the $500 million 6.375% notes of $47 million is being recognized in earnings as a reduction to interest expense over the remaining original term of the underlying debt, or about ten years. The $47 million cash payment received upon termination of the swap is shown in minority transactions and other in the financing section in the 2002 consolidated statement of cash flows. For the year ended December 31, 2003, $5 million was recognized in earnings as a reduction to interest expense ($2 million during the year ended December 31, 2002) and $40 million remains unrecognized at December 31, 2003 ($45 million at December 31, 2002) (see Note 14).

Currency Contracts

Praxair is a party to currency exchange forward contracts to manage its exposure to fluctuations in foreign currency exchange rates. Hedges of balance sheet items are related to recorded balance sheet exposures, including intercompany transactions, and hedges of firm commitments are for the purchase of equipment related to construction projects. Additionally, at December 31, 2002, there were $39 million of notional value of currency exchange contracts that effectively offset each other (none at December 31, 2003).

The net income hedges outstanding at December 31, 2003 are related to anticipated 2004 net income in Canada. The net income hedges outstanding at December 31, 2002 were related to anticipated 2003 net income for the full year in China, Peru, Colombia, India, Thailand and Korea; for nine months in Brazil, and; for six months in Europe. The amounts recorded in other income (expenses) – net as a result of net income hedging contracts includes a loss of $9 million in 2003, a gain of $17 million in December 31, 2002, and a loss of $8 million in 2001 (see Note 6).

Commodity Swaps

At December 31, 2003, Praxair had four (three at December 31, 2002) outstanding commodity swap agreements to hedge its exposure to the variability in future cash flows for forecasted purchases of natural gas. The 2003 outstanding commodity swap agreements settle in 2004 and their impact will not be significant.

Counterparties to interest rate derivative contracts and currency exchange forward contracts are primarily major banking institutions with credit ratings of investment grade or better and no collateral is required. There are no significant risk concentrations. Management believes the risk of incurring losses on derivative contracts related to credit risk is remote and any losses would be immaterial.

54


NOTE 16. SHAREHOLDERS’ EQUITY

At December 31, 2003, there were 500,000,000 shares of common stock authorized (par value $0.01 per share) of which 354,951,262 shares were issued and 326,085,848 were outstanding.

In 2002, the board of directors of Praxair declared a dividend of one purchase right (a “Right”) for each share of Praxair’s common stock held of record at the close of business on June 28, 2002; and that dividend was paid on July 1, 2002. On June 30, 2002, all prior Rights then outstanding expired. In addition, one Right is deemed to be delivered with and attached to each share of Praxair’s common stock issued after June 28, 2002 and before the redemption or expiration of the Rights. Each Right entitles its registered holder, when exercised under certain circumstances, to purchase for $150.00 (subject to adjustment and referred to as the “Exercise Price”) certain securities or assets of Praxair or a surviving entity. The Rights will expire on May 3, 2004, unless exchanged or redeemed prior to that date or unless extended by action of Praxair’s stockholders prior to that date. The redemption price is $0.001 per Right.

The Rights may not be exercised until at least 10 days after a person or group acquires 15 percent or more of Praxair’s common stock, or commences a tender offer that, if consummated, would result in 15 percent or more ownership of Praxair’s common stock. Separate Rights certificates will not be issued and the Rights will not be traded separately from the stock until such time. At no time will a Right confer any voting power to its holder.

Should an acquirer become the beneficial owner of 15 percent or more of Praxair’s common stock (other than as approved by Praxair’s board of directors) and under certain additional circumstances, Praxair Right-holders (other than the acquirer) would have the right to buy common stock in Praxair, or in the surviving entity if Praxair is acquired, having a value of two times the exercise price then in effect. Alternatively, Praxair’s board of directors may elect to exchange all of the Rights (other than the acquirer’s Rights which will have become void) at an exchange ratio of one share of Praxair common stock (and/or other securities, cash or other assets having equal value) per Right (subject to adjustment). Also, under certain circumstances, each Right may entitle the holder to purchase one one-hundredth share of preferred stock or such amount of preferred stock may be substituted for each share of common stock issuable upon the exercise or exchange of a Right.

Praxair’s board of directors may redeem the Rights by a majority vote at any time prior to the 10th day following public announcement that a person or group has acquired 15 percent of Praxair’s common stock. Under certain circumstances, the decision to redeem requires the concurrence of a majority of the independent directors.

NOTE 17. PREFERRED STOCK

At December 31, 2003 and 2002, there were 25,000,000 shares of preferred stock (par value $0.01 per share) authorized, of which no shares were issued and outstanding. No dividends may be paid on Praxair common stock unless preferred stock dividends have been paid, and the preferred stock has limited voting rights. Dividends are included in minority interests on the consolidated statement of income.

In September 2002, the company redeemed all 200,000 outstanding shares of its Series B 6.75% cumulative preferred stock at $100 per share, or $20 million. This is shown in the financing section of the consolidated statement of cash flows in the caption minority transactions and other.

55


NOTE 18. INCENTIVE PLANS AND STOCK OPTIONS

As of March 1, 2001, the 1996 Praxair, Inc. Performance Incentive Plan (the “1996 Plan”) was terminated, and at December 31, 2001, the 1992 Praxair Long-Term Incentive Plan (the “1992 Plan”) expired. Stock option and other incentive compensation awards granted by the company through December 31, 2001 were made under these plans. Both plans provided for granting nonqualified or incentive stock options, stock grants, performance awards, and other stock-related incentives for key employees. The exercise price for incentive stock options was equal to the closing price of Praxair’s common stock on the date of the grant. Options that were granted under both plans became exercisable only after one or more years and the option term could be no more than ten years.

On February 28, 2001, the board of directors of the company adopted the 2002 Praxair, Inc. Long-Term Incentive Plan (the “2002 Plan”), which became effective on January 1, 2002. The shareholders approved the Plan at Praxair’s annual meeting in April 2001. Under the 2002 Plan, the number of shares available for option or stock grants is limited to a total of 15,800,000 shares. As of December 31, 2003, 9,435,170 shares were available for option or stock grants under this plan. The 2002 Plan provides for the granting of only nonqualified and incentive stock options, stock grants and performance awards and further provides that the aggregate number of shares granted as restricted stock or pursuant to performance awards may not exceed 20% of the total shares available under the Plan. The 2002 Plan also provides calendar year per-participant limits on grants of options, restricted stock and performance awards. Exercise prices for options granted under the 2002 Plan may not be less than the closing market price of the company’s common stock on the date of grant and granted options may not be repriced or exchanged without shareholder approval. Options granted under the 2002 Plan become exercisable after a minimum of one year and have a maximum duration of ten years. Both officer and non-officer employees are eligible for awards under the 2002 Plan.

The following table summarizes the changes in outstanding shares under option and performance share equivalents for 2003, 2002, and 2001 (options are expressed in thousands):

                Activity         Options Weighted Average
Exercise Price
   
Outstanding at December 31, 2000       29,092   $ 17.80  
Granted       9,044   $ 23.53  
Exercised       (6,886 ) $ 13.00  
Cancelled or expired       (246 ) $ 22.19  


Outstanding at December 31, 2001       31,004   $ 20.51  
   
Granted       2,648   $ 28.38  
Exercised       (7,626 ) $ 17.47  
Cancelled or expired       (236 ) $ 23.86  


Outstanding at December 31, 2002       25,790   $ 22.18  
   
Granted       3,967   $ 26.46  
Exercised       (7,052 ) $ 20.16  
Cancelled or expired       (251 ) $ 26.08  


Outstanding at December 31, 2003       22,454   $ 23.52  


Exercisable at    
December 31, 2001       16,104   $ 18.56  
December 31, 2002       17,240   $ 20.78  
December 31, 2003       13,985   $ 22.10  

The following table summarizes information about options outstanding and exercisable at December 31, 2003 (options are expressed in thousands, averages are calculated on a weighted basis, life in years):

Outstanding Exercisable


Range of     
Exercise Prices      
Average
Remaining
Life
Number
of
Options
Average
Exercise
Price
Number
of
Options
Average
Exercise
Price
$ 8.94 - $15.85       1.3     498   $ 10.75     497   $ 10.75  
$16.66 - $19.97       5.2     3,082   $ 18.33     3,082   $ 18.33  
$20.28 - $24.97       5.9     9,747   $ 22.29     7,651   $ 22.35  
$25.09 - $30.01       8.3     9,127   $ 27.29     2,755   $ 27.69  

$8.94 - $30.01       6.7     22,454   $ 23.52     13,985   $ 22.10  

56


NOTE 19. RETIREMENT PROGRAMS

Pensions – Praxair has two main U.S. retirement programs which are non-contributory defined benefit plans: the Praxair Pension Plan (formerly, the Retirement Program Plan for Employees of Praxair, Inc. and Participating Subsidiary Companies) and the CBI Pension Plan. The latter program primarily benefits former employees of CBI Industries, Inc. which Praxair acquired in 1996. Effective July 1, 2002, the Praxair Retirement Program was amended to give participating employees a one-time choice to remain covered by the old formula or to elect coverage under a new formula. The old formula is based predominantly on years of service, age and compensation levels prior to retirement, while the new formula provides for an annual contribution to an individual account which grows with interest each year at a predetermined rate. Also, this new formula applies to all new employees hired into businesses adopting this plan. U.S. pension plan assets are comprised of a diversified mix of investments, including domestic and international corporate equities, government securities and corporate debt securities. Pension coverage for employees of certain of Praxair’s international subsidiaries generally is provided by those companies through separate plans. Obligations under such plans are primarily provided for through diversified investment portfolios, with some smaller plans provided for under insurance policies or by book reserves.

Praxair’s U.S. packaged gases business has a defined contribution plan. Company contributions to this plan are calculated as a percentage of salary based on age plus service. Praxair’s U.S. healthcare business sponsors a defined contribution plan which provides for a matching contribution as well as a company contribution that is not dependent on employee contributions. In both plans, U.S. employees may supplement the company contributions up to the maximum allowable by IRS regulations. Certain international subsidiaries of the company also sponsor defined contribution plans where contributions are determined under various formulas. The cost for all defined contribution plans was $8 million in 2003 and $7 million in both 2002 and 2001 (not included in the tables that follow).

U.S. employees other than those in the packaged gases and healthcare businesses are eligible to participate in a defined contribution savings plan. Employees may contribute up to 40% of their compensation, subject to the maximum allowable by IRS regulations. Company contributions to this plan are calculated on a graduated scale based on employee contributions to the plan. The cost for this plan was $12 million, $11 million and $10 million in 2003, 2002 and 2001, respectively (not included in the tables that follow).

Postretirement Benefits Other Than Pensions (OPEB) – Praxair provides health care and life insurance benefits to certain eligible retired employees. These benefits are provided through various insurance companies and health care providers. Praxair is also obligated to make payments for a portion of postretirement benefits related to retirees of Praxair’s former parent. Additionally, as part of the CBI acquisition in 1996, Praxair assumed responsibility for health care and life insurance benefit obligations for CBI’s retired employees. All postretirement health care programs have cost caps that limit the company’s exposure to future cost increases. In addition, as part of the election made for July 1, 2002, all current employees were given the choice of maintaining coverage in retirement under the current plan, or to move to a plan whereby coverage would be provided, but with no Praxair subsidy whatsoever. Praxair does not currently fund its postretirement benefits obligations. Praxair retiree plans may be changed or terminated by Praxair at any time for any reason with no liability to current or future retirees.

Praxair uses a measurement date of December 31 for the majority of its pension and other postretirement benefit plans.

57


Pension and Postretirement Benefit Costs

The components of net pension and OPEB costs for 2003, 2002 and 2001 are shown below:

(Millions of dollars)     Pensions OPEB


Year Ended December 31,       2003     2002     2001     2003     2002     2001  






NET BENEFIT COST    
      Service cost     $ 30   $ 30   $ 26   $ 6   $ 4   $ 5  
      Interest cost       79     73     67     18     16     14  
      Expected return on assets       (82 )   (86 )   (81 )   --     --     --  
      Net amortization and deferral       (1 )   (2 )   (3 )   (5 )   (3 )   (4 )






      Net periodic benefit cost     $ 26   $ 15   $ 9   $ 19   $ 17   $ 15  






The changes in projected benefit obligation (“PBO”) and plan assets and the funded status reconciliation as of December 31, 2003 and 2002 for Praxair’s significant pension and OPEB programs are shown below:

(Millions of dollars) Pensions OPEB


2003 2002 2003 2002




Year Ended December 31, U.S. INTL U.S. INTL
CHANGE IN BENEFIT OBLIGATION (PBO)                            
     Benefit obligation, January 1     $ 901   $ 246   $ 759   $ 236   $ 254   $ 224  
     Service cost       21     8     21     9     5     4  
     Interest cost       61     17     58     15     17     16  
     Participant contributions       --     --     --     1     7     7  
     Actuarial loss (gain)       54     23     85     --     2     26  
     Benefits paid       (43 )   (15 )   (40 )   (15 )   (26 )   (26 )
     Curtailment / settlement (gains)       --     (1 )   --     (1 )   --     --  
     Currency translation       --     40     --     1     6     (4 )
     Other changes       --     --     18     --     --     7  






     Benefit obligation, December 31     $ 994   $ 318   $ 901   $ 246   $ 265   $ 254  






CHANGE IN PLAN ASSETS    
     Fair value of plan assets, January 1     $ 518   $ 230   $ 605   $ 241   $ --   $ --  
     Actual return on plan assets       138     58     (54 )   (5 )   --     --  
     Company contributions       25     9     --     7     --     --  
     Participant contributions       --     --     --     1     --     --  
     Benefits paid       (37 )   (14 )   (33 )   (15 )   --     --  
     Currency translation       --     36     --     1     --     --  






     Fair value of plan assets, December 31     $ 644   $ 319   $ 518   $ 230   $ --   $ --  






FUNDED STATUS RECONCILIATION    
     Funded status, December 31     $ (350 ) $ 1   $ (383 ) $ (16 ) $ (265 ) $ (254 )
     Unrecognized (gains) losses - net       220     11     247     11     28     24  
     Unrecognized prior service cost       (5 )   4     (6 )   2     (4 )   (9 )
     Unrecognized transition amount       --     1     --     1     --     --  






     Net amount recognized, December 31     $ (135 ) $ 17   $ (142 ) $ (2 ) $ (241 ) $ (239 )






AMOUNTS IN THE BALANCE SHEET    
     Prepaid benefit cost     $ --   $ 67   $ --   $ 4   $ --   $ --  
     Accrued benefit liability       (282 )   (55 )   (305 )   (9 )   (241 )   (239 )
     Intangible assets       --     --     --     1     --     --  
     Accumulated other comprehensive income    
       (loss)       147     5     163     2     --     --  






     Net amount recognized, December 31     $ (135 ) $ 17   $ (142 ) $ (2 ) $ (241 ) $ (239 )






PENSION PLANS WITH AN ACCUMULATED    
BENEFIT OBLIGATION IN EXCESS OF PLAN ASSETS    
     Projected benefit obligation     $ 994   $ 200   $ 901   $ 161     N/A     N/A  
     Accumulated benefit obligation (ABO)     $ 927   $ 180   $ 823   $ 138     N/A     N/A  
     Fair value of plan assets     $ 644   $ 117   $ 518   $ 86     N/A     N/A  
   
OTHER INFORMATION    
     Increase/(decrease) in minimum liability    
       included in other comprehensive income     $ (16 ) $ 3   $ 145   $ 2   $ -   $ --  
     Accumulated benefit obligation (ABO)     $ 927   $ 284   $ 823   $ 211     N/A     N/A  

58


Assumptions

Pension OPEB


U.S. Intl


        2003     2002     2003     2002     2003     2002  






Weighted average assumptions used to determine benefit    
    obligations at December 31,    
Discount rate       6.25 %   6.75 %   6.00 %   6.25 %   6.25 %   6.75 %
Rate of increase in compensation levels       3.25 %   3.75 %   3.25 %   3.25 %   3.25 %   3.75 %
   
Weighted average assumptions used to determine net    
    periodic benefit cost for years ended December 31,    
Discount rate       6.75 %   7.25 %   6.25 %   7.25 %   6.75 %   7.25 %
Rate of increase in compensation levels       3.75 %   4.25 %   3.25 %   4.25 %   3.75 %   4.25 %
Expected long-term rate of return on plan assets*       8.50 %   9.25 %   8.00 %   8.75 %

* For 2004, the expected long-term rate of return on plan assets will be 8.50% for the U.S. plans. Expected weighted average returns for international plans will vary. These rates are determined annually by management based on a weighted average of current and historical market trends, historical performance and the portfolio mix of investments.


OPEB

Assumed health care cost trend rates at December 31,       2004     2003  


Health care cost trend assumed       10.00%   11.00%
Rate to which the cost trend rate is assumed to decline (the ultimate trend rate)       5.00%   5.00%
Year that the rate reaches the ultimate trend rate       2008     2008  

These health care cost trend rate assumptions have an impact on the amounts reported; however, cost caps limit the impact on the net OPEB benefit cost. To illustrate the effect, a one-percentage point change in assumed health care cost trend rates would have the following effects:

One-Percentage Point

(Millions of dollars)       Increase     Decrease  


Effect on the total of service and interest            
  cost components of net OPEB benefit cost     $ -   $ --  
Effect on OPEB benefit obligation     $ 1   $ (1 )

Plan Assets

Praxair’s U.S. pension plan weighted-average asset allocations at December 31, 2003 and 2002, and the target allocation for 2003, by asset category are as follows:

Plan Assets at December 31,

2003 Target
Allocations
2003 2002



ASSET CATEGORY                  
Equity securities*     60%-80%     69%   66%
Debt securities     20%-40%     31%   33%
Real estate     --     --     --  
Other     --     --     1%
     Total     100     100%   100%

* Equity securities do not include any Praxair common stock.

The investments of the U.S. pension plan are managed to meet the future expected benefit liabilities of the Plan over the long term by investing in diversified portfolios consistent with prudent diversification and historical and expected capital market returns. When Praxair became an independent publicly traded company in 1992, its former parent retained all liabilities for its term-vested and retired employees. Praxair’s plan received assets and retained pension liabilities for its own active employee base. Therefore, the liabilities under the Praxair U.S. pension plan mature at a later date compared to pension funds of other similar companies. Investment strategies are reviewed and approved by the Board of Directors and investment performance is tracked against appropriate benchmarks.

Contributions

Pension contributions were $34 million in 2003 and $7 million in 2002. The U.S. Congress is still in the process of reviewing and updating legislation relating to the appropriate interest rate for companies to utilize for pension funding purposes. Estimates of required 2004 contributions are in the range of $80 million assuming that interest rate relief will become law. If interest rate relief legislation is not enacted, then our estimates of the 2004 contributions are in the range of $130 million. In February 2004, contributions of $60 million were paid.

59


NOTE 20. COMMITMENTS AND CONTINGENCIES

The company accrues liabilities for contingencies when management believes that it is probable that a liability has been incurred and its amount is reasonably estimable. In the event any losses are sustained in excess of these accruals, they will be charged to income at that time. Commitments represent obligations, such as those for future purchases of goods or services, that are not yet recorded on the company’s balance sheet as liabilities. The company records liabilities for commitments when incurred (e.g. when the goods or services are received).

In the normal course of business, Praxair is involved in legal proceedings and claims with both private and governmental parties. These cover a variety of items, including commercial, patent, product liability, tax and environmental matters. In some of these cases, the remedies that may be sought or damages claimed are substantial.

Among such matters are claims brought by welders alleging that exposure to manganese contained in welding fumes caused neurological injury. Praxair has never manufactured welding consumables; however, such products were manufactured prior to 1985 by a predecessor company of Praxair. As of December 31, 2003, Praxair was a co-defendant with many other companies in 170 lawsuits alleging personal injury caused by manganese contained in welding fumes. The cases were pending in state and federal courts in Illinois, Mississippi, Missouri, Texas, Louisiana, Georgia, West Virginia, Ohio, Arkansas, Indiana and Utah. There were a total of 9,796 individual claimants in these cases. As a result of a number of voluntary dismissals, as of February 5, 2004, there were 190 cases and a total of 8,517 claimants. Ten of the cases are class actions. None of the class actions have been certified. Plaintiffs’ counsel have advised the court in which the class actions are pending that the class action allegations will be dismissed. All of the cases that have been filed in the federal courts have been transferred, under the Multidistrict Litigation procedure, to U.S. District Court for the Northern District of Ohio for coordinated or consolidated pretrial proceedings. The plaintiffs seek unspecified compensatory and, in most instances, punitive damages. In the past, Praxair has either been dismissed from the cases with no payment or has settled a few cases for nominal amounts. Praxair believes that it has meritorious defenses to these cases and intends to defend itself vigorously.

While the outcome of litigation is uncertain, Praxair believes that the resolution of these cases will not have a material adverse effect on its consolidated financial position or on its consolidated results of operations or cash flows in any given year.

The following table sets forth Praxair’s material commitments and contractual obligations as of December 31, 2003 excluding debt, leases, OPEB and long-term pension obligations(see Notes 5, 14, and 19):

(Millions of dollars)
Expiring through
December 31,
Unconditional Purchase
Obligations
Construction
Commitments
Guarantees
and Other
   
2004     $ 108   $ 197   $ 121  
2005       67     25     4  
2006       49     --     --  
2007       41     --     --  
2008       33     --     4  
Thereafter       118     --     --  



      $ 416   $ 222   $ 129  



Unconditional purchase obligations of $416 million represent contractual commitments under various long- and short-term, take-or-pay arrangements with suppliers and are not included on Praxair’s balance sheet. These obligations are primarily minimum purchase commitments for electricity, natural gas and feedstock used to produce atmospheric gases, carbon dioxide and hydrogen. During 2003, payments under these contracts totaled $341 million, including $194 million for electricity and $83 million for natural gas. A significant portion of these risks is passed on to customers through similar take-or-pay contractual arrangements. Purchase obligations which are not passed along to customers do not represent a significant risk to Praxair. In addition, Praxair enters into contracts to purchase products and services that do not have minimum purchase provisions.

Construction commitments of $222 million represent outstanding commitments to customers or suppliers to complete authorized construction projects as of December 31, 2003. A significant portion of Praxair’s capital spending is related to the construction of new production facilities to satisfy customer commitments which may take a year or more to complete.

Guarantees and Other of $129 million include $80 million related to minimum pension contributions $49 million related to Praxair’s off-balance sheet contingent obligations under guarantees of certain debt of unconsolidated affiliates. Unconsolidated equity investees had total debt of approximately $145 million at December 31, 2003, which was non-recourse to Praxair with the exception of the guaranteed portions described above. Praxair has no financing arrangements with closely-held related parties.

60


NOTE 21. QUARTERLY DATA (UNAUDITED)

(Dollar amounts in millions, except per share data)

2003 1Q 2Q 3Q 4Q YEAR
   
Sales     $ 1,337   $ 1,401   $ 1,414   $ 1,461   $ 5,613  
Cost of sales     $ 804   $ 833   $ 832   $ 859   $ 3,328  
Depreciation and amortization     $ 122   $ 127   $ 133   $ 135   $ 517  
Operating profit     $ 215   $ 223   $ 240   $ 244   $ 922  
Net income     $ 130   $ 150   $ 150   $ 155   $ 585  
   
BASIC PER SHARE DATA (a)    
Net income     $ 0.40   $ 0.46   $ 0.46   $ 0.47   $ 1.79  
Weighted average shares (000's)       325,762     326,688     326,430     326,672     326,388  
   
DILUTED PER SHARE DATA (a)    
Net income     $ 0.39   $ 0.45   $ 0.45   $ 0.47   $ 1.77  
Weighted average shares (000's)       329,270     330,850     330,990     331,966     330,991  
   
   
   
2002 1Q 2Q 3Q 4Q YEAR
Sales     $ 1,232   $ 1,307   $ 1,292   $ 1,297   $ 5,128  
Cost of sales     $ 699   $ 755   $ 749   $ 747   $ 2,950  
Depreciation and amortization     $ 121   $ 120   $ 120   $ 122   $ 483  
Operating profit     $ 217   $ 244   $ 235   $ 227   $ 923  
 
Income before cumulative effect of an accounting change     $ 127   $ 150   $ 131   $ 140   $ 548  
Cumulative effect of an accounting change (b)       (139 )   --     --     --     (139 )





Net income     $ (12 ) $ 150   $ 131   $ 140   $ 409  





   
BASIC PER SHARE DATA (a)    
Income before cumulative effect of an accounting change     $ 0.38   $ 0.46   $ 0.40   $ 0.43   $ 1.68  
Cumulative effect of an accounting change (b)       (0.42 )   --     --     --     (0.42 )





Net income     $ (0.04 ) $ 0.46   $ 0.40   $ 0.43   $ 1.26  





Weighted average shares (000's)       327,048     325,394     324,592     325,110     325,536  
   
DILUTED PER SHARE DATA (a)    
Income before cumulative effect of an accounting change     $ 0.38   $ 0.45   $ 0.40   $ 0.43   $ 1.66  
Cumulative effect of an accounting change (b)       (0.42 )   --     --     --     (0.42 )





Net income     $ (0.04 ) $ 0.45   $ 0.40   $ 0.43   $ 1.24  





Weighted average shares (000's)       331,872     329,670     327,912     328,630     329,489  

(a) Earnings per share and weighted average shares outstanding have been adjusted to reflect the December 15, 2003 two-for-one stock split which was effected as a stock dividend (see Note 1).

(b) Related to the adoption of SFAS 142, Goodwill and Other Intangible Assets (see Note 2).

61


MANAGEMENT’S STATEMENT OF RESPONSIBILITY FOR
FINANCIAL STATEMENTS

Praxair’s consolidated financial statements are prepared by management, which is responsible for their fairness, integrity and objectivity. The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America applied on a consistent basis except for accounting changes as disclosed and include amounts that are estimates and judgements. All historical financial information in this annual report is consistent with the accompanying financial statements.

Praxair maintains accounting systems, including internal accounting controls monitored by a staff of internal auditors, that are designed to provide reasonable assurance of the reliability of financial records and the protection of assets. The concept of reasonable assurance is based on recognition that the cost of a system should not exceed the related benefits. The effectiveness of those systems depends primarily upon the careful selection of financial and other managers, clear delegation of authority and assignment of accountability, inculcation of high business ethics and conflict-of-interest standards, policies and procedures for coordinating the management of corporate resources, and the leadership and commitment of top management.

Praxair’s consolidated financial statements are audited by PricewaterhouseCoopers LLP, independent auditors, in accordance with auditing standards generally accepted in the United States of America. These standards provide for a review of Praxair’s internal accounting controls to the extent they deem appropriate in order to issue their opinion on the financial statements.

The Audit Committee of the Board of Directors, which consists solely of non-employee directors, is responsible for overseeing the functioning of the accounting system and related controls and the preparation of annual financial statements. The Audit Committee periodically meets with management, internal auditors and the independent auditors to review and evaluate their accounting, auditing and financial reporting activities and responsibilities. The independent auditors and internal auditors have full and free access to the Audit Committee and meet with the Committee, with and without management present.

/s/ Dennis H. Reilley

DENNIS H. REILLEY
Chairman, President and Chief Executive Officer
  
/s/ James S. Sawyer

JAMES S. SAWYER
Senior Vice President and Chief Financial Officer
 
/s/ Patrick M. Clark

PATRICK M. CLARK
Vice President and Controller

Danbury, Connecticut
February 11, 2004

62


REPORT OF INDEPENDENT AUDITORS

To the Board of Directors and Shareholders of Praxair, Inc.

In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of income, shareholders’ equity and cash flows present fairly, in all material respects, the financial position of Praxair, Inc. and its subsidiaries at December 31, 2003 and 2002, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2003 in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the company’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with auditing standards generally accepted in the United States of America, which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

As discussed in Note 2, the company adopted new accounting standards for goodwill in 2002.

/s/ PricewaterhouseCoopers LLP    

Stamford, Connecticut
February 11, 2004

63


FIVE-YEAR FINANCIAL SUMMARY
(Dollar amounts in millions, except per share data)

Year Ended December 31,       2003     2002     2001 (a)   2000 (a)   1999  





FROM THE INCOME STATEMENT    
Sales     $ 5,613   $ 5,128   $ 5,158   $ 5,043   $ 4,639  
Cost of sales       3,328     2,950     3,060     3,075     2,732  
Selling, general and administrative       766     751     699     683     641  
Depreciation and amortization       517     483     499     471     445  
Research and development       75     69     66     65     67  
Other income (expenses) - net       (5 )   48     (34 )   (42 )   77  





     Operating profit       922     923     800     707     831  
Interest expense       151     206     224     224     204  





     Income before taxes    
        771     717     576     483     627  
Income taxes       174     158     135     103     152  





        597     559     441     380     475  
Minority interests       (24 )   (20 )   (18 )   (27 )   (45 )
Income from equity investments       12     9     9     10     11  





      Income before cumulative effect of accounting
        changes
   
        585     548     432     363     441  
Cumulative effect of accounting changes(b)       --     (139 )   (2 )   --     (10 )





     Net income       585     409     430     363     431  
Add back goodwill amortization, net of tax       --     --     33     29     28  





     Net income excluding goodwill amortization (c)     $ 585   $ 409   $ 463   $ 392   $ 459  





 
PER SHARE DATA(d)    
Basic earnings per share:    
     Income before cumulative effect of accounting
        changes
    $ 1.79   $ 1.68   $ 1.34   $ 1.14   $ 1.38  





     Net income     $ 1.79   $ 1.26   $ 1.33   $ 1.14   $ 1.35  
     Add back goodwill amortization, net of tax       --     --     0.10     0.09     0.09  





     Net income excluding goodwill amortization (c)     $ 1.79   $ 1.26   $ 1.43   $ 1.23   $ 1.44  





Diluted earnings per share:    
     Income before cumulative effect of accounting
        changes
    $ 1.77   $ 1.66   $ 1.32   $ 1.13   $ 1.36  





     Net income     $ 1.77   $ 1.24   $ 1.31   $ 1.13   $ 1.33  
     Add back goodwill amortization, net of tax       --     --     0.10     0.09     0.09  





     Net income excluding goodwill amortization (c)     $ 1.77   $ 1.24   $ 1.41   $ 1.22   $ 1.42  





Cash dividends per share     $ 0.46   $ 0.38   $ 0.34   $ 0.31   $ 0.28  





 
WEIGHTED AVERAGE SHARES
OUTSTANDING (000's) (d)
   
     Basic shares outstanding       326,388     325,536     323,020     318,246     318,560  
     Diluted shares outstanding       330,991     329,489     327,014     322,185     324,445  
 
CAPITAL    
     Total debt     $ 2,816   $ 2,748   $ 2,989   $ 3,141   $ 2,995  
     Minority interests       195     164     141     138     359  
     Preferred stock       --     --     20     20     75  
     Shareholders' equity       3,088     2,340     2,477     2,357     2,290  





     Total capital     $ 6,099   $ 5,252   $ 5,627   $ 5,656   $ 5,719  





 
OTHER INFORMATION AND RATIOS    
     Capital expenditures (e)     $ 983   $ 498   $ 595   $ 704   $ 653  
     Cash flow from operations     $ 1,137   $ 1,001   $ 1,020   $ 899   $ 969  
     Cash flow from operations-to-debt ratio       40.4 %   36.4 %   34.1 %   28.6 %   32.4 %
     Total assets at year end     $ 8,305   $ 7,401   $ 7,715   $ 7,762   $ 7,722  
     Shares outstanding at year-end (000's) (d)       326,086     324,536     324,286     318,758     318,096  
     Debt-to-capital ratio       46.2 %   52.3 %   53.1 %   55.5 %   52.4 %
     Number of employees       25,438     25,010     24,271     23,430     24,102  

(a) In 2001, operating profit includes a $70 million pre-tax charge ($57 million after tax, or $0.17 per diluted share) related to restructuring and other actions (shown $7 million in cost of sales; $5 million in selling, general and administrative expenses; and $58 in other income (expense) - net). In 2000, operating profit includes a $159 million pre-tax charge and income from equity investments includes a $2 million charge ($117 million after tax, or $0.36 per diluted share) related to repositioning and special charges (shown $47 million in cost of sales; $21 million in selling, general and administrative expenses; and $91 million in other income (expenses) - net). These items are collectively referred to as special items.

(b) 2002, 2001 and 1999 net income include the cumulative effect of accounting changes relating to the implementation of new accounting standards for goodwill impairment, derivatives and previously capitalized start-up costs, respectively.

(c) Adjusted net income excludes amortization of goodwill prior to 2002 (see Note 12 to the consolidated financial statements).

(d) Per share data, weighted average and total shares outstanding have been adjusted to reflect the December 15, 2003 two-for-one stock split which was effected as a stock dividend (see Note 1 to the consolidated financial statements).

(e) Capital expenditures for 2003 include the purchase of previously leased assets for $339 million (see Note 5 to the consolidated financial statements).

64


INVESTOR INFORMATION

ELIZABETH T. HIRSCH, Director, Investor Relations
Praxair, Inc.
39 Old Ridgebury Road
Danbury, Connecticut 06810-5113
e-mail: investor_relations@praxair.com
(203) 837-2210

INVESTOR INFORMATION AT WWW.PRAXAIR.COM/INVESTORS

Contact information
Stock information
Business trends
Presentations
Annual reports
Quarterly earnings
SEC filings
Governance
Sustainability Report
FAQs
Five-year financials
Financial news

COMMON STOCK LISTING (SYMBOL: PX)
New York Stock Exchange

OTHER STOCK EXCHANGES TRADING PRAXAIR STOCK

Cincinnati
Midwest
Pacific

NUMBER OF SHAREHOLDERS
There were 23,546 registered shareholders of record as of December 31, 2003.

DIVIDEND POLICY
Dividends on Praxair’s common stock are usually declared and paid quarterly. Praxair’s objective is to continue quarterly dividends and consider annual dividend increases in conjunction with continued growth in earnings per share.

STOCK TRANSFER AGENT AND
STOCK RECORD KEEPING

Registrar and Transfer Company is Praxair's stock transfer agent and registrar, and maintains shareholder records. For information about account records, stock certificates, change of address and dividend payments, contact: 1-800-368-5948
e-mail address for investor inquiries: info@rtco.com
website address: http://www.rtco.com

ADDRESS SHAREHOLDER INQUIRIES TO:
Shareholder Relations Department
Registrar and Transfer Company
10 Commerce Drive
Cranford, NJ 07016

DIVIDEND REINVESTMENT PLAN
Praxair provides investors a convenient, low-cost program that allows purchases of Praxair stock without commissions and automatically reinvests dividends by purchasing additional shares of stock. Contact Investor Relations at Registrar and Transfer Company for full details at the address above.

ANNUAL SHAREHOLDERS MEETING
The 2004 annual meeting of shareholders of Praxair, Inc. will be held at 9:30 a.m. on Tuesday, April 27, 2004 at the Sheraton Danbury, 18 Old Ridgebury Road, Danbury, Connecticut.

NYSE QUARTERLY STOCK PRICE AND DIVIDEND INFORMATION
Stock prices and dividends have been restated to reflect the December 15, 2003 two-for-one stock split (see Note 1 to the consolidated financial statements).

MARKET PRICE TRADING
HIGH
TRADING
LOW
CLOSE DIVIDEND
PER SHARE

 
2003                  
First Quarter     $ 30.07   $ 25.02   $ 28.18   $ 0.1075  
Second Quarter     $ 31.95   $ 27.95   $ 30.05   $ 0.1075  
Third Quarter     $ 32.90   $ 29.34   $ 30.98   $ 0.1075  
Fourth Quarter     $ 38.26   $ 31.15   $ 38.20   $ 0.1350  

 
2002    
First Quarter     $ 30.56   $ 23.98   $ 29.90   $ 0.095  
Second Quarter     $ 30.20   $ 25.75   $ 28.49   $ 0.095  
Third Quarter     $ 29.30   $ 22.28   $ 25.56   $ 0.095  
Fourth Quarter     $ 29.75   $ 24.59   $ 28.89   $ 0.095  

 
2001    
First Quarter     $ 24.79   $ 19.69   $ 22.33   $ 0.085  
Second Quarter     $ 27.00   $ 22.05   $ 23.50   $ 0.085  
Third Quarter     $ 24.82   $ 18.30   $ 21.00   $ 0.085  
Fourth Quarter     $ 27.96   $ 20.35   $ 27.63   $ 0.085  

66


SUBSIDIARIES OF PRAXAIR, INC.

Praxair, Inc. and Subsidiaries


EXHIBIT 21.01

Place of
Incorporation
  
640733 British Columbia Ltd. British Columbia
Accent Cay Holdings Inc. B.V.I.
Adirondack Insurance Company Vermont
Agas Servizi S.r.l Italy
Amko Service Company Ohio
Antwerpse Chemische Bedrijven (LCB) N.V Belgium
Argim Limited Israel
Asian Surface Technologies Pte. Ltd. Singapore
Asistir Ltda Colombia
Beijing Praxair Huashi Carbon Dioxide Co., Ltd. China
BFPC Investment Corporation Delaware
CBI Investments, Inc. Delaware
Chanceller Servicos de Lavanderia Industrial Ltda Brazil
Coatec Gesellschaft Fur Oberflachenveredelung mbH & Co. KG Germany
Consultora Rynuter S.A Uruguay
Cryo Teruel S.A Spain
CSF Technology, LLC Delaware
D'Angelo S.p.A Italy
Domolife S.r.l Italy
Dorsey Gage Co., Inc. New York
Dryce Italia S.r.l Italy
DVCRF Ventures Investment Corporation Delaware
Euro Cantley S.A Colombia
Gases Ensenada S.A Argentina
Grenslandgas GmbH Germany
Grupo Praxair S. de R.L. de C.V Mexico
Guangdong Praxair Shaogang Co., Ltd. China
Helium Centre Pte Ltd. China
Hielo Seco Ltda Bolivia
Indugas Holding B.V Netherlands
Indugas Invest B.V Netherlands
Indugas N.V Belgium
Indugas Netherland B.V Netherlands
Industria Paraguaya de Gases Paraguay
Ingemedical Ltda Colombia
Innovative Membrane Systems, Inc. Delaware
Integrar Comercio e Servicos Industriais Ltda Brazil
International Cryogenic Equipment Corporation Delaware
Interwest Home Medical-Alaska, Inc. Alaska
Julio Pastafiglia & Cia. S.A Argentina
Kelvin Finance Company Limited Ireland
Kolux Holdings S.a.r.l Italy
Korea Liquid Carbonic Company, Ltd. Korea
Kosmoid Finance Ireland
Kosmoid Finance (UK) Limited Ireland
Kunshan Praxair Co., Ltd. China
L. Clausen & CIA. SRL Uruguay
Liquid Carbonic Corporation Delaware
Liquid Carbonic del Paraguay S.A Paraguay
Liquid Carbonic do Nordeste, S.A Brazil
Liquid Carbonic LNG International, Inc. Delaware



SUBSIDIARIES OF PRAXAIR, INC. (Continued)

Place of
Incorporation
  
Liquid Carbonic of Oklahoma, Inc. Oklahoma
Liquido Carbonico Colombiana S.A Colombia
Liquid Quimica S.A Brazil
Magaldi Life S.r.l Italy
Malaysian Industrial Gas Company Sdn. Bhd Malaysia
Maxima Air Separation Center Limited Israel
Medical Gases S.R.L Argentina
MetFabCity Inc. Delaware
Neotex Solucoes Ambientais Ltda Brazil
Nitraco N.V Belgium
Nitropet, S.A. de C.V Mexico
Nitroxide (1993) Production and Marketing Ltd. Israel
Old Danford S.A Uruguay
Oxigenos Camatagua, C.A Venezuela
Oxigenos de ColombiaLtda Colombia
Oximesa S.L Spain
Oxirent Argentina
Parkgas B.V.B.A Belgium
Praxair (Beijing) Semiconductor Gases Co., Ltd. China
Praxair (China) Investment Co., Ltd. China
Praxair (Nanjing) Carbon Dioxide Co. Ltd. China
Praxair (Shanghai) Co., Ltd. China
Praxair (Shanghai) Semiconductor Gases Co., Ltd. China
Praxair (Thailand) Company, Ltd. Thailand
Praxair (Wuhan), Inc. China
Praxair (Yueyang) Co., Ltd. China
Praxair Alberta Inc. Canada
Praxair Alberta Partnership Canada
Praxair Asia Management Consulting (Shanghai)
  Company Limited China
Praxair Asia, Inc. Delaware
Praxair Argentina S.A Argentina
Praxair Australia Pty. Ltd. Australia
Praxair B.V Netherlands
Praxair Bolivia, Ltda Bolivia
Praxair Canada Inc. Canada
Praxair Carbondioxide Private Limited India
Praxair Chemax Semiconductor Materials Co. Taiwan
Praxair Chile Ltda Chile
Praxair CMP Products, Inc. New Hampshire
Praxair e Companhia - Comercio e Servicos Portugal
Praxair Costa Rica, S.A Costa Rica
Praxair Deer Park Cogen, Inc. Delaware
Praxair Distribution, Inc. Delaware
Praxair Distribution Southeast, LLC Delaware
Praxair do Brasil Ltda Brazil
Praxair E-Services Private Limited India
Praxair Energy Resources, Inc. Delaware
Praxair Energy Services, Inc. Delaware
Praxair Espana, S.L Spain
Praxair Euroholding, S.L Spain



SUBSIDIARIES OF PRAXAIR, INC. (Continued)

Place of
Incorporation
  
Praxair Gases Alberta Inc. Canada
Praxair G.m.b.H Germany
Praxair Healthcare Services, Inc. Delaware
Praxair Holding Company Canada
Praxair Holding Latinoamerica, S.L Spain
Praxair Holding N.V Belgium
Praxair Holdings International, Inc. Delaware
Praxair Hungary Kft Hungary
Praxair Hydrogen Supply, Inc. Delaware
Praxair Iberica, S.A Spain
Praxair India Private Limited India
Praxair Investments B.V Netherlands
Praxair K.K Japan
Praxair Korea Company Limited South Korea
Praxair Latin America Holdings LLC Delaware
Praxair Management Services, Inc. Delaware
Praxair Meishan (Nanjing)Co., Ltd. China
Praxair Mexico, S.A. de C.V Mexico
Praxair Maritime Company Canada
Praxair MRC S.A.S France
Praxair N.V Belgium
Praxair Pacific Limited Mauritius
Praxair Partnership Delaware
Praxair PC Partnership Canada
Praxair Polska, SP. Z O.O Poland
Praxair Paraguay S.R.L Paraguay
Praxair Peru S.A Peru
Praxair Plainfield, Inc. Delaware
Praxair Portugal Gases S.A Portugal
Praxair Produccion Espana, S.L Spain
Praxair Production N.V Belgium
Praxair Puerto Rico B.V Netherlands
Praxair Puerto Rico, Inc. Delaware
Praxair S.A.S France
Praxair S.p.A Italy
Praxair S. T. Technology, Inc. Delaware
Praxair Sante S.A.S France
Praxair Services (UK) Limited United Kingdom
Praxair Services Canada Inc. Canada
Praxair Services et Systemes S.A France
Praxair Services G.m.b.H Germany
Praxair Services, Inc. Texas
Praxair Shanghai Meishan Inc. China
Praxair Sixon (Anhui) Industrial Gases Co., Ltd. China
Praxair Soldadura S.L Spain
Praxair Sudamerica, S.L Spain
Praxair Surface Holdings SARL France
Praxair Surface Technologies do Brazil Ltda Brazil
Praxair Surface Technologies Co., Ltd. Korea
Praxair Surface Technologies Espana S.A Spain
Praxair Surface Technologies (Europe) S.A Switzerland



SUBSIDIARIES OF PRAXAIR, INC. (Continued)

Place of
Incorporation
  
Praxair Surface Technologies G.m.b.H Germany
Praxair Surface Technologies, Inc. Delaware
Praxair Surface Technologies K.K Japan
Praxair Surface Technologies Ltd. United Kingdom
Praxair Surface Technologies Mexico, S.A. de C.V Mexico
Praxair Surface Technologies Pte. Ltd. Singapore
Praxair Surface Technologies S.A.S France
Praxair Surface Technologies S.p.A Italy
Praxair Taiwan Co., Ltd. Taiwan
Praxair Technology, Inc. Delaware
Praxair Technology Solutions, Inc. Delaware
Praxair Uruguay Ltda Uruguay
Praxair Venezuela, S.C.A Venezuela
Praxair-Ozone, Inc. Delaware
Praxair.com GmbH Switzerland
Praxair & M.I. Services France S.a.r.l France
Praxair & M.I. Services, S.r.l Italy
Production Praxair Canada Inc. Canada
Productos Especiales Quimicos, S.A Mexico
Rapidox Gases Industriais Ltda Brazil
RBG Comercio de Metais Ltda Brazil
Rhee Beheer B.V Netherlands
Risorse S.p.A Italy
Rivoira S.p.A Italy
Shanghai Chemical Industry Park Industrial
 Gases Co., Ltd. China
Shanghai Praxair-Yidian, Inc. China
Smeding B.V Netherlands
Soudobeam S.A Belgium
TAFA Incorporated Delaware
Tianjin Praxair Inc. China
Topaz Consultora S.A Uruguay
Tradewinds Insurance Limited Bermuda
Transportes Flamingo S/A Peru
Treffers Precision, Inc. Arizona
Unigas Co., Ltd. B.V.I.
Voets B.V Netherlands
Wall Chemicals, Inc. Illinois
Welco-CGI Gas Technologies, LLC Delaware
Weld Consult S.A Belgium
Westair Cryogenics Company Delaware
Westair Cryogenics Holding Company Delaware
Westair Gas and Equipment, L.P. Texas
White Martins e White Martins Comercio e Servicos Portugal
White Martins de Camacari S.A Bahia
White Martins e Companhia Comercio e Servicos Portugal
White Martins Gases Industriais do Nordeste S.A Brazil
White Martins Gases Industriais do Norte S.A Brazil
White Martins Gases Industriais Ltda Brazil
White Martins Investimentos Ltda Brazil



CONSENT OF INDEPENDENT ACCOUNTANTS

Praxair, Inc. and Subsidiaries


EXHIBIT 23.01

        We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 33-48480, 33-93444, 333-304, 333-18141, 333-40003, 333-57386, and 333-102020) and in the Registration Statements on Forms S-8 (Nos. 33-48479, 33-48478, 33-87274, 33-92868, 333-18111, 333-18113, 333-33801, 333-64608, 333-81248, and 333-97191) of Praxair, Inc. of our report dated February 11, 2004 relating to the financial statements, which appears in the Annual Report to Shareholders, which is incorporated in this Annual Report on Form 10-K.

/s/ PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP
Stamford, Connecticut
March 8, 2004




RULE 13A-14(A) CERTIFICATIONS

Praxair, Inc. and Subsidiaries


EXHIBIT 31.01

I, Dennis H. Reilley, certify that:

1.  

I have reviewed this annual report on Form 10-K of Praxair, Inc.;


2.  

Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.  

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.


4.  

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:


(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)

[not used]


(c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting ; and


5.  

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing equivalent function):


(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


     
 
     
Dated: March 8, 2004   /s/ Dennis H. Reilley

Dennis H. Reilley
Chairman, President and
Chief Executive Officer
(principal executive officer)
     



RULE 13A-14(A) CERTIFICATIONS

Praxair, Inc. and Subsidiaries


EXHIBIT 31.02

I, James S. Sawyer, certify that:

1.  

I have reviewed this annual report on Form 10-K of Praxair, Inc.;


2.  

Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.  

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.


4.  

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:


(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)

[not used]


(c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.  

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing equivalent function):


(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.


     
 
     
Dated: March 8, 2004   /s/ James S. Sawyer

James S. Sawyer
Chief Financial Officer
(principal financial officer)